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Abstract 
 
Interleukin-13 (IL-13) has been implicated as a critical inducer of a number 
of features of allergy and asthma including the induction of nonspecific airway 
hyperresponsiveness (AHR), eosinophilic inflammatory response, eotaxin 
production, excess mucus formation, and fibrosis. Determining the mechanism(s) of 
AHR, a hallmark of asthma, is crucial to our understanding of both the pathogenesis 
and successful treatment of asthma. After carrying out initial experiments to 
determine the effect of IL-13-induced AHR on murine and rat tracheal rings, mice 
tissues were chosen for subsequent experiments due to their consistent results and the 
fact that the mouse genetic map was completed in 1996, which will enable 
subsequent gene therapy work. Human and mouse share a high percentage of their 
genes with an average of 85 percent homology. Numerous IL-13 signalling studies 
have concentrated on the JAK/STAT6 pathway. IL-13 also activates 
phosphoinositide 3-kinase (PI3K) and downstream effector molecules. In 
experiments presented in this thesis pharmacological and genetic approaches 
implicate the involvement of PI3K and its individual isoform PI3Kδ in IL-13 induced 
AHR in vitro and this involvement was confirmed using a small interference RNA 
(siRNA) technology approach. However, IL-13 induced an early activation of PI3K, 
whereas increased responsiveness was not observed until overnight incubation. 
Arginase I induction was demonstrated to be another PI3K-dependent potential 
mechanism of IL-13-induced hyperresponsiveness. The epithelium is also implicated 
in IL-13-induced hyperresponsiveness, however, the induction of arginase I was 
demonstrated in both intact and denuded epithelium tracheal rings. The siRNA 
approach was also employed in 9HTEo-, A549 and BEAS-2B cell lines using 
different transfecting agents. From these findings, it is concluded that class IA p110δ 
could be a useful target for the treatment of asthma by preventing IL-13-induced 
airway smooth muscle hyperresponsiveness and also that arginase I may be involved 
in IL-13-induced hyperresponsiveness through PI3K- and epithelial-dependent 
pathways. 
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1.1 Inflammatory lung diseases 
 
Lung diseases are a major cause of disability and death around the world. 
Respiratory diseases cause a huge economic burden. With one in five deaths due to 
respiratory diseases (Hubbard, 2006), the UK has one of the highest death rates from 
such diseases. Additionally, as extensively reviewed by Aїt-Khaled et al. (2001), 
most developing countries have no standard protocols for assessing and managing 
chronic non-communicable respiratory diseases such as chronic obstructive 
pulmonary disease (COPD) and asthma. These diseases affect 15% of the population 
in Latin America, 34% in the Arab world, 45% in Sub-Saharan Africa and Southeast 
Asia (Aїt-Khaled et al., 2001). Lung inflammation and its associated disease states 
are challenging due to their multiple signalling pathways and these, together with the 
structural features of the lung, make targeting and delivery of therapeutics to the lung 
a continuing problem in medicine.  
 
Asthma, COPD and cystic fibrosis (CF) together account for more than half of 
lung disease patients (Figure 1.1), totalling half a billion people worldwide. Much 
interest has been generated in better understanding the role of inflammatory 
mediators in the development of inflammatory lung diseases. Such diseases clearly 
have a large impact on health care worldwide, with COPD affecting 24 million 
Americans and 2 million Britons. The diagnosis of asthma is increasing in frequency. 
Moreover, economic costs can be billions of dollars (Donnelly & Rogers, 2008). A 
differential diagnosis between COPD and asthma is important for subsequent 
treatment options. The Dutch hypothesis (Sluiter et al., 1991; Orie, 2000) postulates 
that asthma and COPD share common origin, with overlapping obstructive clinical 
features. Asthma may evolve into COPD with the development of obstruction 
depending on inflammation, airway hyperresponsiveness and host hereditary factors, 
but modulated by exogenous factors. The British hypothesis proposes that asthma and 
COPD are distinct and generated by distinct mechanisms. Much debate between these 
theories has been discussed, but the similarities between asthma and COPD favour 
the Dutch hypothesis (Chang & Mosenifar, 2007). Although the airways obstruction 
in asthma is largely reversible, it was demonstrated that asthmatics can show 
irreversible airflow obstruction (Ulrik & Backer, 1999). Also, COPD patients with 
reversible airways obstruction have been documented (Chanez et al.
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Figure 1.1 Worldwide prevalence of inflammatory and other lung diseases (after 
Donnelly & Rogers, 2008). 
 
1.1.1 Asthma 
 
Asthma was first recorded in the Ebers Papyrus, one of the most important 
medical papyri of ancient Egypt of about 1550 BC, which described asthma 
treatment in the form of inhaled mixture of herbs heated on a brick. Hippocrates, the 
great Greek physician during 460 - 375 BC was the first to describe asthma spasms 
and nearly 250 years later Galen, a Greco-Roman doctor attributed the cause of 
asthma to bronchial obstructions. The name asthma was derived from an ancient 
Greek meaning gasping or panting to describe the nature of illness (Cohen, 1992). 
Ancient Chinese used ephedrine thousands of years ago prior to western doctors 
adopting it as a method of treatment (Chu & Drazen, 2005). Twenty years ago, many 
parts of the world were experiencing the second peak of asthma deaths of the 
millennium pointing to needs of alternative treatments for asthma to meet the 
requirements of all asthmatic patients (Partridge, 2007). 
 
Asthma is defined as a chronic inflammatory disorder of the airways, which 
causes an associated increase in AHR that leads to recurrent episodes of wheezing, 
breathlessness, chest tightness, and coughing, particularly at night or in the early 
morning. These episodes are usually associated with widespread and variable airflow 
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obstruction that is often reversible either spontaneously or with treatment (Chang & 
Mosenifar, 2007). The prevalence of asthma in children has dramatically increased in 
the last decades all over the world (Ronchetti et al., 2001). It is estimated that 300 
million people worldwide suffer from asthma, furthermore, there may be an 
additional 100 million persons with asthma by 2025 (Masoli et al., 2004). According 
to the World Health Organization, 255,000 died of asthma in 2005 (Bloemen et al., 
2007). The exact cause of asthma remains uncertain with several factors influencing 
the disease, for example genetic factors (e.g. a history of asthma in the family, 
atopy), environmental factors (e.g. air pollution, occupational exposure, viral 
infections, allergen exposure) and lifestyle factors (e.g. smoking habits, food) 
(Bloemen et al., 2007). Asthma can be classified according to its stimuli into allergic 
and non-allergic asthma (Hurwitz, 1955). Nonallergic asthma is characterized by 
negative skin tests and no clinical or family history of allergy with normal serum 
total IgE concentrations. Patients with nonallergic asthma are usually older than their 
allergic counterparts and have onset of symptoms in later life as reviewed in 
Humbert et al. (1999). Allergic asthma is characterized by:  
 Allergen-induced airway obstruction, in which early asthmatic 
reaction (EAR) develops rapidly and is reversible within 1-2 h. EAR 
is usually followed by a late phase asthmatic reaction (LAR), which 
develops after 4-7 h after allergen exposure and can last for up to 24 h 
after provocation (Booij-Noord et al., 1971). 
  The allergic cascade of asthma (Figure 1.2), characterized by 
infiltration, priming and activation of various inflammatory cells in 
airway tissues (Holgate & Polosa, 2008). 
 Non-specific AHR in asthma might be caused by increased force 
generation in the smooth muscle itself; due to either increased 
receptor numbers, increased affinity of ligand-receptor interaction, or 
modified intracellular contractile signalling pathways (Fernandes et 
al., 2003). 
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Figure 1.2 Inflammatory and immune cells involved in asthma adapted from Holgate 
& Polosa (2008). 
 
A challenge of asthma treatment lies in differentiation between asthma cases 
and COPD and which treatment paradigm to adopt to control asthma symptoms and 
lung function. Therapy for COPD is directed at relief of symptoms, whereas for 
asthma the treatment is to reduce inflammation (Stirling & Chung, 2001; Chang & 
Mosenifar, 2007). Sensitization is fundamental to the development of allergic 
diseases. Therefore, avoidance of allergens before or after sensitization could be 
beneficial as primary or secondary prophylaxis (Holgate & Polosa, 2008). Inhaled 
corticosteroids and β2-adrenoceptor agonists are the mainstay of asthma (Holgate & 
Polosa, 2008) but there is an increasing finding that many patients with asthma are 
resistant to conventional bronchodilating and anti-inflammatory therapies. Different 
terms are used by clinicians to describe complicated cases of asthma such as "chronic 
severe", "acute severe", "therapy-resistant", "difficult-to-control", "refractory", 
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"corticosteroid -resistant or -dependent", "near-fatal", and "fatal asthma" (Stirling & 
Chung, 2001). The need for new asthma treatment is increasing and to identify 
possible target(s) against which treatment will be directed will be a first step towards 
asthma management of those cases. Treatment strategies of asthma are summarised 
in Table 1.1 
 
Table 1.1 Treatments strategies of asthma 
Treatment Comment Reference(s) 
Short-acting  
β-agonists 
First line of treatment Chang & Mosenifar, 2007; 
Holgate & Polosa, 2008 
Inhaled corticosteroids Mainstay treatment Holgate & Polosa, 2008; 
Barnes, 2008 
Immunotherapy e.g. low-
dose methotrexate, 
azathioprine or 
cyclosporine A 
Inconsistent results 
Common side effect 
up to anaphylaxis  
Holgate & Polosa, 2006 
Anti-immunoglobulin E 
e.g. omalizumab 
Used in severe 
allergic asthma 
Babu et al., 2001; Djukanovic 
et al., 2004; Holgate et al., 
2005 
Mast cells inhibitors  
 
Nedocromil sodium 
 
Edwards & Howell, 2000 
Cytokine-based 
immunotherapies 
Monoclonal 
antibodies, fusion 
proteins 
Holgate & Polosa, 2008 
Leukotriene antagonists 
e.g. montelukast and 
zafirlukast 
Modest effect Misson et al., 1999 
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1.1.2 COPD 
 
COPD is a major global health problem that is expected to be the third most 
common cause of death in the world by 2020 (Lopez & Murray, 1998). It is 
characterized by airflow limitation that is not fully reversible. The airflow limitation 
is usually both progressive and associated with an abnormal inflammatory response 
of the lungs to noxious particles or gases. Asthma and COPD have differences and 
similarities (Table 1.2), thus the differentiation between both conditions is essential 
for subsequent diagnosis and treatment.  
 
Table 1.2 Differential diagnosis between COPD and asthma 
  Asthma COPD Reference(s) 
AHR Significant Insignificant Welte & Groneberg, 
2006; Medina-Tato et 
al., 2006 
Airway obstruction Variable 
Reversible  
Progressive  
Largely irreversible 
(about 10 % are 
reversible)  
Barnes, 2008 
Location  
of inflammation  
Mainly large 
airways  
Small airways Chang & Mosenifar, 
2007 
Inflammatory cells   
Mast cells 
 
 
Eosinophils 
 
Neutrophils 
 
Lymphocytes 
 
Increased  
 
 
Increased 
 
-  
 
CD4   
 
- 
 
 
- 
 
Increased  
 
CD8  
 
Brightling et al., 2002; 
Barnes, 2008 
 
Barnes, 2008 
 
Welte & Groneberg, 
2006 
Medina-Tato et al., 
2006; Barnes, 2008 
Oxidative stress + +++ Barnes, 2008 
ASM hypertrophy 
and hyperplasia 
Usually found  Not usually increased Chang & Mosenifar, 
2007 
Epithelial cells Friable  Pseudostratification  Barnes, 2008 
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Basement membrane Thickened  - Barnes, 2008 
Fibrosis Subepithelial Peribronchiolar Barnes, 2008 
Angiogenesis Detected  - Siddiqui et al., 2007 
Lung parenchema 
integrity 
- Destructed Chang & Mosenifar, 
2007 
Mediators produced LTB4, Histamine, 
IL-4, IL-5, IL-13, 
Eotaxin, 
RANTES  
LTB4, TNF, IL-8 Barnes, 2000; Elias, 
2004 
Short-acting  
β-agonists 
First-line of 
treatment  
Needed basis 
treatment and no 
advantage to their 
regular use 
Chang & Mosenifar, 
2007 
Long-acting  
β-agonists 
Uncertain benefit Used in later stages Chang & Mosenifar, 
2007 
Short-acting 
anticholinergics 
Uncertain benefit Mainstay of treatment Chang & Mosenifar, 
2007 
Response to steroid Present Variable  Welte & Groneberg, 
2006 
 
 
1.1.3 Cystic fibrosis  
 
CF is an autosomal recessive disease considered to be the most lethal 
inherited trait among Caucasians affecting the exocrine glands of the lungs, liver, 
pancreas, and intestines causing progressive multisystem failure. CF is one of the 
most common life-shortening, childhood-onset inherited diseases. Over 8,000 
children, young people and adults in the UK are affected by cystic fibrosis (Harrop, 
2007). It is caused by a mutation in a gene called the cystic fibrosis transmembrane 
conductance regulator (CFTR). The product of this gene is a chloride ion channel 
important in creating sweat, digestive juices, and mucus (Figure 1.3). The basis of 
management are proactive treatment of airway infection, and encouragement of good 
nutrition. Additionally, therapies such as transplantation and gene therapy hold 
promise therapeutic strategy.  
Table 1.2 Differential diagnosis between COPD and asthma – continued. 
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          Figure 1.3 Pathogenesis of cystic fibrosis. Cystic fibrosis transmembrane 
          conductance regulator (CFTR) receptor does not operate in CF. 
 
1.2 Cytokine profiles in  lung diseases 
 
Professional antigen-presenting cells, including dendritic cells, process 
exogenous antigens before presentation to T cells. Naive T helper (Th0) cells are 
activated and differentiate into either Th1 or Th2 cells. Th1 cells are characterised by 
the production of interferon-γ, and are associated with autoimmune diseases. Th2 
cells secrete IL-4, IL-5, IL-9 and IL-13 and are involved in humoral (B cell) 
responses and IgE production, as well as tissue fibrosis, mastocytosis and 
eosinophilia. Allergy results from an imbalance in favour of a Th2 response and 
dysregulation of Th2 responses and is implicated in various atopic diseases (Holgate 
& Polosa, 2008). In asthma and COPD, cytokines play a critical role in orchestrating 
and perpetuating inflammation, and several specific cytokine and chemokine 
inhibitors are in development for treatments of these diseases (Barnes, 2000; Temann 
et al., 2007). Th2-dominated tissue inflammation is believed to play a central role in 
asthma pathogenesis. IL-4, IL-5, IL-9, and IL-13 have been extensively reviewed, and 
increase significantly in the asthmatic airway (Jaffar et al., 1999; Elias, 2004; 
  
 - 10 - 
Bloemen et al., 2007). The biology of IL-13 and IL-13 receptors is discussed further 
in section 1.4, in this section its role in allergic diseases is discussed. 
 
The Th2 cytokine IL-4 (Brusselle et al., 1995; Corry et al., 1996) and the 
closely related cytokine IL-13 (Grunig et al., 1998; Izuhara, 2003; Yang et al., 2004; 
Yang et al., 2005) have strong associations with allergic disease. IL-4Rα is a unique 
member of the common-gamma chain (γc) family of receptors (Nelms et al., 1999). 
IL-4 binds IL-4Rα chain with high affinity (Kd 20 to 300 pM) with the ability to 
signal within IL-4Rα/IL-4Rα, IL-4Rα/γc (Type I) and IL-4Rα/IL-13Rα1 (Type II) 
receptor complexes (Nelms et al., 1999; Andrews et al., 2006). The type II receptor is 
a functional receptor for IL-4 as well as IL-13 (Obiri et al., 1995; Hilton et al., 1996) 
which can explain the overlap of the biological effects between IL-4 and IL-13. Type 
I receptor complexes can only be formed by IL-4 and are more active in regulating 
Th2 development. In contrast, the Type II receptor complex formed by either IL-4 or 
IL-13 is not found on T cells and is more active in regulating cells that mediate 
airway hypersensitivity and mucus secretion (Andrews et al., 2006). 
 
The role of IL-13 in inflammatory diseases of the lung has been investigated 
in different disease models including asthma (Grunig et al., 1998; Wills-Karp et al., 
1998; Munitz et al., 2008), emphysema (Zheng et al., 2000), anaphylaxis (Fallon et 
al., 2001) and hyperoxic acute lung injury (Corne et al., 2000). Although IL-4 and 
IL-13 are capable of inducing an asthma-like phenotype, IL-13 seems to have a 
superior role during the effector phase of the disease. It is proposed that IL-4 
production at the site of inflammation is short lived and that IL-13 may persist or IL-4 
is difficult to be measure at the site of inflammation (Kroegel et al., 1996). The 
biological role of IL-13 in asthma has been intensively studied. Pulmonary expression 
of IL-13 induces an asthma-like phenotype in mice, including a mononuclear and 
eosinophilic inflammatory response, mucus cell metaplasia, airway fibrosis, eotaxin 
production, airways obstruction, and AHR (Zhu et al., 1999). In addition to 
enhancing polarisation of T-lymphocytes to a Th2 phenotype and promoting B-cell 
synthesis of IgE (Levy et al., 1997; Hajoui et al., 2004), IL-13 may contribute 
towards asthma via tissue remodelling (Kumar et al., 2002), epithelial activation 
(Lordan et al., 2002), decreasing β2 adrenoceptor function (Laporte et al., 2001) and 
enhancing contractility of airway smooth muscle in human and IgG1 in mice. 
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IFN-γ causes an emphysema like-phenotype. IFN-γ transgenic mice show 
massive alveolar destruction and pulmonary emphysema associated with neutrophil-
rich tissue inflammatory response. Neutrophils, lymphocytes and macrophages (but 
not eosinophils) are increased in BAL fluid compared with transgene-negative 
controls. Mucous metaplasia is not a prominent finding in these animals and tissue 
fibrosis is not detected (Wang et al., 2000). In contrast, the same group demonstrates 
that IL-13-induced emphysema is associated with eosinophilia, mucus 
hyperproduction, pulmonary fibrosis and mucous metaplasia with little parenchymal 
fibrosis and is due to protease-mediated epithelial apoptosis, stimulated matrix 
metalloproteinases (MMPs), cathepsins, and α1-antitrypsin inhibition (Zheng et al., 
2000). They suggested that their finding can explain the British/Dutch hypothesis on 
the basis that the Th1/TC1 pathway (increases in MMPs and cathepsins, decreases in 
secretory leukocyte proteinase inhibitor apoptosis-dependent, and apoptosis-
independent-alveolar destruction) predominates in patients with definite COPD 
symptoms (British hypothesis) and that the Th2/TC2 pathway (increases in MMPs 
and cathepsins, decreases in α1-antitrypsin and increases in adenosine and genetic 
factors) dominates in patients with features of asthma and emphysema (Dutch 
hypothesis). 
 
IL-13 plays a key role in asthma pathogenesis. Both in vivo and in vitro 
studies demonstrate IL-13 induces IgE production (Grunig et al., 1998; Kuperman et 
al., 2002; Wills-Karp, 2004; Zheng et al., 2008), mucus production and mucous cell 
metaplasia (Grunig et al., 1998; Kuperman et al., 2002; Wills-Karp, 2004; Zheng et 
al., 2008), generation of extracellular matrix proteins (Lanone et al., 2002; Zheng et 
al., 2008), airway eosinophilia and eotaxin production (Zhu et al., 1999; Kumar et al., 
2002; Wills-Karp, 2004), airway fibrosis (Grunig et al., 1998; Kuperman et al., 2002; 
Wills-Karp, 2004; Zheng et al., 2008), as well as AHR and enhanced contractility of 
airway smooth muscle cells (Grunig et al., 1998; Kuperman et al., 2002; Foster et al., 
2003; Wills-Karp, 2004; Zheng et al., 2008). 
 
IL-12 can suppress IgE production. Th1 cells transferred into IL-12 knockout 
mice do not inhibit IgE production, but can be inhibited by transfer of bone marrow-
derived dendritic cell precursors from IL-12 competent mice as well as transfer of IL-
18-competent wild-type bone marrow-derived dendritic cells indicating that both 
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IL-12 and IL-18 are needed for Th1 mediated immunity (Thomas et al., 2002; 
Salagianni et al., 2007). These findings are associated with negligible amounts of 
IFN-γ. In OVA-sensitized BALB/c mice an association of IL-12 with enhanced IL-4, 
IL-5, and IL-13 production in BAL fluid was demonstrated. When anti-IL-12p35 or 
anti-IL-12p40 mAb administered to these mice it was demonstrated decreased level 
of those cytokines with lack of methacholine-induced bronchial hyperresponsiveness 
and eosinophilia (Meyts et al., 2006). In contrast intranasal mice administration of 
Lactococcus lactis as a source of IL-12 is associated with elevated IFN-γ and 
decreased IL-4 (Wu et al., 2006). 
 
The role of IL-5 in eosinophil expansion and priming has been established in 
many studies. Recently, it was observed that small interfering RNA against IL-5 
decreases airway eosinophilia and eotaxin levels in BAL fluid, IL-5 mRNA levels in 
lungs and hyperresponsiveness to methacholine, but not OVA-specific IgE level in a 
mouse model of asthma (Huang et al., 2008). In a study using atopic asthmatic 
patients exposed to humanized anti–IL-5 monoclonal antibody (mepolizumab), it was 
demonstrated mepolizumab decreased eosinophilia, the expression of tenascin, 
lumican and procollagen III in the bronchial mucosal biopsy compared with placebo 
suggesting the mechanism of IL-5 in asthma tissue remodelling is through the 
deposition of extracellular matrix proteins (Flood-Page et al., 2003). The role of IL-5 
in tissue remodelling, and eosinophils as a source of TGF-β, was confirmed in a study 
conducted using IL-5–deficient mice (Cho et al., 2004). Clinical trials using two 
humanized monoclonal anti-IL-5 antibodies (mepolizumab and SCH55700) 
demonstrated that although both sputum and blood eosinophils were reduced to very 
low levels after intravenous administration of mepolizumab to asthmatic patients, 
modulation of the late asthmatic reaction or airway hyperresponsiveness to histamine 
was not detected (Leckie et al., 2000). Similarly SCH55700, adminstered 
intravenously to difficult-to-treat asthma patients (who were already on inhaled or 
oral corticosteroid), reduced blood eosinophils but improved FEV1 only with the use 
of higher dose (Kips et al., 2003). In a recent study to evaluate the efficacy of 
mepolizumab conducted in more than 300 moderate to severe asthmatic patients a 
pronounced reduction in blood eosinophils was observed. However, mepolizumab 
had no significant effect on FEV1 with a nonsignificant 50 % decrease in 
exacerbation rates which did not add clinical benefit to the patients (Flood-Page et al., 
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2007). IL-5 and eotaxin-deficient mice do not have tissue eosinophilia or 
methacholine induced-AHR, which is associated with impaired IL-13 level, corrected 
by eosinophil transfer to those mice, which suggests that, both IL-5 and eotaxin 
modulate IL-13 production (Mattes et al., 2002). Targeted deletion of IL-13 prevents 
expression of AHR in allergen-challenged mice, despite maintenance of elevated IL-4 
and IL-5 release (Walter et al., 2001). Likewise, neutralization of IL-13 using IL-13 
receptor constructs or antibodies reduces AHR without influencing IL-5 levels (Eum 
et al., 2005). IL-13-induced hyperresponsiveness can be inhibited by anti-IL-5 
antibody in the rabbit trachea (Grunstein et al., 2002). However, overexpression of 
IL-13 in the mouse lung does not result in IL-5 (or IL-4) up-regulation (Zhu et al., 
1999), IL-13-induced in vivo AHR is maintained in IL-5 knock-out mice (Yang et al., 
2001), and antigen-induced AHR is inhibited by anti-IL-13 but not anti-IL-5 
treatment (Grunig et al., 1998). 
 
1.3 Airway hyperresponsiveness 
 
In 1921 Alexander and Paddock observed enhanced bronchoconstriction in 
asthmatic patients compared to non-asthmatic patients after exposure to pilocarpine. 
These findings were confirmed by findings that asthmatic subjects develop increased 
bronchoconstriction and carbon dioxide tension in response to histamine compared to 
healthy volunteers (reviewed in O'Byrne & Inman, 2003). AHR involves two 
phenomena, a shift of the constrictor dose-response curves to the left (airway 
hypersensitivity) and increased slope of the curves with greater maximum degree of 
induced-constriction (airway hyperreactivity) (Woolcock et al., 1984; Sterk & Bel, 
1989). Airway sensitivity can be a result of epithelial damage and malfunction, neural 
control, and changed inflammatory cell number or activity, while determinants of 
airway reactivity include ASM contractility, the elastic load on ASM shortening, 
swelling of the airway wall, and intralumenal exudate and secretions (Niimi et al., 
2003). 
 
1.3.1 Indices of airway hyperresponsiveness 
 
AHR can be classified into variable (inducible or episodic) AHR and 
persistent AHR. The variable AHR may reflect airway inflammation, thus 
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representing acute aspect of the disease while the baseline persistent AHR likely 
relates to structural airway changes referred to as airway remodelling and probably 
reflects chronicity of disease (Cockcroft & Davis, 2006). Direct and indirect stimuli 
are used to measure airway responsiveness. The direct stimuli act directly on 
receptors on airway smooth muscle e.g. histamine and methacholine, while the 
indirect stimuli act through intermediate pathway(s), most commonly acting via 
release of mediators from inflammatory cells e.g. exercise, cold air and mannitol 
(Van Schoor et al., 2005).  
 
1.3.2 Mechanisms of airway hyperresponsiveness 
 
The mechanism of airway hyperresponsiveness in asthma remains unclear. 
Many studies have been performed to determine the correlation of inflammatory cells 
in BAL fluid with AHR. Although some of these studies detected the correlation it is 
weak and most often when bronchoconstriction or response to direct stimuli is 
measured (Boulet et al., 1993; Oddera et al., 1998). Still, both inflammatory 
mediators and resident airway cells could be involved in the mechanisms of AHR. It 
is suggested that acute exposure to the inflammatory mediators results in increased 
ASM responsiveness in vitro due to: 
• Enhancing contractile agonist-stimulated increases in inositol 1,4,5-
trisphosphate and augmentation of peak and sustained intracellular calcium 
levels (Martin et al., 2000). 
• Blunting ASM relaxation, normally induced by β2-adrenoceptor stimulation, 
through β2-adrenoceptor phosphorylation, Gs protein dysfunction, increased 
prostanoid and peptide leukotriene release.  
• Increasing the activity and/or content of smooth muscle MLCK (Jiang et al., 
1995; Ammit et al., 2000).  
 
However, growing evidence indicates the crucial role of different resident 
cells to mediate AHR (Kuperman et al., 2002; Tliba et al., 2003; Syed et al., 2005). 
Airway epithelium is composed of a heterogenous population of cells, which act more 
than just a physical barrier, but also possesses a number of diverse functions (Spina & 
Page, 1992). The integrity of airway epithelium has an important role in defence 
mechanisms both physically and functionally. In a trial to restore damaged airway 
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epithelium, asthmatic patients demonstrated elevated epidermal growth factor 
receptor expression (Puddicombe et al., 2003). For example, AHR was not 
demonstrated in IL-13-defecient mice exposed to OVA stimulation despite the 
presence of eosinophilic pulmonary inflammation (Walter et al., 2001). Alternatively, 
IL-13 may induce AHR via direct effects on airway epithelial cells. Epithelial cells 
that are devoid of STAT6 are not affected by IL-13-induced AHR, and have reduced 
mucus production (Kuperman et al., 2002). 
 
ASM releases several inflammatory mediators under various conditions of 
stimulation indicating the likelihood that they may contribute to chronic inflammatory 
processes in the airway (Table 1.3). ASM can exhibit various states: a synthetic 
phase, a proliferative phase as well as a contractile phase. The contractile phenotype 
of ASM cells under culture is well recognized in enzyme-dissociated cells seeded in 
primary culture within 24-48 h, with intense immunostaining for muscle specific 
contractile proteins and with visible contraction to constrictor agonists (reviewed in 
Hirst, 1996). Serum can affect the phenotype acquired during culture (Chamley-
Campbell et al., 1979). Serum deprivation for 10 days in canine isolated tracheal 
smooth muscle cells allows the acquisition of a subpopulation of myocytes with a 
morphological and functional contractile phenotype (Halayko et al., 1999). In the 
presence of proliferating stimuli, such as foetal calf serum, contractile airway smooth 
muscle changes into a "synthetic" phenotype, characterized by increased mitogenic 
activity; expression of intracellular organelles associated with synthesis; and a 
decrease in immunostaining for smooth muscle specific contractile proteins. It was 
shown in proliferating tracheal smooth muscle cells that the levels of smooth muscle 
myosin heavy chain are markedly reduced with a reduction in mRNA for this protein 
and α-actin, (Halayko et al., 1996). The synthetic cells produce extracellular matrix 
components and also autocrine growth-promoting factors, and these could in turn 
influence the contractile or synthetic phenotype (Chung, 2000). 
 
ASM is considered a crucial component of AHR (Figure 1.4). As reviewed in 
Parameswaran et al. (2002) increased intracellular calcium is responsible for AHR 
but it is also documented in studies conducted in asthmatic patients that voltage-
dependent calcium channel-blocking drugs do not attenuate AHR, implicating 
inflammatory process for the studied AHR. The demonstrated hypertrophy and /or 
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hyperplasia or increased muscle-shortening velocity in asthmatic subjects can explain 
hyperreactivity but not hypersensitivity. TNFα and IL-13 significantly increased 
cultured murine tracheal ring contractile responses to carbachol and KCl without 
affecting changes in receptor affinity, suggesting modulation of ASM responsiveness 
at a site downstream from receptor activation (Chen et al., 2003; Tliba et al., 2003). 
Epithelium-denuded rabbit tracheal segments sensitized passively with IgE show 
enhanced response to ACh and isoproterenol, which is inhibited by the presence of 
anti-IL-4Rα antibodies. Furthermore, IgE-sensitized cultured human ASM cells 
exhibit IL-13 mRNA and protein upregulation, whereas IL-4 expression is not 
detected (Grunstein et al., 2002). Also, human ASM cells show increased CD38 
expression associated with enhanced intracellular calcium responses to bradykinin, 
thrombin, and histamine compared with controls (Deshpande et al., 2004). 
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     Figure 1.4 Proposed model for the pathological roles of ASM in asthma. 
     Increase ASM number (hyperplasia) and size (hypertrophy) cause elevated 
     muscle mass. This leads to AHR, bronchoconstriction, airway wall thickening 
     (remodelling), and production of several inflammatory mediators  
     (Amrani & Panettieri, 2003). 
  
 
Table 1.3 Cytokines, mediators enzymes and receptors produced by airway smooth 
muscle cells in culture (Chung, 2000) 
Cytokines/ 
chemokines 
Growth 
factors 
Receptors/ surface 
molecules 
Lipid mediators/ enzymes 
MCP-1, 2 & 3  
RANTES  
Eotaxin 
IL-8 
GM-CSF 
IL-6 
IL-11 
IL-5 
IFNγ 
IL-2 
IL-12 
PDGF-BB  
MMP-1 
Stem cell factor 
IL-2R 
IL-12R 
IFNγR 
ICAM-1 
VCAM-1 
CD44 
CD40 
MHC Class 2 
PGE2 
s-PLA2 
NOS 
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Fibroblasts also contribute to AHR. Anatomically, they are a hetreogenous 
group of differentiated cells of mesenchymal origin. They provide both cellular and 
extracellular stroma for epithelial cell layers (Quan et al., 2004). A main function of 
fibroblasts is the production and homeostatic maintenance of the extracellular matrix 
components including collagens, proteoglycans, tenascin, laminin and fibronectin 
(McAnulty, 2007). Each cell can synthesise approximately 3.5 million procollagen 
molecules/cell/day (McAnulty et al., 1991). A potential role of fibroblasts is related 
to wound repair and inflammatory fibrosis (Bucala et al., 1994).  
 
Fibroblasts may convert into elongated cells termed myofibroblasts 
containing intracellular filaments, irregularly shaped nuclei and filaments. Exposure 
to IL-4 or IL-13 (100 ng/ml) increases α-smooth muscle actin protein expression 
indicating that these cytokines are capable of inducing the phenotypic change to 
myofibroblasts (Hashimoto et al., 2001). 
 
Goblet cells, which are glandular simple columnar epithelial cells situated in 
the conducting airways and whose function is to secrete mucus, play a pivotal role in 
protecting the airway surface from inhaled particles which become trapped in the 
mucus before cleared by the mucociliary mechanism (Rogers, 2004). Goblet cell 
hyperplasia is a characteristic feature in bronchial asthma and chronic bronchitis 
causing airway narrowing by changing epithelial barrier function (Kamachi et al., 
2001). IL-13 induces mucus production, possibly through induction of soluble TGF-
α from lung epithelium (Yoshisue & Hasegawa, 2004). Human airways are 
innervated by populations of afferent nerves, stimulation of which result in reflex 
cough and bronchoconstriction. The bronchial hyperresponsiveness seen in asthma 
might be also explained on the basis of an increase in afferent activity due to the 
effect of different inflammatory mediators, including prostaglandins, neuropeptides, 
cytokines and growth factors lead to activation of inflammatory cells and airway wall 
remodelling (Spina et al., 1998).  
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1.4 Interleukin-13 
 
1.4.1 IL-13 production 
 
Murine IL-13, previously known as P600, was identified in vitro using 
activated mouse lymphocytes (Cherwinski et al., 1987). Human IL-13 is secreted 
mainly by Th2 CD4
+
 T cells was then cloned and shown to be a pleiotropic cytokine 
produced by a variety of cell types (McKenzie et al., 1993b). In addition to T-cells, 
IL-13 is also produced by numerous non-T-cell populations that are of particular 
importance to the allergic response such as mast cells, basophils, and eosinophils. 
Natural killer T cells may be an important source of IL-13 early in the allergic 
response (Akbari et al., 2003). In addition IL-13 has been shown to be released from 
structural cells such as ASM (Grunstein et al., 2002). A number of cytokines and 
mediators have been implicated in the regulation of IL-13 production including IL-5, 
IL-9, IL-25, histamine, adenosine, and endothelin-1 (Fort et al., 2001; Wills-Karp, 
2004; Temann et al., 2007). 
 
1.4.2 IL-13 protein structure 
 
The IL-13 gene is located on human chromosome 5q31 or mouse 
chromosome 11 in the cluster of genes encoding IL-3, IL-4, IL-5, IL-9, and 
granulocyte-macrophage colony-stimulating factor (GM-CSF). The IL-13 gene is 
located between the GM-CSF and the IL-4 gene, with the IL-13 gene in close 
vicinity of the IL-4 gene, being 12 kb upsteam difference. Although the IL-13 protein 
has only about 25% homology with IL-4 (Minty et al., 1993), it shares many 
structural characteristics and functional properties with IL-4 due to a shared chain in 
their individual multimeric receptor complexes (Zurawski et al., 1993) or due to the 
homology in the first and last α-helical regions of IL-4 and IL-13 (Minty et al., 
1993). Both mouse and human IL-13 genes are formed by 4 exon : 3 introns (Table 
1.4) with intron size 1055, 251, and 345 in the human IL-13 gene and 1258, 576, and 
311 in the mouse IL-13 gene (McKenzie et al., 1993b). Transcriptional regulatory 
sequence motifs in the human and mouse IL-13 genes studies show that a TATA box 
which is a DNA sequence found in the promoter region of most genes and to which 
transcription factors or histones bind is located at positions 697-701 and 786-790 of 
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h- and m-IL-13 genes respectively. The polyadenylation sequence of h-IL-13 gene is 
found between positions 4055-4060 and between positions 3633-3638 in m-IL13 
gene. Sequence homology between h-IL-13 and m-IL-13 cDNA is 66% and after the 
translation stop codon they have 70% homology. Also both genes show a relatively 
high degree of nucleotide identity in their 5’-flanking regions (McKenzie et al., 
1993b). 
 
IL-13 is secreted mainly as unglycosylated protein of approximately 12 kDa. 
The mature protein contains 3 (mouse) or 4 (human) potential N –glycosylation sites 
so that minor glycosylation of the protein that results in higher molecular weight can 
occur (McKenzie et al., 1993a). The cDNA for human IL-13 was cloned 
approximately 15 years ago by 3 groups (Morgan et al., 1992; Minty et al., 1993; 
McKenzie et al., 1993a). The nucleotide sequence of IL-13 encodes a protein of 131 
(murine) and 132 (human) amino acids (Table 1.4) each containing a putative 20 
amino acid signal peptide sequence with approximately 58% sequence homology at 
the amino acid level (Minty et al., 1993; McKenzie et al., 1993b). Human IL-13 acts 
on mouse and rat cells but with low affinity for mouse receptors (Cash et al., 1994), 
while mouse and human IL-13 are equally active on human cells (McKenzie et al., 
1993a). A comparison between m- and h-IL-13 is shown in Figure 1.5 & Table 1.4. 
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Figure 1.5 Multiple alignment of mouse, rat and human IL-13. * indicates identical 
sequences between the three species, : conserved substitution, . semi-conserved 
substitutions 
 
 
 
             Table 1.4 Human and murine IL-13 physicochemical properties 
             (Minty, 1997) 
 Human Mouse 
  
132 (146)
a
 131 
20 (34)
a
 18
b
 
Amino acids 
     Precursor 
     Signal sequence 
     Mature 112
c
 111
b
 
Potential N-glycosylation sites 4 3 
Disulfide bonds 
 
28-56 
44-70 
 
                          a
Two methionine initiation codons, the most probable initiation 
                  codon would give 132 amino acids and a signal peptide of 20 
                  amino acids. 
                          b
prediction based on homology with human protein without 
                  experimental determination. 
                           c
determined experimentally in recombinant expression system in  
                   CHO cells. 
 
 
P20109|IL13_MOUSE      MALWVTAVLALACLGGLAAPGPVPRSVSLPLTLKELIEELSNITQDQ-TPLCNGSMVWSV 59 
P42203|IL13_RAT        MALWVTAVLALACLGGLATPGPVRRSTSPPVALRELIEELSNITQDQKTSLCNSSMVWSV 60 
P35225|IL13_HUMAN      MALLLTTVIALTCLGGFASPGPVPPST----ALRELIEELVNITQNQKAPLCNGSMVWSI 56 
                       *** :*:*:**:****:*:****  *.    :*:****** ****:* :.***.*****: 
 
P20109|IL13_MOUSE      DLAAGGFCVALDSLTNISNCNAIYRTQRILHGLCNRKAPT-TVSSL--PDTKIEVAHFIT 116 
P42203|IL13_RAT        DLTAGGFCAALESLTNISSCNAIHRTQRILNGLCNQKASD-VASSP--PDTKIEVAQFIS 117 
P35225|IL13_HUMAN      NLTAGMYCAALESLINVSGCSAIEKTQRMLSGFCPHKVSAGQFSSLHVRDTKIEVAQFVK 116 
                       :*:** :*.**:** *:*.*.** :***:* *:* :*..    **    *******:*:. 
 
P20109|IL13_MOUSE      KLLSYTKQLFRHGPF- 131 
P42203|IL13_RAT        KLLNYSKQLFRYGH-- 131 
P35225|IL13_HUMAN      DLLLHLKKLFREGRFN 132 
                       .** : *:*** *    
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1.4.3 IL-13 receptors and signalling  
 
IL-13 mediates its action via a complex receptor system that includes the 
IL-4Rα chain and at least two other IL-13-binding proteins designated as IL-13Rα1 
and IL-13Rα2 (Hilton et al., 1996). It was shown that IL-13R (IL-4Rα/IL-13Rα1) is 
expressed on both hematopoietic and non-hematopoietic cells for example B cells, 
monocytes/macrophages, dendritic cells, eosinophils, basophils, fibroblasts, 
endothelial cells, airway epithelial, and ASM cells (Hershey, 2003). Expression of 
IL-13 Rα2 has been reported on fibroblasts, airway epithelial cells, ASM cells, B 
lymphocytes and macrophages cells (Laporte et al., 2001; Daines & Hershey, 2002; 
Zheng et al., 2003; Yoshikawa et al., 2003). 
 
IL-13Rα1 is expressed as a 60-70 kDa glycosylated protein that binds IL-13 
but not IL-4. The cytoplasmic domain of IL-13Rα1 contains a membrane–proximal 
proline-rich region termed box-1 and two tyrosine residues, Tyr-402 and Tyr-405, 
with the latter in a YXXQ sequence motif that binds the SH2 domain of STAT3 
(Stahl et al., 1995). The proline-rich box region in the intracellular domain is needed 
for binding of JAK. JAKs are tyrosine kinases that each contains a true catalytic 
domain and a pseudokinase domain. There are 4 JAKs: JAK1, JAK2, JAK3, and 
Tyk2. JAK1, JAK2, and Tyk2 are ubiquitously expressed, while JAK3 is expressed 
mainly in hematopoietic cells. IL-4Rα, γc, and IL-13Rα1 bind JAK1, JAK3, and 
Tyk2, respectively (reviewed in Leonard & Lin, 2000). 
 
The IL-13Rα2 gene was first cloned in Caki-1 human renal carcinoma cell 
line (Caput et al., 1996) while the murine homologue m-IL-13Rα2 was detected in 
murine serum and urine (Zhang et al., 1997). Comparisons of the h-, m- and r-IL-
13Rα2 receptors show that they all have an N-terminal signal sequence, an N-
terminal fibronectin type III domain in the extracellular domain, four putative N-
glycosylation sites, four conserved cysteine residues and a conserved WSEWS motif 
(Wu & Low, 2002). The IL-13Rα2 amino acid sequence among rat, human and 
mouse shows that rat IL-13Rα2 protein is most closely related to that of mouse with 
91.2% homologous amino acid residues and the similarity between rat and human is 
about 54.2% at the amino acid sequence level (McKenzie et al., 1993b; Wu & Low, 
2002). 
  
 - 23 - 
IL-13 binds to IL-13Rα1 first with low affinity (Kd 4 nM) and then recruits 
IL-4Rα to the complex, generating a high affinity receptor (Kd ~50 pM). 
Heterodimerization of IL-13Rα1 with IL-4Rα causes activation of JAK, TYK2 and 
JAK1, constitutively associated with IL-13Rα1 and IL-4R, respectively, followed by 
activation of STAT6. STAT6 is a transcription factor usually considered critical for 
IL-13 signals. Activated JAKs results in tyrosine phosphorylation in IL-4Rα, leading 
to the recruitment of STAT6 to the receptor, which in turn phosphorylates STAT6. 
The association of STAT6 with tyrosine-phosphorylated regions of cytokine 
receptors occurs through its SH2 domain. Phosphorylated STAT6 molecules 
dimerize and activated STAT6 dimers translocate to the nucleus where it activates 
transcription of downstream genes (Figure 1.6). A study using peritoneal 
macrophages isolated from STAT6-deficient mice revealed that IL-13 does not 
decrease nitric oxide production (Takeda et al., 1996) which demonstrates an 
IL-13/STAT6 dependent pathway. 
 
Binding of ligands to the IL-4 type 1 receptor recruits IRS-1 and IRS-2 to 
phosphorylated Y497 of IL-4Rα leading to phosphorylation and activation of IRS-1 
and IRS-2 (Jiang et al., 2000). Y497 and the surrounding motif are found to be 
essential for recruitment of IRS-1 (Keegan et al., 1994). Phosphorylated IRS-1 and 
IRS-2 activate PI3K through an interaction with the p85α subunit (Jiang et al., 2000). 
The importance of PI3K in IL-13 signalling has been demonstrated in several studies. 
In the human colonic epithelial cell line HT-29 it was shown that IL-13 increases 
PtdIns(3,4)P2 and PtdIns(3,4,5)P3 as well as lipid kinase activity of p85 
immunoprecipitates. Both effects are inhibited by wortmannin and LY294002 
(Wright et al., 1997). Using another human colonic epithelium T84 cells it was 
demonstrated that changes in transepithelial resistance can be still observed after 
pretreatment with transcription factor decoys which inhibit STAT6 activation but not 
after pre-treatment with PI3K inhibitors wortmannin or LY294002. GRB-2 is a small 
SH2- and SH3 domain-containing adapter protein that associates with the 
mammalian SOS homolog to activate ras during growth factor signalling (Myers, Jr. 
et al., 1994; White, 1998). 
 
The other IL-13-binding unit, IL-13Rα2, binds IL-13, but not IL-4 with high 
affinity (Kd 50 pM). It was identified in both human and mice with 59% overall 
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identity of protein sequence (Donaldson et al., 1998). It thought that the IL-13Rα2 
receptor acts usually as a non-signalling “decoy” receptor in which its cytoplasmic 
tail is short and does not contain any obvious signalling motif, or that it may combine 
with IL-13Rα1 to facilitate the formation of a high affinity signalling complex 
(Wills-Karp & Chiaramonte, 2003; Arima et al., 2005). However, the cytoplasmic 
domains of m-IL-13Rα2 and m-IL-13Rα1 are dissimilar, and the cytoplasmic 
domains of both the m- and h-IL-13Rα2 are short. In addition co-expression of IL-
13Rα2 with IL-4Rα fails to induce a response to IL-13, and its co-expression with 
IL-4Rα/IL-13Rα1 fails to modify the binding affinity for IL-13. Furthermore, no box 
1 or box 2, needed for activation and association with JAK1 respectively, signalling 
motifs are present, although a putative consensus phosphorylation site at Y343PKM 
may interact with SH2-containing downstream signalling components (Kawakami et 
al., 2001b; Usacheva A et al., 2002). IL-13Rα2 was found to modulate IL-13 
signalling in the BEAS-2B cell line (Yasunaga et al., 2003). These findings together 
support the decoy receptor function of IL-13Rα2. 
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Figure 1.6 IL-13/IL-4 receptor structure and signal transduction pathways. The 
functional IL-13 receptor consists of a heterodimeric complex composed of the 
IL-4Rα and IL-13Rα1 chains. IL-13 and IL-4 can induce heterodimerization of the 
IL-4Rα and IL-13Rα1 chains, and dimerization of both chains induces 
phosphorylation and activation of Janus kinases (JAK). Activated JAK 
phosphorylates tyrosine residues of the IL-4Rα chain. Signal transducers and 
activators of transcription 6 (STAT6) are attached with phosphorylated tyrosine. 
Phosphorylated STAT6 proteins dimerize and translocate to the nucleus where they 
bind to specific DNA sequences. IL-4 can also signal through a receptor complex 
composed of the IL-4Rα and the common γ chain. The IL-13Rα2 chain binds only 
IL-13, not IL-4, with high affinity. Insulin receptor substrate (IRS) and STAT6 are 
attached with phosphorylated tyrosine via Src homology domains and 
phosphorylated by JAK. Phosphorylated IRS1/2 is associated with several signalling 
molecules, such as phosphoinositide 3 kinase (PI3K), Grb2, and Shc that mediate 
downstream signals for growth and cell proliferation (adapted from Wills-Karp, 
2004). 
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1.4.4 Regulation of IL-13 signalling 
 
Regulators of IL-13 signalling pathway include many intracellular molecules 
for example SH2-containing phosphatases (SHP-1), suppressors of cytokine 
signalling (SOCS), and protein inhibitors of activated STAT (PIAS). SHP-1 is 
involved in the negative regulation of many cytokine receptors, for example 
erythropoietin, IL-2, IL-3, CSF, and IL-4Rα (reviewed in Hershey, 2003). Bone 
marrow-derived macrophages isolated from motheaten mice that express reduced 
levels of SHP-1 activity show enhanced activation of STAT6 after treatment with 
IL-4, implicating SHP-1 in the negative regulation of the IL-4/IL-13-activated JAK-
STAT pathway (Haque et al., 1998). SHP inhibitory mechanism(s) can be through 
binding to receptors, or SHP-1 can bind JAK2 directly (Klingmuller et al., 1995; 
Kashiwada et al., 2001). 
 
SOCS is another regulator of IL-13 signalling. SOCS genes are induced after 
cytokine stimulation and SOCS proteins form a negative feedback loop to inhibit 
cytokine signalling. SOCS-1 has been shown to bind and inhibit JAKs (Chen et al., 
2000) but this might not be true of all SOCS family members. In an OVA-induced 
asthma model using SOCS-5 transgenic mice, lung and BAL fliud eosinophilia, 
increased IL-5 and IL-13 in BAL fluid and enhanced AHR to methacholine were 
observed compared with wild-type mice (Ohshima et al., 2007). In human primary 
bronchial epithelial cell cultures, pretreatment with IFN-γ decreases IL-4–induced 
nuclear- and cytoplasmic phospho-STAT6, induces IL-13Rα2 mRNA expression and 
does not decrease mRNA for IL-4Rα or IL-13Rα1. All these previous findings were 
associated with increased mRNA for both SOCS-1 and SOCS-3 (Heller et al., 2004), 
and using the lung epithelial cell line A549, IL-4 and IL-13 were shown to induce 
SOCS-1 gene expression (Hebenstreit et al., 2003). 
 
Another important family of proteins involved in the regulation of the 
JAK/STAT pathway is PIAS. PIAS binds to phosphorylated STAT dimers and 
prevents them from binding DNA. It is thought that degradation and regulation of 
STAT6 involved in IL-13 signalling is via proteasomal degradation or 
dephosphorylation through specific phosphatase because no PIAS has been identified 
for STAT6 (Hershey, 2003). 
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1.4.5 IL-13 functions 
 
IL-13 effector functions include a diverse array of biological activities on 
wide varieties of cells mostly related to allergic disorders (Wynn, 2003). IL-13 
promotes proliferation of B-cell and induces class switching to IgE (D'Amato, 2003). 
It induces expression the low-affinity IgE receptor CD23 (FcεRII) and MHC class II 
(Defrance et al., 1994; Hart et al., 1999). IL-13 also enhances the expression of many 
integrin family molecules important in adhesion such as CD11b, CD11c and CD18 
(Oyoshi et al., 2008), but in a study using denderitic cells it was demonstrated that 
IL-13 does not enhance CD11b expression (D'Amico et al., 1998). IL-13 promotes 
eosinophil chemotaxis (Pope et al., 2001; Pope et al., 2005). The action of IL-13 on 
nonhematopoietic cells has been extensively studied especially in cells involved in 
allergic lung diseases (Lee et al., 2001; Laoukili et al., 2001; Akaiwa et al., 2001; 
Kawakami et al., 2001a; Kondo et al., 2002; Kuperman et al., 2002; Izuhara, 2003). 
However, the role of IL-13 as an anti-inflammatory mediator can be demonstrated in 
studies that show that IL-13 inhibits the production of prostaglandins and TNF-α and 
leukocyte accumulation after OVA stimulation (Endo et al., 1996; Watson et al., 
1999). 
 
IL-13 seems to play a critical role in the pathogenesis of asthma (Wills-Karp, 
2004). Several mechanisms have been suggested including isotype switching of 
B-cells to Ig-E synthesis, downregulation of production of pro-inflammatory 
cytokines (TNF-α and IL-1β), RANTES, IL-12, upregulation of expression of 
VCAM-1, increase in eosinophil survival, chemotaxis, activation of fibroblasts and 
stimulation of mucus production (Kips, 2001). Pulmonary expression of IL-13 
induces an asthma-like phenotype in mice, including a mononuclear and eosinophilic 
inflammatory response, mucus cell metaplasia, airway fibrosis, eotaxin production, 
airway obstruction, and nonspecific AHR (Zhu et al., 1999). In addition it enhances 
polarization of T lymphocytes to a Th2 phenotype (Levy et al., 1997; Hajoui et al., 
2004), and IL-13 may contribute to asthma via tissue remodelling (Kumar et al., 
2002), epithelial activation (Lordan et al., 2002), decreasing β2 adrenoceptor 
function (Laporte et al., 2001), and enhancing contractility of airway smooth muscle 
(Tliba et al., 2003).  
 
  
 - 28 - 
Although several Th2 cytokines have been implicated in antigen-induced 
AHR, IL-13 seems to play a pre-eminent role. Targeted deletion of IL-13 prevents 
expression of AHR in allergen-challenged mice, despite maintenance of elevated 
IL-4 and IL-5 release (Walter et al., 2001). IL-4 expression fails to elicit an asthma 
phenotype and both wild and IL-4 knock-out Balb/c mice display reduced airway 
eosinophilia without an effect on AHR, denoting that IL-4 plays a pivotal role in 
eosinophilic inflammation, but not AHR (Cohn et al., 1998). Likewise, neutralization 
of IL-13 using IL-13 receptor constructs or antibodies reduces AHR without 
influencing IL-5 levels (Grunig et al., 1999; Eum et al., 2005). The exact 
mechanisms by which IL-13 induces airway obstruction or AHR are currently 
unknown. Several lines of evidence suggest that IL-13 can induce AHR in the 
absence of inflammatory cells. Although IL-13 is able to direct the recruitment of 
inflammatory cells into the airways, they are likely not required for induction of 
AHR. IL-13 may induce AHR via direct effects on resident airway cells (Kuperman 
et al., 2002). 
 
A cytokine trap is a high affinity blocker consisting of fusions between the 
constant region of IgG and the extracellular domains of two distinct cytokine 
receptor components involved in cytokine binding. A trap containing IL-13Rα1 and 
IL-4R to block both IL-4 and IL-13 has been created and can be used to alleviate 
experimental asthma in animal models (Economides et al., 2003). Laporte and 
associates (2001) demonstrated that IL-13, but not IL-4, significantly reduces β 
adrenoceptor-induced relaxation of cell stiffness of human ASM cells through a 
MAP kinase-dependent pathway. Studies by Kuperman et al. (2002) also provide 
strong support for a central role of the airway epithelium in IL-13 induced AHR. 
Specifically, they showed that expression of STAT6 only in the airway epithelium 
reproduces the allergic phenotype including AHR and mucus hypersecretion. 
Interestingly, IL-13 transgenic mice expressing STAT6 only in the epithelium do not 
manifest eosinophilic inflammation suggesting that eosinophils are not required for 
the development of AHR and that signals from the epithelium are not sufficient to 
regulate eosinophil recruitment. Epithelial-derived mediators such as TGF-β may 
also contribute to increases in stiffness of the airway wall. Although the fibrotic 
changes induced via IL-13 stimulation of epithelium are likely important in chronic 
disease, Kuperman’s data suggest that IL-13-induced AHR is independent of fibrotic 
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changes in the airways and they also added that IL-13 is known to regulate the 
production of a number of secreted molecules that alter the contraction or relaxation 
of ASM cells. Whether IL-13 mediates AHR via these known actions or by as yet 
undescribed pathways, the epithelium clearly plays an important role in IL-13 
mediated AHR. It is probable that AHR arises via the combined actions of IL-13 on 
the epithelium and ASM.and IL-13 could contribute to AHR and eosinophilia in 
mouse asthma models independently of IL-4 (Wills-Karp et al., 1998; Grunig et al., 
1999). 
 
1.4.6 IL-13 genetic variants in asthma 
 
Genetic studies strongly support the role IL-13 genetic variants in the 
development of asthma. Commonly identified IL-13 variants associated with asthma 
are 1111C > T (The IL-13 -1055 TT genotype) (van der Pouw Kraan et al., 1999) 
and +2043G > A (R130Q) (van der Pouw Kraan et al., 1999; Howard et al., 2001). 
Sequencing of the IL-13 gene and its promoter from various groups originating from 
East and West Africa, Europe, China and South America demonstrated that R130Q is 
the only variant detected in these groups (Tarazona-Santos & Tishkoff, 2005). In 
vivo and in vitro studies of this variant indicated enhanced IL-13–dependent gene 
induction. Furthermore, BALB/c mice treated with R130Q IL-13 variant displayed 
increased AHR (Chen et al., 2004). It is concluded from these studies that allergic 
asthma and the R130Q polymorphism are associated with increase in the activity of 
IL-13. A 1111C > T variation is located in the IL-13 promoter region (van der Pouw 
Kraan et al., 1999), however the associations between -1111C > T and asthma-
related phenotypes may be independent of the R130Q polymorphism. It has also 
been demonstrated in primary bronchial fibroblasts isolated from non-smoker 
nonatopic asthmatic patients that binding of the R130Q variant to human IL-13Rα1 
is not significantly different from wild type binding, but binding to soluble h-IL-
13RILα2 is different (Andrews et al., 2007). The IL-13 α1 receptor subunit is 
involved in the control of IgE production. The promoter and coding region of IL-
13Rα1 located on chromosome Xq24 were screened in asthmatic Caucasian families 
but the two identified polymorphisms (281T>G and 1365A>G) were not associated 
with asthma susceptibility or severity (Konstantinidis et al., 2007). 
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1.5 Phosphoinositide 3-kinases (PI3K) 
 
PI3K family plays an important role in inflammatory lung diseases 
particularly asthma. PI3K control inflammatory cells growth, differentiation, 
survival, migration, proliferation, and mediator production (reviewed in Finan & 
Thomas, 2004; Medina-Tato et al. 2007; Ito et al. 2007). IL-13 binding to 
IL-13Rα1/IL-4αR can elicit airway hyperreactivity, independently of inflammation, 
mainly through the Janus kinase/STAT6 pathway (Yang et al., 2001). However, IL-
13 binding can also results in inducing intrinsic kinase activities that initiate 
intracellular signal transduction cascades including the PI3Ks (Ceponis et al., 2000; 
Hershey, 2003). 
 
The phosphoinositol cycle was uncovered in the 1950s by Lowell and Mabel 
Hokin (Hokin & Hokin, 1953). The Hokins discovered that phosphatidylinositol 
(PtdIns) could be sequentially phosphorylated on its myo-inositol ring to generate a 
phosphatidylinositol bisphosphate that was likely to be phosphatidylinositol 4,5-
bisphosphate (PtdIns(4,5)P2) and was thought to be a precursor to other lipid 
signalling molecules. It is now clear that PtdIns (4,5)P2 is widely recognized as a 
potent messenger itself, and a major mediator of biochemical activities and cellular 
functions (Heck et al., 2007). PtdIns(4,5)P2 directly regulates an array of protein 
interactions and cellular processes, including vesicular trafficking (Wenk & De, 
2004), secretion (Martin, 2001), cell motility /cytoskeletal assembly (Janmey, 1994; 
Yin & Janmey, 2003), ion channels (Suh & Hille, 2005; Delmas et al., 2005), and 
nuclear signalling pathways (Gonzales & Anderson, 2006). 
 
1.5.1 PI3K family 
 
Phosphoinositide 3-kinases (PI3K) are a family of related enzymes that are 
capable of phosphorylating the 3 position hydroxyl group of the inositol ring of 
phosphatidylinositol and the serine residues of certain proteins (Rameh & Cantley, 
1999). This family has been linked to an extraordinarily diverse group of cellular 
functions and disease states. The PI3K family plays a prominent role in various 
inflammatory conditions by controlling cell growth, differentiation, survival, 
proliferation, and cytokine production through its downstream components (Duan et 
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al., 2005). The PI3K family has been divided into three classes according to their 
structure and lipid substrate specificity (Table 1.5). As seen in Table 1.5, class I 
PI3K comprises four distinct protein species of approximately 110 kDa (p110α, 
p110β, p110γ and p110δ). Class I PI3K are largely cytosolic in resting cells, but 
upon stimulation are recruited to membranes via interactions with receptors or 
adaptor proteins. They are thought to function primarily at the plasma membrane, but 
there have been reports of class I PI3K associated with vesicular and nuclear 
membranes (Rameh & Cantley, 1999; Katso et al., 2001). The class I family is 
further subdivided into two groups on the basis of their regulatory partners and 
mechanisms of activation. 
 
Table 1.5 Characteristics of the PI3K family (Ito et al., 2007) 
PI3K 
Family 
Isoforms Catalytic 
Molecule 
Regulatory 
Molecule 
In vitro Substrate Distribution 
Ia PI3Kα 
PI3Kβ 
PI3Kδ 
p110α 
p110β 
p110δ 
p85 α, p85 β 
p55γ 
p85α, p85β 
PtdIns 
PtdIns(4)P 
PtdIns(4,5)P2 
Ubiquitous 
Ubiquitous 
Whole blood, 
thymus 
Ib PI3Kγ p110γ p101 
p84/p87
FIKAP
 
PtdIns(4,5)P2 Whole blood, 
thymus 
II  C2α 
C2β 
C2γ 
Clathrin 
Clathrin 
Clathrin 
PtdIns,PtdIns(4)P, 
PtdIns 
PtdIns 
Widely expressed 
Widely expressed 
Prostate, Liver, 
Breast 
III  Vps34p Vps15p (p150) 
Beclin 1 
PtdIns Ubiquitous 
Constitutive 
 
 
Class I PI3K has been widely reported in the literature. Upon activation, class 
I PI3K converts PtdIns(4,5)P2 into PtdIns(3,4,5)P3, a ubiquitous second messenger 
(Figure 1.7). PtdIns(3,4,5)P3 then acts as a targeting site for downstream signalling 
molecules, such as protein serine/threonine kinases (including protein kinase B/Akt). 
This class is further divided into class IA and class IB PI3K. Structurally, PI3K IA 
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exists as heterodimeric complexes in which a catalytic p110 subunit (α, β or δ) is in 
association with particular regulatory subunits (designated p85α, p55α, p50α, p85β 
or p55γ). The first three regulatory subunits are all splice variants of the same gene 
(Pik3r1), the other two being expressed by other genes (Pik3r2 and Pik3r3). The 
most highly expressed regulatory subunit is p85α. All three catalytic subunits are 
expressed by separate genes (Pik3ca, Pik3cb and Pik3cd for p110α, p110β and 
p110δ, respectively). p110α and p110β isoforms are ubiquitously expressed, and 
genetic knockout leads to early embryonic death. Expression of the p110δ was 
considered to be restricted to the hematopoietic systems, and mice lacking expression 
of PI3Kδ do not show any overt adverse phenotype. PI3K IA signals downstream of 
receptor tyrosine kinase and Ras while the single class PI3K Ib consists of the p110γ 
catalytic subunit complexed to the p101 regulatory subunit and signals downstream 
of GPCRs and Ras. GPCR can bind a diverse array of peptides and non peptide 
ligands leading to activation of heterotrimeric Gαβγ protein to exchange the GDP 
molecule bound to the Gα subunit for GTP which leads to the dissociation of the 
GTP-bound Gα subunits from the Gβγ subunits. Free Gβγ subunit binds and activates 
p110γ which is stimulated by the regulatory subunit, p101 (Stephens et al., 1997; 
Krugmann et al., 1999). Class Ib PI3K differs from other class Ia members because 
they are activated by βγ subunits of GPCR. βγ subunits of GPCR could activate 
p110γ either directly (Stoyanov et al., 1995) or through the binding of regulatory 
p101 subunit to βγ subunits (Stephens et al., 1997). Class Ib PI3K is abundant in 
leukocytes and involved in immune system regulation. Gene deletion of Pik3cg 
responsible for p110γ protein expression displayed different phenotypes i.e lack of 
neutrophils and macrophages recruitment and reduced ability to produce superoxide 
production needed for chemoattraction (Li et al., 2000), colorectal cancer (Sasaki et 
al., 2000). In a study conducted in neutrophils isolated from mice lacking p110γ or 
p101 or expressing p110γ
DASAA/DASAA
 the migration was reduced, and peritoneal 
neutrophil migration was reduced in vivo implicating the associated role of βγ 
subunits, p101 and Ras in the regulation of PI3Kγ in immune function (Suire et al., 
2006). 
 
Class II PI3K predominantly use PtdIns and PtdIns(4)P substrates (Table 1.5). 
They are mainly associated with the phospholipid membranes and are present in the 
endoplasmic reticulum and Golgi apparatus (Domin et al., 1997). The class II enzymes 
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differ significantly from the class I enzymes in their mode of regulation and substrate 
preference. Three mammalian isoforms, PI3KC2α, PI3KC2β, PI3KC2γ, and one 
Drosophilia homolog are known. They are larger proteins, with a molecular weight of 
170 kDa, characterized by the presence of a C-terminal C2 domain which is sufficient 
and necessary for recruitment of PI3KC2α and PI3KC2β (Arcaro et al., 2000). 
Deletion of this domain increases the catalytic activity of PI3KC2β implicating its 
negative regulatory role on the catalytic activity of the enzyme (Arcaro et al., 1998). 
PI3KC2α and PI3KC2β are widely distributed while PI3KC2γ is less distributed (Ito et 
al., 2007). Both isoforms can function downstream of several receptors including 
tyrosine kinases, integrin receptors and cytokine receptors (Turner et al., 1998; Brown 
et al., 1999), however, a precise function of this class is unclear. 
 
Class III PI3K is the homolog of the yeast vesicular-protein-sorting protein 
Vps34p (Schu et al., 1993). Both the catalytic subunit, Vps34p and the serine 
threonine protein kinase, p150, are important for targeting the Vps34p to membranes. 
The major cellular function of the class III PI3Ks is in intracellular trafficking (Katso 
et al., 2001). Class III PI3K is reported to be involved in macroautophagy, which is a 
multistep process responsible for the degradation of long-lived proteins and organelle 
renewal, and starts with the formation of an autophagosome. This pathway is 
important in the maintenance of cell function during periods of nutrient deprivation. 
Class III PI3K uses only membrane PtdIns as a substrate and generates PtdIns(3)P. 
Cellular levels of PtdIns(3)P are usually maintained at constant levels, suggesting 
that the class III isoform does not respond to extracellular stimuli (Krymskaya et al., 
2001). 
 
1.5.2 PI3K signalling 
 
Termination of PI3K signalling by degradation of PtdIns(3,4,5)P3 can be 
mediated by at least two different types of phosphatases, namely Src homology 2-
containing inositol 5-phosphatase (SHIP) and phosphatase and tensin homolog 
deleted on chromosome 10 protein (PTEN) (Koyasu, 2003) (Figure 1.7). PTEN 
removes the 3-phosphate of PtdIns(3,4,5)P3 and, thus, directly counteracts all types 
of PI3K by catalyzing the opposite reaction. It was reported that the PTEN knockout 
mice is embryonically lethal and PTEN plays a pivotal role in Th2-mediated airway 
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inflammation and airway responsiveness (Kwak et al., 2003). In addition, PTEN 
overexpression reduced airway hyperresponsivenss and vascular endothelial growth 
factor expression in a murine model of asthma (Lee et al., 2006b). In contrast, SHIP 
removes the 5-phosphate from the inositol ring of PtdIns(3,4,5)P3 to generate 
PtdIns(3,4)P2, and this dephosphorylation of PtdIns(3,4,5)P3 by SHIP impairs 
downstream effects of PI3K. Although PtdIns(3,4)P2, the metabolic product of SHIP, 
may also mediate PI3K-dependent responses. SHIP knockout mice show increased 
mast cell degradation, B-cell activation, and increased chemotaxis. These mice also 
suffer from a lethal accumulation of macrophages and neutrophils in the lungs; 
therefore, persistent high levels of PtdIns(3,4,5)P3 and subsequent activation of its 
downstream effectors might lead to excessive inflammation (Rauh et al., 2003). 
 
 
Figure 1.7 PI3K signalling pathway. Activation of PI3K through tyrosine kinase or 
G-protein coupled receptors (GPCR). PtdIns(4,5)P2 converts into PtdIns(3,4,5)P3. 
Akt, PDK1, guanidine nucleotide factor (GEF), Rac/Rho kinase, Tec kinases and Btk 
are activated downstream of PI3K to carry out different cell functions e.g. cell 
growth, metabolism, angiogenesis, glucose uptake, survival, metabolism. PTEN 
dephosphorylates PtdIns(3,4,5)P3 and returns it to PtdIns(4,5)P2. SHIP can also 
dephosphorylate PtdIns(3,4,5)P3 to generate PtdIns(3,4)P2. 
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1.5.3 PI3K inhibitors 
 
The availability of two PI3K inhibitors, wortmannin, a naturally occurring 
metabolite of Penicillin funiculosum and an irreversible inhibitor, and LY294002, a 
reversible inhibitor derived from the broad-spectrum kinase inhibitor quercetin, has 
contributed greatly to the understanding of the biological role of PI3K and its 
effector proteins (Ward & Finan, 2003). However, wortmannin and LY294002 have 
no selectivity for individual PI3K isoforms, and have poor stability, solubility, 
toxicity, and absorption. In addition, wortmannin and LY294002 exhibit some 
compound-specific toxicity and possess off-target effects. For example wortmannin 
inhibits myosin light chain kinase and LY294002 inhibits casein kinase-2 (CK2). 
ICOS Corporation has described several p110δ inhibitors, including IC87114, a 
selective p110δ inhibitor, and this has been used to investigate the role of p110δ in 
allergic airway inflammation and hyperresponsiveness using a mouse asthma model 
(Lee et al., 2006a). IC87114 significantly reduced the serum levels of total 
immunoglobulin (IgE), OVA-specific IgE, leukotriene C4 release into the airspace, 
OVA-induced lung tissue eosinophilia, airway mucus production, and importantly 
OVA-induced increase in expression of IL-4, IL-5, IL-13, intercellular adhesion 
molecule-1, vascular cell adhesion molecule-1, CCL5, and CCL11. Furthermore, 
IC87114 significantly suppressed OVA-induced AHR to inhaled methacholine, and 
this corresponded with a reduction in OVA-induced Akt serine phosphorylation. 
These results are supported by the in vitro findings that p110δ is involved in B- and 
T-cell antigen receptor signalling and activation and allergen-IgE-induced mast cell 
degranulation. There is also evidence from studies in knockout mice that PI3Kp110δ 
is an important component in the pathogenesis of asthma (Nashed et al., 2007). PI3K 
inhibitors are illustrated in Figure 1.8 and Table 1.6. 
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Figure 1.8 Some PI3K inhibitors (Stokoe, 2005). 
 
Table 1.6 Specificity profile of some PI3K inhibitors (Marone et al., 2008) 
IC50 (µM)  
p110α 
p110β 
p110γ 
p110δ 
Name Corporation Comment 
200  
16  
61 
0.13 
IC87114/ ICOS Selective p110δ inhibitor  
Cell permeable 
 
1–3  
1–3 
2 
ND 
LY294002 Lilly Pan-PI3K inhibitor  
~ 0.004  
~ 0.004  
~ 0.004  
~ 0.004  
Wortmannin Wander AG, 
Lilly 
High nM  
Active against DNA-PK, mTOR, ATR, 
ATM, PI4K, MLCK 
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1.5.4 PI3K and inflammatory lung diseases 
 
PI3K may contribute to the pathogenesis of asthma by effecting the 
recruitment, activation, and apoptosis of inflammatory cells (Medina-Tato et al., 
2007). Administration of wortmannin or LY294002, two broad-spectrum inhibitors 
of PI3K, attenuates inflammation in murine models of allergic asthma (Ezeamuzie et 
al., 2001; Kwak et al., 2003). Intratracheal administration of LY294002 significantly 
inhibits most of the pathological characteristics of the mouse asthma model, 
including increased eosinophil counts and eotaxin, IL-5, and IL-13 levels in 
bronchoalveolar lavage fluid. Furthermore, lung tissue eosinophilia, airway mucus 
production, and AHR to inhaled methacholine are all significantly suppressed (Duan 
et al., 2005). Although these studies with broad-spectrum inhibitors provide good 
evidence for a role for PI3K in allergic airway dysfunction, these inhibitors do not 
distinguish among the four class I PI3K isoforms (Davies et al., 2000). The 
development of isoform selective inhibitors, as well as genetically modified mice, 
allow the characterization of the different roles of individual PI3K isoforms in 
airway disease. In addition to contributing to the AHR seen in asthma, airway 
smooth muscle cells are potentially linked with many other features of asthma, 
including the production of cytokines and inflammatory mediators involved in tissue 
remodelling. PI3K signalling and its putative roles in lung disease have been 
extensively reviewed (Vanhaesebroeck et al., 2001; Medina-Tato et al., 2007; Ito et 
al., 2007).  
 
1.6 Arginase and Arginine metabolism 
 
Arginase activity is regulated by Th2 cells and their cytokines (Munder et al., 
1999). A potential mechanism of IL-13-induced hyperresponsiveness is the induction 
of arginase, which can compete with nitric oxide synthase (NOS) for the common 
substrate arginine, and remove the modulatory effects of NO on airway smooth 
muscle contraction (Meurs et al., 2003). Furthermore, attenuation of IL-13-induced 
airway hyperresponsiveness was observed in vivo using RNA interference towards 
arginase I (Yang et al., 2006). 
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Figure 1.9 Arginine – its source and fates 
 
It was the discovery of the urea cycle by Krebs and Henseleit in 1928 that 
brought arginine to the focus of many studies. Arginine is classified as semiessential 
or conditionally essential amino acid because endogenous arginine synthesis cannot 
fully meet the needs of infants and growing children or adults under catabolic stress, 
trauma, surgery (Wakabayashi et al., 1994), kidney or small intestine dysfunction, 
inflammation, or sepsis (Morris, Jr., 2002). L-Arginine is a precursor in protein 
synthesis (Figure 1.9) and a substrate for a number of enzymes, including nitric oxide 
synthase (NOS), arginase, arginine:glycine aminotransferase and arginine 
decarboxylase, yielding nitric oxide (NO) and L-citrulline, L-ornithine and urea, 
creatine, and agmatine, respectively (Wu & Morris, 1998). 
 
1.6.1 Arginase isozymes 
 
 Arginase (also known as L-arginine ureahydrolase, or amidinohydrolase) 
(Jenkinson et al., 1996) has the highest potential activity of all the urea cycle enzymes 
in the liver which is responsible for a very low level of arginine liver extractability 
(0.007 mmol/g wet weight), whereas higher levels of arginine are detected in the gut 
(0.45), heart (0.13), stomach (0.13), erythrocyte (0.11), muscle (0.11), kidney (0.08) 
and lung (0.05) (White, 1985). L-Arginine is also the substrate for NOS, which 
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generates NO. Although the affinity of L-arginine is much higher for purified NOS 
(Km ~ 2–20 µM) than for arginase (Km ~ 1–5 mM), the maximum activity of arginase 
is more than 1,000 times that of NOS suggesting similar rates of substrate utilization 
at physiologic L-arginine concentrations (Durante et al., 2007).  
 
 Arginase is a 105 kDa homotrimeric enzyme that requires manganese for the 
hydrolysis of L-arginine to form L-ornithine and urea. It is widely distributed 
throughout different organisms including bacteria, yeasts, plants, invertebrates and 
vertebrates (Jenkinson et al., 1996; Ash, 2004). Arginase's active site is 
extraordinarily specific due to the high number of hydrogen bonds between the 
substrate and the enzyme, so modifying the substrate structure and/or stereochemistry 
will markedly lower the kinetic activity of the enzyme. Two genetically distinct 
isozymes, arginase I and II, have been identified with differing tissue distributions 
and subcellular locations in mammals (Wu & Morris, 1998). Arginase I and II are 
encoded by different genes which are located on chromosomes 6q23 and 14q24 
respectively (Sparkes et al., 1986; Gotoh et al., 1997). Both isozymes are 
constitutively expressed in the airways, particularly in the epithelium, endothelium, 
(myo) fibroblasts and alveolar macrophages (Que et al., 1998; Klasen et al., 2001; 
Lindemann & Racke, 2003) and share approximately 60% amino acid sequence 
homology. Arginase I is located predominantly in the liver cytoplasm, where it 
catalyzes the final step of the urea cycle and is responsible for the generation of ~10 
kg of urea per year by the average human adult. However, other studies report a wider 
distribution of arginase I including airway epithelial cells (Cederbaum et al., 2004; 
Bergeron et al., 2007). Arginase II is a mitochondrial enzyme being more widely 
distributed in the kidney, prostate, brain, skeletal muscle, and poorly expressed in the 
liver (Morris et al., 1997; Durante et al., 2007).  
 
1.6.2 Arginase regulation and inhibitors 
 
 The interplay between NO synthases and arginase pathways generated 
significant interest concerning their regulation through competitive pathways. Arginase 
activity can effectively inhibit NO-dependent processes for example smooth muscle 
tone by depleting the substrate pool (arginine) available for NO biosynthesis. In LPS 
activated macrophages cell line it was demonstrated that arginase II activity has been 
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increased together with induction of iNOS. These findings have been prevented by 
IFN-γ (Wang et al., 1995). In cultured rat LPS-treated peritoneal macrophages changes 
have been demonstrated in iNOS and arginase I mRNAs both in vivo and in vitro but 
not in arginase II-mRNA. Moreover, in primary murine bone marrow-derived 
macrophages arginase activity was increased by Th2 cytokines i.e. IL-4 and IL-10 and 
PGE2, while the Th1 cytokine IFN-γ induces NO synthesis in these cells suggesting a 
Th1/Th2cytokines-dependent cytokines regulatory role of arginase/NO synthesis by 
intracellular substrate depletion (Corraliza et al., 1995).  
 
 Arginase I is induced in rat aortic smooth muscle cells by IL-4 associated with 
increased cell proliferation and an increase in polyamine (spermidine and spermine) 
production after 24 h incubation (Ignarro et al., 2001). Intimal hyperplasia was detected 
in premenopausal human uterine arteries with enhanced arginase activity in both 
endothelial cells and the smooth muscle layer, and impaired cyclic GMP production in 
endothelial cells, which suggests a role of arginase in vascular remodelling (Loyaga-
Rendon et al., 2005). Different regulators of arginases are shown in Table 1.7. N-
Hydroxy-L-arginine an intermediate of NO biosynthesis is an arginase inhibitor; 
however, 2(S)-amino-6-boronohexanoic acid and (S)-2-boronoethyl-L-Cysteine-HCl 
(Figure 1.10), which are boronic acid derivatives, are not inhibitors of NOS. It is 
possible that these synthetic boronic acid-based arginine analogues inhibit arginase 
leading to increased arginine availability for NOS (Colleluori & Ash, 2001; Durante et 
al., 2007). In addition, the arginase product L-ornithine acts as a competitive inhibitor 
of arginase activity and also inhibits cellular L-arginine transport (Messeri et al., 2000; 
Cox et al., 2001). 
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         Figure 1.10 Structure of some arginase inhibitors. (Christianson, 2005) 
         NOHA:  N-Hydroxy-L-arginine, nor-NOHA:  N-Hydroxy-nor-L-arginine, 
         ABH:  2(S)-amino-6-boronohexanoic acid, 
         BEC:  (S)-2-boronoethyl-L-cysteine-HCl  
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Table 1.7 Regulation of arginase I and II  
Arginase regulator Model Reference(s) 
IL-4, IL-10, PGE2 Murine macrophages Modolell et al., 1995; Corraliza et al., 1995; 
 Munder et al., 1999  
IL-4, IL-13 Rat airway fibroblasts 
Murine macrophages  
Dendritic cells 
Munder et al., 1999; Lindemann & Racke,  
2003; Barksdale et al., 2004 
TGF-β  Rat peritoneal macrophages 
Murine macrophages  
Dendritic cells 
Boutard et al., 1995 
PDE inhibitors Alveolar macrophages 
RAW 264.7 cells 
Hammermann et al., 2000; Erdely et al., 2006 
Oxygen tension Rat peritoneal macrophages 
Murine macrophage cell lines 
Louis et al., 1998 
Cigarette smoke Asthmatic subjects 
Airway epithelial cells 
Smooth muscle  
BEAS-2B cell line 
Bergeron et al., 2007 
 
1.6.3 Arginase and asthma  
 
 Changes in L-arginine homeostasis in the airways may contribute to key 
features of allergic asthma, such as AHR, inflammation and remodelling of the 
airway wall (de Gouw et al., 1999; Takemoto et al., 2007; Maarsingh et al., 2008b). 
L-arginine is uptaken intracellularly via specific cationic amino acids transporters 
(CAT) (reviewed in White, 1985). Arginases transform arginine into ornithine, which 
gives rise to polyamines and proline (Figure 1.11). Polyamines are essential for cell 
proliferation and differentiation demonstrated by the failure of Chinese hamster ovary 
(CHO) cell line, deficient in arginase, to proliferate unless provided with polyamines 
i.e. putrescine, spermidine or spermine (Holtta & Pohjanpelto, 1982). Overexpression 
of ornithine decarboxylase, a rate-limiting enzyme in polyamine biosynthesis, in 
fibroblasts results in increased expression of genes implicated in cell proliferation by 
promoting histone acetyltransferase activity and chromatin hyperacetylation (Hobbs 
& Gilmour, 2000). 
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 The role of proline in collagen formation, which might underlies subepithelial 
fibrosis seen in asthma, was demonstrated as collagen I mRNA, arginase I and II 
mRNA are induced in a mouse model of bleomycin-induced lung fibrosis (Endo et 
al., 2003). Arginine is also a substrate for NOS, which generates NO, an essential 
regulator of airway smooth muscle tone (reviewed in Fischer et al., 2002). The NOS 
and arginase pathways, through substrate competition, can modulate each other. Th2 
cytokines induce arginase expression (Munder et al., 1999; Yang et al., 2006). 
Increased expression of arginase I subjected to intratracheal adminstration of IL-13 
correlates with AHR and mucus overproduction in OVA-sensitised as well as wild-
type mice (Yang et al., 2006). Overexpression of arginase I in lung epithelial cells 
increases basal and cytokine-induced NF-κB activity and is associated with reduced 
NO production and decreased S-nitrosylation of p50 (Ckless et al., 2007). Lung 
inflammation in the form of eosinophilia, together with up-regulation of eotaxin-1 
and IL-4 is detected in L-arginine transporter (CAT-2) knockout mice and NO 
production by activated alveolar macrophages is diminished in these animals 
(Rothenberg et al., 2006). 
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Figure 1.11 Metabolic fate of arginine in health and allergic asthma. L-Arginine is 
transported by specific cationic amino acid transporters (CAT) and can be 
metabolized by constitutive nitric oxide (cNOS) and arginase. The bioavailability of 
L-Arg determines the production of bronchodilating NO that regulates airway 
function. L-Arg bioavailability to NOS is also regulated by substrate competition. 
Arginase converts L-Arg into L-ornithine and urea. L-Orn is the precursor of 
polyamines (putrescine, spermidine and spermine) by ornithine decarboxylase (ODC) 
and L-proline by ornithine aminotransferase (OAT). Polyamines and L-Pro are 
involved in cell proliferation and collagen synthesis, respectively. L-Citrulline, the 
co-product in NO synthesis, can be recycled to L-Arg in two steps via 
argininosuccinate synthase (ASS) and argininosuccinate lyase (ASL) (Maarsingh et 
al., 2008a).  
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1.7 Gene therapy in lung diseases 
 
1.7.1 Introduction 
 
 Gene therapy is defined as the introduction of nucleic acids into cells for the 
purpose of altering the course of a medical condition or disease (Kay et al., 1997). 
The introduced nucleic acid can replace a defective or absent gene (Kolb et al., 2006). 
Indeed, transgenic, knockout and knockin mice can be the best available in vivo tool 
to study lung diseases models. However, generating these genetically engineered 
animals requires a significant amount of time, money, and effort (Dillon et al., 2005). 
The lung represents an ideal organ for gene therapy because of its accessibility for 
drug delivery through both airways and vasculature. Either route of administration, or 
even a combination of both, might be advantageous in the targeting of lung diseases. 
The transfer of genes via the airway results in gene manipulation mainly in lung 
epithelial cells with minimal systemic distribution and low systemic side effects. The 
IV route of gene therapy transduces predominantly endothelial cells and can access 
primary or metastatic lung tumors. The epithelial cells of the large and small airways 
are usually the targets for gene therapy while entry to the parenchyma is considered to 
be more difficult. CF and α1-antitrypsin deficiency, being a single gene defects 
diseases are the most amenable respiratory diseases for gene therapy. However, 
COPD, asthma, or interstitial lung diseases, being multifactorial diseases can be 
amenable to transient gene therapy by short-term overexpression of protective genes 
or the suppression of damaging genes (Kolb et al., 2006). Surfactant protein B (SP-B) 
deficiency, an autosomal recessive pulmonary disease in neonates, which leads to 
lethal respiratory failure within the first year of life, might require prenatal or fetal 
gene therapy (Korst et al., 1995). 
 
 CF has been considered the major lung disease for intervention by transfecting 
pulmonary cells with a functioning gene copy of the wild-type (normal) CFTR gene. 
The feasibility of gene replacement therapy for CF was first shown in experiments 
demonstrating that the introduction of normal CFTR gene into cultured CF airway 
epithelial cells restores normal chloride ion transport (Rich et al., 1990; Drumm et al., 
1990). As extensively reviewed in Kolb et al. (2006), several problems have been 
identified and interfer with the restoration of human CF gene. The ideal vector system 
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has not yet been developed, gene transfection has been achieved the levels of 
expression are short-lived. Mucous plugs and local infections render gene therapy to 
the superficial epithelium not within reach by the aerosols. Thus, better access by the 
vasculature and systemic vector application can be achieved (Kolb et al., 2006). 
 
 α1-Antitrypsin (α1 AT) deficiency is a second pulmonary disease with an 
underlying single gene defect and a target for gene therapy. α1- AT protein is a serum 
glycoprotein that is synthesized and secreted primarily from the liver, however its 
major site of action is the lower respiratory tract where its passive diffusion into the 
alveoli protect against neutrophil elastase-mediated proteolysis (Kueppers, 1973). 
Still short-lived expression and not high enough protein concentration delivered are 
problems facing gene therapy for those patients. Intratracheal administration of 
adenoviral vector encoding human α1 AT gene to rats resulted in the synthesis and 
secretion of human α1 AT, detected in the lung for at least 1week (Rosenfeld et al., 
1991). Adenovirus-vector induces inflammation, which means that repeated 
adminstration would not solve the problem of transient expression. An alternative 
vector, liposomes, were used in New Zealand white rabbits by either aerosol or 
intravenous route to deliver α1 AT cDNA, and resulted in local protein expression 
that last for 4 weeks without detected toxicity (Canonico et al., 1994).  
 
 Gene therapy is also being considered as a rational therapeutic option for the 
treatment of inflammatory diseases of the lung including asthma and COPD. In these 
cases, disease is not the result of a single genetic defect but may be consequence of 
multiple factors (Kolb et al., 2006). Canonico and coworkers have shown that the 
release of neutrophil chemoattractants from human airway epithelial cells exposed to 
human neutrophil elastase was prevented if the cells were transfected with the human 
α1 AT cDNA prior to elastase exposure. This suggests that the general anti-
inflammatory properties of antiproteases could be exploited for gene therapy in 
COPD (Canonico et al., 1996). The mainstay treatment of asthma is inhaled 
corticosteroids and bronchodilators but this does not hold for all cases. Asthmatic 
patients who receive high doses of systemic corticosteroids or those with 
corticosteroid-resistant asthma can benefit from gene therapy. Both intratracheal and 
intravenous IFN-γ gene delivery significantly inhibit AHR and airway eosinophilia in 
mice with OVA-induced AHR (Dow et al., 1999). In a similar study, IL-4Rα 
  
 - 47 - 
antagonist delivered via recombinant adeno-associated virus vector to the airways of 
mice reduces AHR and airway eosinophilia triggered by either m-IL-13 or m-IL-4 
(Zavorotinskaya et al., 2003). In addition, the pulmonary circulation could be used to 
access primary or metastatic lung tumors (Kolb et al., 2006). Hence, there are many 
lung disease states for which it might prove beneficial to deliver genes.  
 
1.7.2 Vehicles of gene transfer 
 
Table 1.8 Gene transfer vehicles taken from Kay et al., 1997 and Kolb et al., 2006 
Vector  Advantages Disadvantages   
Viral 
  Retrovirus 
 
Integration into host DNA 
All viral genes removed 
Relatively safe 
 
Transduction requires cell 
division  
Semi-random integration 
Relatively low titer  
  Adenovirus  Higher titer  
Efficient transduction of 
nondividing cells in vitro and 
in vivo 
Toxicity 
Immunological response  
  Adeno-associated 
virus  
 
All viral genes removed  
Safe  
Transduction of nondividing 
cells  
Stable expression  
Small genome limits size of 
foreign DNA  
Labor-intensive production  
Status of genome not fully 
elucidated  
 Parainfluenza virus 1 
Sendai virus  
RNA genome  
Targets apical surface of 
epithelium 
Replicates in cytoplasm 
Particles are inflammatory, 
induce immunity 
Nonviral 
• Liposomes  
 
Simple, inexpensive, safe 
Nonimmunogenic 
 
Inefficient gene transfer into 
the nucleus   
Lack of persistence of DNA  
• Naked DNA  Simple, nonimmunogenic, 
inexpensive, safe 
Inefficient transduction 
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 Viral and nonviral vectors are used for gene transfer (Table 1.8). Gene transfer 
can be attempted by two approaches: an ex vivo approach where cells are removed, 
genetically modified, and transplanted back into the same recipient, and in vivo 
therapy adopted by direct transfer of genetic materials (Kay et al., 1997). 
 
1.7.3 RNA interference  
 
DNA has been used for most transfections. It is more stable than RNA and 
can be produced in large quantities. The half-life of stable mRNA species in the 
mammalian cell is less than 24 hours, while unintegrated DNA can persist and 
function in nondividing cells for months. However, a potentially significant 
advantage of using RNA-encoded antigens is safety. Although RNA transfection 
results in low level of intact protein expression it may offer a significant advantage to 
decrease expected immune response (Mitchell & Nair, 2000). 
 
 RNAi is the process of sequence-specific, post-transcriptional gene silencing 
in animals and plants, initiated by double-stranded RNA (dsRNA) that is homologous 
in sequence to the silenced gene (Fire, 1999). RNAi has become a widely used 
simple, cheap, and powerful experimental tool to explore the function of mammalian 
genes, both in vitro and in vivo. RNAi can be induced by the introduction of synthetic 
double-stranded small interfering RNAs (siRNAs) 21–23 base pairs (bp) in length or 
by plasmid and viral vector systems that express double-stranded short hairpin RNAs 
(shRNAs) that are subsequently processed to siRNAs by the cellular machinery to 
specifically target a gene's product, resulting in null or hypomorphic phenotypes. 
RNAi is considered as an important tool not only for functional studies, but also to 
silence disease-associated genes in tissue culture, animal models and the development 
of RNAi-based reagents for clinical applications. The identification of most of the 
genes in the human genome generated large number of potential new drug targets that 
await discovery. However, the main limitation is to know which gene products are 
functionally involved in the pathology of a disease (target validation) (Dillon et al., 
2005; Leung & Whittaker, 2005). 
 
 RNAi was first observed by plant biologists in the late 1980s, but its 
molecular mechanism remained unclear until the paper in the late 1990s by Fire et al. 
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1998 (Fire et al., 1998). The mechanism of RNAi is shown in Figure 1.12. Briefly, 
long double-stranded RNAs (dsRNAs; typically >200 nt) is processed to a 20-25 bp 
nucleotide siRNAs by an RNase III-like enzyme called Dicer (initiation step). Then, 
the siRNAs assemble into endoribonuclease-containing complexes known as RNA-
induced silencing complex (RISC), unwinding in the process. The siRNA strands 
subsequently guide the RISCs to complementary RNA molecules, where they cleave 
and destroy the cognate RNA (effector step). Cleavage of cognate RNA takes place 
near the middle of the region bound by the siRNA strand. In mammalian cells, 
introduction of long dsRNA (>30 nt) initiates a potent antiviral response, exemplified 
by nonspecific inhibition of protein synthesis and RNA degradation. This mammalian 
antiviral response can be bypassed by the introduction or expression of siRNAs 
(Dykxhoorn et al., 2003). 
 
 
 
Figure 1.12 The mechanism of RNA interference. Long double-stranded RNAs 
(dsRNAs) is cleaved to a 20-25 bp nucleotide siRNAs by Dicer. siRNAs assemble 
into RNA-induced silencing complex (RISC). The siRNA strands guide the RISCs to 
complementary mRNA molecules to cleave the mRNA.  
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The functional role of individual genes using siRNA has been commonly 
used in different diseases as extensively reviewed in Dillon et al. (2005). The use of 
inhaled antisense oligonucleotides (Tanaka & Nyce, 2001) suggest that the delivery 
of siRNA molecules to the lung might be a viable approach to the treatment of 
respiratory diseases such as cystic fibrosis, asthma and COPD. Cell-specific targeting 
of siRNA is an important issue to consider during therapy. RNAi silencing 
specifically in rat lung alveolar epithelial type II cells using adenoviral vectors 
containing various shRNAs under the control of the surfactant protein C promoter 
was demonstrated both in vitro and in vivo (Gou et al., 2004). Also, using siRNA to 
knock down TGF-α production diminishes mucus production in NCI-H292 human 
airway epithelial cells (Shao et al., 2004).  
 
Currently, developing clinical applications of siRNA in various human 
diseases is in the spot-light of many pharmaceutical companies (Howard, 2003; 
Leung & Whittaker, 2005). RNAi has the advantages of easy synthesis, low 
production costs (compared with protein or antibody therapies), and delivery to a 
wide range of organs. However, blood stability, delivery, poor intracellular uptake, 
and nonspecific immune stimulation still present significant challenges for the 
development of RNAi reagents for clinical use (Leung & Whittaker, 2005).  
 
Off-target effects, defined as siRNAs effects on non-target genes causing change 
in their expression (Dillon et al., 2005), can be an obstacle for usage of siRNA. Off-
target effects depend on the concentration of siRNAs and similarities between the 
non-target genes and the 5' ends of siRNAs (Jackson et al., 2003; Persengiev et al., 
2004). A second major limitation is an antiviral interferon response and apoptosis, 
however dsRNAs that are less than 30 bases in length are able to silence gene 
expression in a specific manner without triggering the interferon response (Elbashir 
et al., 2001). Still some studies demonstrated that short dsRNAs trigger an interferon 
response (Bridge et al., 2003; Sledz et al., 2003). RNAi may act on dendritic cells in 
vivo by activation of Toll-like receptors, leading to unwanted immune response 
(Maguire et al., 2008). Application of siRNA molecules as therapeutics from cells to 
man is still challenging. Perhaps the most significant limitation is the safe, efficient 
and effective delivery of RNAi reagents. 
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1.7.4 Recent clinical gene therapy research 
 
Results of subretinal injections of recombinant adeno-associated virus vector 
contains the human RPE65 coding retinal pigment epithelial (RPE65) for inherited 
blindness show sight improvement, a landmark for gene therapy technology 
(Bainbridge et al., 2008). Researchers at the National Cancer Institute (NCI), part of 
the National Institutes of Health, successfully re-engineer lymphocytes, to target 
advanced metastatic melanoma (Rosenberg et al., 2008). Another progress in gene 
therapy technology to evaluate the safety, and efficacy of repeated intratumoral 
injections of adenovirus-IL-2 (TG1024) in patients with advanced solid tumors and 
melanoma, only injection site reactions and flu-like syndrome were noticed in those 
patients (Dummer et al., 2008). However, leukaemia due to inadvertent vector-
mediated upregulation of host cellular oncogenes is recorded in two clinical studies 
of gene therapy (Hacein-Bey-Abina et al., 2003; Howe et al., 2008). Gene therapy 
for CF started in 1990 with the demonstration that ion conductance could be restored 
by giving CF cells a normal copy of the CFTR gene. The UK cystic fibrosis gene 
therapy consortium announced two clinical trials were completed in 2006/2007 to 
measure CFTR expression and function in patients to select the most effective 
methods to measure changes in the lung after gene therapy. One of these studies used 
BAL fluid from 39 CF children and 38 respiratory disease controls and the most 
discriminatory biomarker found had a mass of 5.163 kDa (Macgregor et al., 2008). 
 
1.8 Aims of the study 
 
This research is based on the finding that IL-13 is implicated as a key 
cytokine in the pathogenesis of allergy and asthma. Pulmonary expression of IL-13 
induces an asthma-like phenotype in mice. AHR is a key sign of asthma and 
underlies the spontaneous airflow limitation seen in asthma. AHR characterizes a 
complex interaction between resident and recruited inflammatory cells at sites of 
injury. However, growing evidence indicate the crucial role of different resident cells 
to mediate AHR. One aim of this study to use an in vitro isolated tracheal ring model 
to investigate the role of resident cells in IL-13-induced hyperresponsiveness. Also, 
which rodent species displays the most IL-13-induced hyperresponsiveness and the 
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effect of murine-, rat- and human-IL-13 on two commonly used animal model 
species i.e. mouse and rat. 
 
The mechanism(s) by which IL-13 induces hyperresponsiveness remains 
unclear. PI3K is known to play a role in inflammatory lung diseases; therefore it is 
an attractive target for the potential treatment of respiratory diseases. Furthermore, 
targeting specific PI3K isoforms that may be overexpressed or overactive may allow 
control for conventional drugs resistant cases. Another aim of this work to test the 
hypothesis that IL-13-induced hyperresponsiveness in isolated murine tracheal rings 
is regulated by PI3K. As mice lacking p110δ exhibit a high degree of normal 
development and growth, investigation of the role of p110δ can characterize the roles 
of this PI3K isoform in IL-13-induced hyperresponsiveness. The non-isoform-
selective inhibitors wortmannin and LY294002, or the selective inhibitor of p110δ, 
IC87114 will be studied. To investigate further evidence for the role of p110δ in IL-
13-induced hyperresponsiveness, tracheae from genetically–modified mice will be 
employed. The role of IL-13 in induction of arginase I as a potential mechanism of 
IL-13-induced hyperresponsiveness, with an assessment of the role of the epithelium, 
will be undertaken. Moreover, the possible link between PI3K and arginase I in IL-
13-induced hyperresponsiveness will be studied. 
 
The development of siRNA has facilitated a better understanding of the role 
that each member of PI3K family plays in the physiology and pathology of the 
respiratory system. A significant part of of this study to deliver siRNA to inhibit 
expression of determined target(s). For this purpose, the use of lipid based vectors for 
non-viral gene delivery or the employment of a reverse permeabilization technique in 
tracheal segments will be investigated. Determination of target(s) involved in IL-13-
enhanced hyperresponsiveness will help in the development of new therapeutic 
strategies for the effective treatment of inflammatory lung diseases such as asthma. 
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Chapter Two 
 
Methods and Materials 
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2.1 Organ bath experiments 
 
2.1.1 Animals 
 
Male CD1 mice (25-30 g, 8-10 week-old) and Wistar rats (200-300 g, 8 week-
old), were used in this study (University of Bath). In another set of experiments, 
tissues from genetically modified mice (male or female, 6-8 week-old) expressing a 
catalytically inactive p110 isoform of PI3K (p110δ
D910A/D910A
) and matched DO11.10 
control mice (Okkenhaug et al., 2002) were kindly provided by Dr. K. Okkenhaug 
(Babraham Institute, Cambridge, UK). Breeding and maintenance of animals was 
according to UK Home Office regulations and guidelines for the care and welfare of 
laboratory animals, and fed with standard rodent chow and water ad libitum. 
 
2.1.2 Tissue preparation and tracheal organ culture 
 
Animals were killed by exposure to a rising concentration of CO2. The thorax 
and ventral surface of the neck were opened by a mid-line longitudinal incision, and 
the trachea from the larynx to the carina rapidly removed. The oesophagus was 
carefully separated, and the trachea cleared of loose connective tissue and divided 
into 2-4 segments according to the subsequent experiment. Tissues were placed 
individually into multiwell plates containing Dulbecco’s modified Eagle’s medium 
(DMEM) containing 25 mM D-glucose, 1 mM sodium pyruvate, 100 U/ml penicillin, 
100 µg/ml streptomycin, 4 mM L-glutamine, 2.5 µg/ml Fungizone, and 0.1% w/v 
bovine serum albumin (BSA). Tracheal segments were incubated at 37 °C in a 
humidified 5% CO2 gassed incubator in the presence or absence (control) of IL-13. 
The effect of PI3K inhibition was assessed by treating murine tracheal rings with 
wortmannin (100 nM), LY294002 (10 µM), or IC87114 (10 µM) 30 min before IL-13 
addition. These inhibitor concentrations were chosen based on their in vitro potencies  
Tracheal rings treated with dimethyl sulfoxide (DMSO) [0.05% (v/v)] served as 
vehicle controls in inhibitor experiments. In another set of experiments, tracheal 
segments were incubated in the presence or absence of IL-13 or an arginase inhibitor, 
L-norvaline (10 mM), for 24 h. 
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2.1.3 Isometric recording of airway smooth muscle 
 
Trachea smooth muscle reactivity was assessed using temperature-controlled 
(37 °C) organ baths containing Krebs-Henseleit buffer solution (see section 9.1) 
continuously bubbled with 5% CO2 and 95% O2. Tracheal segments were mounted in 
organ baths between two metal hooks. One hook was connected via a loop of thread 
to a K30 force displacement transducer (Hugo Sachs Elektronik, March, Germany); 
the other hook connected to the base of displacement rod in order to be able to change 
the tension of the mounted segments. Murine segments were suspended under 
approximately 5 mN resting tension for continuous recording of isometric tension 
while rat tracheal segments suspended using 10 mN tension. Care was taken to mount 
the tracheal segments so that the membranous part of the rings was not in contact 
with the hook. The tissues were equilibrated in the organ bath for 1 h, during which 
time each tissue exposed to 60 mM KCl three times with 15 min resting period in 
between each addition. At the plateau of KCl induced-contraction, each preparation 
was washed with Krebs-Henseleit solution until active tension returned to baseline. 
Isometric contractile responses were recorded with a MacLab/4e and Quad bridge 
amplifier linked to a PC running Chart 4 software for Windows (ADInstruments Ltd, 
Chalgrove, Oxfordshire, UK). Cumulative concentration-response curves to carbachol 
(10
-8
 to 10
-5
 M) or KCl (10 to 100 mM) were determined. Relaxation response curves 
after contracting the tissue with a submaximal dose of CCh were recorded using 
isoprenaline (10
-8
 to 10
-5
 M).  
 
2.1.4 Epithelial removal 
 
Mechanical removal of the airway epithelial layer was achieved by gently 
rubbing the luminal surface of the murine tracheal segments either before or after 
incubation with m-IL-13 or media alone (control). Epithelium denudation was 
confirmed by histological examination of the segments (see section 2.4.1 & 2.4.2). 
 
 
 
 
 
  
 - 56 - 
2.2 Cell lines 
 
2.2.1 Airway epithelial cell lines 
 
9HTEo-, A549 and BEAS-2B were used in this study. 9HTEo-
 
are SV40 
transformed human tracheal epithelial cells which retain phenotypic characteristics of 
epithelial cells such as chloride ion transport, keratin, microvilli, and tight junctions 
(Gruenert et al., 1988). A549 are human alveolar epithelial cells (Giard et al., 1973) 
obtained from the European Collection of animal cell culture while BEAS-2B are 
adeno 12 SV40-transformed human bronchial epithelial cells (Reddel et al., 1988) 
obtained from American Tissue Culture Collection. 
 
2.2.2 Thawing cell lines 
 
Flasks used for BEAS-2B cells were precoated for at least 4 h at 37 °C with a 
mixture of 0.01 mg/ml fibronectin, 0.03 mg/ml bovine collagen type I and 0.01 
mg/ml BSA dissolved in basal LHC medium. The fibronectin, collagen and BSA 
were gently mixed in basal LHC medium, not vortexed. The bottom half of the 
cryotube containing the cell line was placed in a 37 °C water bath until the cells were 
defrosted. Immediately afterwards, the cryotube was wiped with 70% ethanol and all 
operations from this point were carried out under aseptic conditions. The contents of 
the cryotube were transferred dropwise into a sterile 15 ml plastic tube containing 10 
ml prewarmed media. The tube was then centrifuged for 10 min at 20 ºC. The 
supernatant was discarded and cells pellet thoroughly resuspended in fresh warmed 
media. Cell viability and number were checked using a Neubauer haemocytometer 
after mixing 1:1 with 0.4% trypan blue. More than 90% of the cells were viable. Cells 
were then seeded into 75 cm
2
 tissue culture flasks containing 15 ml warm media and 
maintained at 37 °C in a 5% CO2 humidified incubator. On the following day the 
media were replaced with fresh warm media and replaced again every 2 days. Cells 
reached 60-80% confluence after 4-5 days (see section 9.2 for each cell line cultured 
conditions).  
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2.2.3 Subculture  
 
After reaching 60-80 % confluence, media were removed and the cells washed 
twice with warm sterile D-PBS to get rid of any serum. The flasks were incubated 
with 3 ml of prewarmed trypsin-EDTA for 3-10 min at 37 °C, removed from the 
incubator and 10 ml prewarmed media added to inhibit the effect of the trypsin. The 
side of the flask was tapped to dislodge any remaining adherent cells. The dislodged 
cells were centrifuged for 5 min at 20 °C for subsequent cell counting and seeding in 
75 cm
2
 tissue culture flasks for further subculture or into 12-, 96-well plates or 35 mm 
diameter petri dish (see section 9.2 for each cell line cultured conditions). 
 
2.2.4 Freezing cell lines  
 
Cells were grown to 50-60% confluence, dislodged by trypsinization and 
checked for viability and counted using trypan blue exclusion. Cells were 
resuspended at 2x10
6
 cells / ml of freezing media into sterile labelled cryotubes with 
the name of cell line, medium, date and passage number (see section 9.2). Cryotubes 
containing either 9HTEo- or A549 were gradually cooled in isopropyl alcohol at -80 
°C for 16 h, and stored into liquid nitrogen tanks while cryotubes containing BEAS-
2B cells were stored straightaway in liquid nitrogen vapour phase tanks. 
 
2.3. Histology 
 
2.3.1 Embedding and sectioning  
 
A plastic tube, to store the tissue-mounted disks, was placed into liquid nitrogen. A 
glass beaker was half filled with isopentane and placed in liquid nitrogen to allow the 
isopentane to cool. Isopentane turns white as it solidifies on the base of the beaker. 
Then enough Optimum Cutting Temperature (OCT) compound was added onto the 
surface of a cork disk for embedding the tissue. The cork disk was held in the cold 
isopentane for a few seconds or until it began to solidify and then removed from the 
isopentane. The solution was gently removed from around the tissue about to be 
frozen, the tracheal ring placed into the OCT and manipulated so that the lumen is 
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facing upward. Air bubbles were avoided and more OCT was added if necessary so 
that no bare areas were observed. The disk with sample was placed back into the 
isopentane and stored at -80 °C until use. The samples were sectioned using a cryostat 
(5030 Microtome, Bright Instruments company Ltd., Huntingdon, England) to obtain 
5 µm flat, thin, wrinkle-free, fully intact, frozen sections  bonded to Superfrost Plus 
microscopic slides (VWR International). 
 
2.3.2 Haematoxylin and eosin stain 
 
Slides were immersed in cold acetone (4 °C) for 5 min, and then rehydrated in 
tap water for 5 min. From this point onwards sections were not allowed to dry out. 
The slides were immersed in Harris Haematoxylin (HH, diluted 1 part HH to 3 parts 
water) for 5 min and shaken to remove the excess. Then they were immersed in 
running water for 5 min, immersed in acid/alcohol (IMS with 1% v/v HCl) for up to 
30 seconds and agitated gently to differentiate the stain. The slides were then rinsed 
in water for 5 min, immersed in eosin for 30 s, rinsed again in running water for 5 
min and excess water gently removed. Dehydration was then induced by immersing 
the slides in IMS for 1 min. Excess IMS was shaken off and the slides were immersed 
again in a second bath of IMS. This, and subsequent steps were carried out in a fume 
hood. Sections were then cleared by immersing in xylene for 1 min twice. The 
transfer of water to IMS and of IMS to xylene was avoided. Sections were mounted 
using DePeX mounting medium, the under-surface of the slides was cleaned using 
tissue soaked with xylene, and slides were allowed to dry for at least an hour before 
microscopic examination. 
 
2.3.3 Specimen preparation for immunohistochemistry 
 
Mice tracheae were dissected, treated with IL-13 with or without the inhibitors 
or the control vehicle, and fixed in 4% paraformaldehyde (PFA) for 24 h at 4 °C. 
After fixation, the tissue blocks were embedded in paraffin. The embedding of 
paraffin blocks were carried out using Leica TP1020 automatic tissue processor 
(Leica Microsystems) then cut into 5 µm sections using a microtome. Sections were 
then transferred onto Superfrost Plus microscopic slides, left overnight to dry to 
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remove any water that may be trapped under the section, and stored at 4 °C until 
microscopic examination.  
 
2.3.4 Preparation of 4% PFA for fixation 
 
PFA was prepared by the addition of 4 g of PFA into 65 ml of distilled water 
heated up to 60 °C. The solution was stirred, maintained at 60 °C on hot plate in the 
fume hood and then approximately 2-4 drops of 2 M NaOH were added. The solution 
was removed from the heater, 21 ml of 3X PBS added and the pH then adjusted to 7.2 
with 1 M aq. HCl. Deionized water was added to a final volume of 100 ml, the 
solution filtered and then stored at -20 °C for up to a month. 
 
2.4 Immunoblotting 
 
Immunoblot analysis is a technique of identifying specific proteins in a given 
sample of cell or tissue homogenate. It uses gel electrophoresis to separate denatured 
proteins according to their molecular weight. The proteins are then transferred to a 
nitrocellulose or polyvinylidene fluoride membrane, and detected using antibodies 
(primary antibodies) specific to the target protein. Afterwards, the membrane is 
exposed to another antibody known as secondary antibody which is commonly 
horseradish peroxidase-linked to catalyse a reaction that, in the presence of 
chemilumnescent reagents produces luminescence in proportion to the amount of 
protein and is detected using photosensitive film. 
 
2.4.1 Tissue lysis 
 
After 24 h incubation with or without IL-13 and/or inhibitors, tracheal rings 
were rapidly frozen and stored in liquid nitrogen until used. Then, they were broken 
down mechanically using PowerGen 125 homogenizer (Fisher Scientific Co., 
Loughborough, UK) in 200 µl cold lysis buffer (see section 9.3) per 6-8 pooled 
tracheal rings. Lysates were rotated at 4
o
C for 15 min to allow inhibition of proteases, 
centrifuged at 15,400g for 15 min at 4 °C, and the supernatant collected. 
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2.4.2 Quantification of protein 
 
Protein concentration was quantified using the Bradford assay (Bio-Rad 
Laboratories, Hercules, USA) (Bradford, 1976). BSA solution (1 mg/ml) was 
prepared and used to construct a standard curve at concentrations of 0-32 µg/ µl. 
Equal volumes (2 µl) of each lysate sample were added to 250 µl of Bio-Rad 
Bradford dye reagent (BioRad). Both the standard and lysate samples were carried 
out in triplicate using a 96-well microtitre plate. Protein concentration was measured 
at 595 nm with a microplate reader using Softmax Pro software (Molecular Devices, 
VERSAmax, U.S.A.).  
 
2.4.3 Sample preparation 
 
After determining protein concentrations, lysate samples were diluted with 
ice-cold lysis buffer to normalize the protein concentrations between the samples and 
100 µl of each diluted sample mixed with 25 µl of 5X sodium dodecyl sulphate 
sample buffer (see section 9.3) to give a final protein concentration of approximately 
1.5-2 µg/µl. The samples were then mixed, boiled at 100 °C for 5 min using Techne 
dri block DB 2A (Techne Cambridge Limited, Cambridge, UK), and transferred 
immediately into ice. At this point, the samples could be stored at -20 °C for 
subsequent Western immunoblotting.  
 
2.4.4 Gel electrophoresis 
 
One-dimensional polyacrylamide gels were employed which allows 
separation of proteins according to their molecular weight, thus smaller proteins 
migrate faster than proteins of higher molecular weight. The proteins of the samples 
were separated using Bio-Rad Mini Protean II system (Bio-Rad Labs. Hemel 
Hempstead, UK). The resolving and stacking recipe were prepared following the 
recipe described in section 9.4. The resolving gel was prepared at 10 % of acrylamide 
for all proteins studied. The resolving gel was pipetted between the assembled glass 
plates and overlaid with deionized to create a uniform surface. The resolving gel 
would polymerize after 40 min, the water was withdrawn and the stacking gel poured 
on top of the resolving gel. A gel comb (which formed the wells where prepared 
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samples and ladder were placed) was inserted into the stacking gel and the gel left to 
polymerize for another 20 min. After that, the comb was removed and the wells 
washed thoroughly with deionized water and then filled with running buffer (see 
section 9.3). With the use of a micropipette, 20 µl (~30 µg of protein per lane) of the 
samples were loaded into the bottom of the wells. One lane was reserved for a marker 
(5-10 µl), a commercially available mixture of proteins having defined molecular 
weights. The gels were run at 20 °C at 80 V until the bromophenol blue tracking 
contained in the samples entered the resolving gel, and then the voltage increased to 
180 V. The gels were then run until the desired separation of bands in reference to the 
molecular weight markers was achieved, then gels were removed from the 
electrophoresis equipment and placed into semi-dry transfer buffer (see section 9.3). 
 
2.4.5 Transfer of proteins to nitrocellulose membrane  
 
In order to make the proteins accessible to antibody detection, they were 
moved from within the gel onto a membrane made of nitrocellulose using the graphite 
electrode of transfer apparatus (Transblot SD cell; Bio-Rad Laboratories, USA). As 
shown in Figure 2.1, four pieces of Whatman paper were placed on the bottom 
electrode followed by the nitrocellulose membrane. Then the resolving gel was placed 
on top of the nitrocellulose paper, followed by another four pieces of Whatman paper. 
Blotting and nitrocellulose papers were cut to the size of the gel and pre-soaked in the 
semi-dry transfer buffer before placed. The layers were pressed gently to expel any 
air bubbles to ensure efficient electroblotting, and then the upper negative electrode, 
dampened with transfer buffer, positioned. The proteins were electro-transferred from 
the gel on the membrane at 20 °C with the following settings, 1 h duration, at 0.8 mA 
current per 1 cm
2
 of gel (approximately 40 mA per gel). When the transfer was 
completed, the nitrocellulose membrane was placed in Tris buffered saline (TBS, see 
section 9.3 for composition) plus 0.1% Tween 20 (TBS-Tween 20). TBS-Tween 20 
was thrown away and the membrane was gently shaken in Ponceau S at 20 °C for 1-2 
min to verify successful protein transfer.  
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Figure 2.1 Transfer of proteins to nitrocellulose membrane. 
 
2.4.6 Antibody probing and immunoblot developing 
 
To block non-specific binding sites on the nitrocellulose membrane, it was 
incubated with 10 ml TBS-Tween 20 with 5% w/v non-fat milk and left to shake for 1 
h at 20 °C. The membrane was then washed using 1x TBS-Tween 20 three times, 5 
min per wash, and incubated for 16 h at 4 °C under gentle agitation with 10 ml of 
TBS-Tween 20 with 0.1% sodium azide and the desired concentration of the primary 
antibody (see section 9.5). The antibody solution was removed and kept for future 
use. On the following day, the membrane was washed three times in 1x TBS-Tween 
20, 5 min per wash, and incubated with horseradish peroxidase-conjugated secondary 
antibody at the recommended concentration (see section 9.5) in 10 ml TBS-tween 20 
and 1% (w/v) non-fat milk for two hours with gentle agitation at 20 °C. The 
membrane was again washed three times in TBS-Tween 20, 5 min per wash and 
bound antibody detected using Enhanced Chemiluminescent Lumigen (ECL) reagent 
according to the manufacturer’s instruction, placed in cling film to prevent drying and 
exposed to photosensitive film (Fujifilm Corporation, Tokyo, Japan) using an X-ray 
film processor (model RGII, Fuji). The intensity of the specific bands was quantified 
by densitometric analysis using Labimage software (Kapelan Bio-imaging Solutions, 
Halle, Germany). 
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2.5 Immunohistochemistry (IHC) 
 
2.5.1 Deparaffinization and rehydration of sections 
 
The sections were dewaxed by immersing the slides into Histoclear I and then 
Histoclear II, for 7 min each. Then the slides were immersed twice into 100% ethanol 
for 1 min each and then 95%, 90%, 70% and 50% ethanol, 1 min each. The slides 
were rinsed in distilled H2O for 1 min. From this point onwards the slides were not 
allowed to dry to avoid non-specific antibody binding that causes high background. 
The slides were washed twice in PBS, 5 min per wash and tracheal sections 
permeabilized by immersing the slides in 0.5% Triton X 100 in PBS for 30 min at 20 
°C. After permeabilization, the slides were washed twice with PBS for 5 min per 
wash. 
 
2.5.2 Antigen retrieval and antibody staining 
 
Most formalin-fixed tissue requires an antigen retrieval step before 
immunohistochemical staining due to the formation of protein cross-links that mask 
the antigenic sites in tissue specimens giving weak or false negative staining. EDTA 
buffer was used to break the protein cross-links and unmask the antigens in formalin-
fixed and paraffin embedded tissue sections.  
 
The sections were covered with EDTA buffer and the slides placed on a 
holder in a humid box at 37 °C for 1 h. The slides were then washed twice with PBS 
with 5 min per wash. After washing, the sections were framed using PAP pen to 
decrease the volume of the antibody used. Peroxo-Block was added for 1-2 min to 
quench endogenous peroxidase activity, and sections were then washed twice with 
PBS for 5 min per wash. The tracheal sections were covered with 5% FBS in PBS for 
20 min to block non- specific binding, then washed twice with PBS, 1 min per wash. 
Rabbit polyclonal anti-arginase I antibody 1:100 dilution in PBS was applied on the 
tracheal tissue sections and the slides placed in a moistened chamber at 4 °C for 16 h. 
Mouse liver tissue sections, as a positive control, and tracheal rings sections in which 
the primary antibody was omitted to exclude non-specific binding, as a negative 
control, were used. On the following day, the slides were washed twice with PBS, 5 
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min per wash, and then the SuperPicTure™ Polymer Detection Kit used according to 
the protocol provided by the manufacturer (Zymed Laboratories, Invitrogen). The 
slides were immersed in two separate IMS solutions for 3 min each and then two 
separate xylene solutions for 3 min each. The sections were mounted using DePeX 
mounting medium and visualised using an inverted microscope stage (Olympus 
1X51). 
 
2.6 siRNA 
 
2.6.1 Transfection of cell lines with fluorescent siRNA  
 
The Label IT
® 
RNAi delivery control was used for this experiment. For the 
siRNA-vector complex formation, two solutions were prepared for each well of a 12-
well plate, solution A (RNA) and solution B (transfecting reagents). Solution A was 
prepared by diluting 1.25 µl siRNA solution (10 µM) to 12.5 µl (1 µM) using 1X 
RNAi dilution buffer in a 1.5 ml sterile plastic tube, gently mixing and incubating for 
20 min at 20 °C. Solution B was prepared by adding TransIT–TKO Transfection 
reagent 10 µg/ 12.5 µl of 1 µM siRNA stock, 4 µl C20/ 12.5 µl of 1 µM siRNA stock 
and 6 µl C22/ 12.5 µl of 1 µM siRNA stock into Opti-MEM using a 1.5 ml sterile 
plastic tube, which was gently mixed and incubated for 20 min at 20 °C. The complex 
was then prepared by gently mixing solution A and B and incubated for 20 min at 20 
°C. 
  
For transfection, 5x10
4 
cells of A549 and 1x10
5 
cells of 9HTEo- were seeded 
in 12-well plates in 2 ml of complete medium per well and maintained at 37 °C in a 
5% CO2 humidified incubator for 24 h to reach 50-60 % confluence. Prior to 
transfection, the media was replaced with 437.5 µl of Opti-MEM into which 62.5 µl 
of the transfection complex was added dropwise for final volume of 500 µl/well with 
the exception of the control cells where 500 µl of Opti-MEM was used. The plates 
were gently rocked back and forth and from side to side to distribute the complex 
evenly, then maintained at 37 °C in a 5% CO2 humidified incubator for 24 h. After 
that, the media was removed, replaced with 2 ml of complete media and incubated for 
a further 48 h. 
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2.6.2 Cytotoxicity (MTT) assay of RNAi-lipospermine complex  
 
The MTT assay is a colorimetric assay used to evaluate the metabolic activity 
of viable cells in which a soluble tetrazolium salt [3-(4, 5-dimethylthiazol-2-yl)-2,5-
diphenyl tetrazolium bromide (MTT)] is converted into an insoluble formazan crystal 
(Mosmann, 1983). It was used to investigate the cytotoxic effects of lipopolyamines 
and lipoplexes (siRNA complexes). RNase and DNase free water was used to dilute 
10X RNAi to 1X RNAi dilution buffer. Two solutions, solution A and solution B 
were prepared. Solution A (siRNA) was prepared by diluting 0.25 µl solution siRNA 
(2.5 pmoles/well) to 2.5 µl using 1X RNAi dilution buffer in a 1.5 ml sterile plastic 
tube, gently mixed and incubated for 20 min at 20 °C. Solution B (transfection 
reagents) was prepared by diluting the transfection reagents solution to the same 
concentrations mentioned in section 2.6.3 in a 1.5 ml sterile plastic tube with Opti-
MEM, gently mixing and incubating for 20 min at 20 °C. The complex was then 
prepared by mixing solution A and B and incubated for 20 min at 20 °C. For the 
assay, 8000 cells/well were seeded in 200 µl of complete medium using 96-well 
plates. Cells were maintained at 37 °C in 5% CO2 humidified incubator for 24 h to 
reach 50-60 % confluence. The medium was removed and replaced with 87.5 µl of 
complete medium to which 12.5 µl of either the transfection complex (lipoplex), the 
free lipopolyamine, or the free RNA (naked RNA) were added to give a final volume 
of 100 µl, with the exception of the control cells where 100 µl of serum Opti-MEM 
was added. The plates were then maintained at 37 °C in 5% CO2 humidified incubator 
for 24 h. After that, the medium was removed and replaced with 200 µl of complete 
medium and maintained for a furthur 48 h. The medium was then replaced with 90 µl 
of fresh medium and 10 µl of sterile filtered MTT solution (5 mg/ml) to reach a final 
concentration of 0.5 mg/ml. The plates were then incubated for 4 h at 37 
o
C in 5% 
CO2 humidified incubator. Following incubation, the media and the un-reacted dye 
were removed and the formed blue formazan crystals dissolved in 200 µl/well of 
DMSO. The colour produced was measured using a plate-reader (VERSAmax, 
Molecular Devices, Crawley, UK) at a wavelength of 570 nm. The percentage 
viability with respect to control wells containing cells without siRNA and/or 
lipopolyamines was calculated according to the following formula:  
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viabilitycell           (Fischer et al., 1999) 
 
2.6.3 Preparation of cells for flow cytometry analysis  
 
After 72 h incubation, the medium was removed and cells washed twice with 
PBS solution. Cells were detached using 500 µl of 0.05 % (w/v) trypsin and 0.02% 
(w/v) EDTA and incubated for 5 min at 37 °C in a 5% CO2 humidified incubator. 
After that, the plates were gently tapped to further detach the cells. The trypsin 
reaction was stopped by the addition of 1 ml of complete medium into each well. The 
cell suspension was transferred to 1.5 ml plastic tubes and centrifuged twice with PBS 
at 375 g, 5 min each at 20 ºC. A cell suspension for FACS analysis was obtained by 
resuspending the pellet in 500 µl PBS/tube and an untransfected cell sample used as a 
control. Flow cytometry was performed with a FACSCanto flow cytometer and 
analyzed with Cell Quest pro software (Becton Dickinson, MA, USA). Prior to 
analysis, all samples were gated by both forward and side scatter to eliminate data 
interference by dead cells. 
 
2.6.4 Transfection of tracheal segments with fluorescent siRNA 
 
The Label IT
® 
RNAi delivery control was needed for this experiment, which 
consists of fluorescein-labeled double-stranded RNA duplexes, that have the same 
length, charge, and configuration as standard siRNA used in RNAi studies. The 10X 
RNAi dilution buffer provided was adjusted to 1X RNAi dilution buffer using RNase 
and DNase free water. Fluorescent siRNA was diluted using 1X RNAi dilution buffer 
to a final concentration of 50 and 100 nM /well. TransIT–TKO transfection reagent 
and synthetic lipospermine transfecting reagents C20 and C22 (University of Bath) 
were added to 250 µl Opti-MEM without serum. The volumes of the transfection 
reagents used were according to positive results achieved using 9HTEo- and A549 
cell lines. Diluted siRNA or different transfection reagents were then mixed gently 
and incubated at 20 °C for 15 min. The diluted flourescent siRNA was added to the 
different transfecting reagents, mixed and incubated at 20 °C for another 15 min. The 
transfecting reagent/fluorescent siRNA complex mixtures were then added dropwise 
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to the wells containing murine tracheal segments such that the final volume in the 
well was 1 ml. The plate was rocked gently back and forth and from side to side to 
distribute the complexes evenly and then incubated at 37 °C for 72 h before preparing 
slides as mentioned in section 2.3.1. The slides were washed three times with PBS at 
20 °C, fixed with 4% PFA for 4 min at 20 °C, rewashed three times with PBS, 
mounted in 20 µl Vectashield, antifade mounting media, a cover slip placed onto the 
slides and left in the dark for 20 h before subsequent confocal microscopic 
examination. 
 
2.6.5 Reverse permeabilization 
 
Reverse permeabilisation is a method used to study the role of specific 
intracellular proteins in intact tissues and determining their effects on functions, such 
as contractility especially if it not normally measured in cultured cells due to 
dedifferentiation in culture to noncontracting phenotypes. Reversible membrane 
permeabilization depends on using high ATP concentration in divalent cation–free 
solutions resulting in increase in membrane permeability. This is reversed by removal 
of extracellular ATP and addition of high [Mg
2+
] followed by a gradual restoration of 
the physiological concentrations of extracellular Mg
2+
 and Ca
2+
 (Steinberg et al., 
1987). Reverse permeabilization was used to introduce siRNA into murine tracheal 
segments based on a method described by Corteling et al., 2007. Isolated tracheal 
segments were exposed to four successive solutions (see Table 2.1) Murine tracheal 
segments were then placed in DMEM medium (supplemented with 100 U/ml 
penicillin, 100 µg/ml streptomycin, 2.5 µg/ml Fungizone, and 0.1% w/v BSA) and 
maintained at 37 °C in a humidified CO2 gassed incubator for 48 h. The medium was 
then changed to medium with or without the presence of m-IL-13 and the segments 
further incubated for 24 h. The segments were subjected to organ bath experiments as 
described in section 2.1.3, homogenized in lysis buffer and Western blotting was 
carried out as previously described in section 2.4. In another set of experiments, 
reverse permeabilisation was carried out using different concentration of the 
fluorescein-labeled double-stranded RNA duplexes (20, 50 and 100 nM). The rings 
were then embedded in OCT and kept at -80 °C until sectioned by cryostat as 
previously described in section 2.3.1. The slides were washed with PBS three times at 
20 °C, and fixed with 4% PFA for 4 min at 20 °C. After fixation, the slides were 
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washed three times with PBS at 20 °C, 20 µl of vectorshield antifade mounting media 
added on top, and a slide cover was placed onto the slide. The slides were left in the 
dark for 20 h before using confocal microscopy to detect the fluorescein-labeled 
siRNA. 
 
Table 2.1 Solutions used in reverse permeabilisation (mM) 
Solution (1) 10 EGTA, 120 KCl, 5 ATP, 2 MgCl2, 20 TES (pH 6.8; 20 min, 4 °C) 
 
Solution (2) 120 KCl, 5 ATP, 2 MgCl2, and 20 TES with 20 nM siRNA (pH 6.8; 3 
h, 4 °C) 
 
Solution (3) 120 KCl, 5 ATP, 10 MgCl2, and 20 TES with 20 nM siRNA (pH 6.8; 
30 min, 4 °C). 
 
Solution (4) 140 NaCl, 5 KCl, 10 MgCl2, 5 glucose, and 2 MOPS (pH 7.1, 22 °C) 
and [Ca
2+
] was gradually increased from 0.01 to 0.1 to 1.8 mM every 
15 min. 
 
 
2.7 Flow cytometry 
 
Surface expression of IL-13 Rα2 by 9HTEo-cells was analysed to determine 
its possible role in IL-13 treated cells. 9HTEo- cells were cultured as mentioned in 
section 2.2, and incubated with IL-13 (1, 10, 30 and 100 ng/ml, 24 h). After 24 h 
incubation, the cells were washed twice in PBS/0.1% BSA, detached by incubation of 
the cells with 500 µl of 0.05% trypsin and 0.02% EDTA for 5 min at 37 °C. The 
trypsin/EDTA reaction was stopped by the addition of 1 ml prewarmed complete 
media to the cultured dish and the content of the dish pipetted several times, 
transferred into 1.5 Plastic tubes and washed twice using cold PBS/ 0.1% BSA by 
centrifuging the cells at 9600 g for 1 sec. The cells were resuspended in 500 µl cold 
PBS/0.1% BSA then 10 µl of anti-human IL-13 Rα2 antibody was added and 
incubated in the dark for 30 min. The cells were rewashed twice using cold PBS/ 
0.1% BSA by centrifuging the cells at 9600 g rpm for 1 s. After washing, 10 µl of 
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FITC-conjugated secondary antibody was added, incubated in the dark on ice for 30 
min, and washed twice using cold PBS/0.1% BSA. The cells were then resuspended 
in 400 µl cold PBS/0.1% BSA as a final volume and transferred to flow cytometer 
polypropylene tubes. Flow cytometry was performed with a FACSCanto flow 
cytometer using wavelengths of 488 nm for excitation and 520 nm for emission and 
analyzed with Cell Quest Pro software (Becton Dickinson, MA, USA). Prior to 
measurement, all samples were gated by both forward and side scatter to eliminate 
data interference by dead cells. 
 
2.8 Reverse transcription-polymerase chain reaction 
 
To evaluate expression of IL-13 Rα1 and IL-13 Rα2 on IL-13 treated 9HTEo- 
cells, reverse transcription PCR for each receptor was carried out. Extracted RNA 
was reverse transcribed to complementary (cDNA) which was amplified to generate 
millions or more copies of the DNA piece.  
 
2.8.1 RNA extraction 
 
After culturing 2 X 10
5
 9HTEo- cells in a 3.5 cm diameter dish cells with 
IL-13 for 24 h as mentioned in section 2.2.3, the cells were washed twice with sterile 
PBS. Then, 1 ml of TRIZOL reagent was added, passed several times through a 
pipette and incubated for 5 min at 20 °C. Chloroform (0.2 ml per 1 ml of TRIZOL 
reagent used) was added to the samples, vortexed and incubated at 20 °C for 2-3 min. 
The samples were then centrifuged at 15,400 g for 15 min at 4 °C. Following 
centrifugation, the mixture was separated into a lower red, phenol-chloroform phase, 
an interphase, and a colorless upper aqueous phase containing RNA. The aqueous 
phase was transferred to a sterile 1.5 ml plastic tube with the RNA being precipitated 
by adding 0.5 ml of isopropyl alcohol per 1 ml of TRIZOL reagent used for the initial 
lysis. Samples were then incubated at 20 °C for 10 min and centrifuged at 15,400g for 
10 min at 4 °C where the RNA was precipitated in the form of a gel-like pellet. The 
supernatant was removed and the pellet washed once by adding 1 ml of 75% ethanol 
per 1 ml of TRIZOL reagent used, and mixed by vortex before centrifugation at 
15,400g for 5 min at 4 °C. The supernatant was removed and the RNA pellet was air-
dried for 5-10 min, resuspended in 50 µl of sterile water and heated to 55°C for 10 
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minutes to break secondary structures within the RNA and enhance its solubility. 
RNA concentration and purity for each sample was determined using a 1:100 dilution 
of the RNA and the absorbance measured at 260 nm and 280 nm using the 
GeneQuant II spectrophotometer (GeneQuant II, Pharmacia Biotech Ltd., Cambridge, 
UK). The concentration of RNA was determined using the following estimation: 
Concentration of RNA (µg/ml) = dilution factor x 40* x A260 
* The standard consideration is that 40 µg/m1 of RNA has an absorbance of 1 at 260 
nm –of ratio values of 1.8-2.0 verified acceptable RNA purity. RNA samples were 
then stored at -80 °C until used. 
 
2.8.2 PCR 
 
For cDNA synthesis, 1 µg of RNA was reverse transcribed into its DNA 
complement, using Omniscript RT Kit (Quiagen GmbH, Hilden, Germany) with 
anchored oligo dT primers (ABgene, Surrey, UK) in presence of an RNase inhibitor 
(RNasin Plus, Promega, Madison, WI, USA) according to the manufacturer’s 
instructions using a Perkin Elmer GeneAmp PCR System 2400 thermal cycler with 
the following setup: 40°C for 60 minutes followed by 70°C for 10 minutes to 
inactivate the reverse-transcriptase reaction (see section 9.6 for reaction mixture). 
Reverse transcriptase -negative samples were also prepared to exclude any possible 
genomic DNA contamination within RNA samples. cDNAs produced were stored at  
-20°C. 
 
PCR is an in vitro method for the enzymatic synthesis of specific DNA 
sequences, using two oligonucleotide primers that bind to opposite strands and flank 
the region of interest in the target DNA. Numerous cycles involving template 
denaturation to open the double stranded DNA, primer annealing, and the extension 
of the annealed primer by a DNA polymerase such as Thermus aquaticus (Taq) result 
in exponential accumulation of specific fragments defined by the 5’ ends of the 
primers. The products synthesised at the end of each cycle then serve as the template 
in the next round, hence the number of target DNA copies double at every cycle. 
Refer to section 9.7 for the design and sequences of primers used in this study 
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All PCR reactions were carried out in 25 µl reaction volumes in thin walled 
PCR tubes as follows 
 
Component Volume (µl) 
PCR Master Mix (Promega) 12.5 
Sense primer (0.5 µM final) 0.5 
Antisense primer (0.5 µM final) 0.5 
cDNA template  1-2.5 
PCR grade H2O to 25 
 
At the beginning of each run, the samples were incubated at 95°C to enable 
activation of the thermostable recombinant Taq DNA polymerase (hot start DNA 
polymerase) by the removal of specific blocking groups. The cDNA was amplified 
using a Perkin Elmer GeneAmp PCR System 2400 thermocycler, and the 
amplification cycles (30 second at 94°C, and 1min each 57 and 72 ° C) for 30 cycles 
PCR products were then analysed by agarose gel electrophoresis. 
 
2.8.3 Agarose gel electrophoresis  
 
Electrophoresis grade agarose (0.5 g) was added to 50 ml of the 1 X 
Tris/Borate/EDTA (TBE) buffer. The agarose was heated in microwave for 1.5 min 
then cooled to about 50 °C in a water bath for 5 min and the volume readjusted to 50 
ml using warm ultrapure water. The sides of the tray were secured using autocave 
tape before the agarose was poured into; the comb inserted, and the gel allowed to 
solidify at 4 °C. The comb was removed and the buffer solution was poured into the 
gel box to a level of 2-3 mm above the gel, which was sufficient to prepare a small 8-
sample gel. The formed wells were loaded with 20 µl of the following a mixture: 
Deionzed H2O (10 µl), 6X Track-it load buffer (3.3 µl) and DNA samples (6.7 ul). A 
spare well was used to load a low molecular weight DNA ladder marker. The gel was 
run at 80 V using a Kodac Biomax Qs 710 gel electrophoresis chamber attached to 
BioRad PowerPac 300 unit for approximately 1.5 h until the bands were clearly 
separated, as visualised by the migration of orangeG at 50 bp and bromophenol blue 
at 300 bp. Afterward, the gel was placed in the staining tray containing ethidium 
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bromide 50 µl in 100 ml TBE buffer for 10 min, rinsed twice with distilled water, 
illuminated at 254 nm wavelength and photographed using Gene Genius Gel 
Documentation System (Syngene Inc., Cambridge, UK). 
 
2.9 Statistical analysis 
 
Contractions evoked by KCl and CCh are expressed as mN/mg of wet weight 
tissue, and all values are presented as mean ± s.e.m. Nonlinear regression analysis 
using Prism software (version 4; GraphPad Software, San Diego, CA) was used to 
determine Emax. Comparisons among groups were performed by Student's paired 
t-test or ANOVA with Dunnett's or Tukey-Newman-Keuls post hoc tests as 
appropriate for n = 4-12 mice. 
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2.10 Materials 
 
Materials Catalog No. Company 
Absolute ethanol E7148 Sigma-Aldrich (Poole, UK) 
30% Acrylamide-Bis 
acrylamide solution 
161-0158 Bio-rad (Hercules, USA) 
Adenosine triphosphate A7699 Sigma-Aldrich (Poole, UK) 
Agarose A5304 Sigma-Aldrich (Poole, UK) 
Alpha-D(+)-Glucose 17008-0025 Fisher Scientific (Loughborough, UK) 
Ammonium persulfate 327081000 Fisher Scientific (Loughborough, UK) 
Anchored oligo dT AB-1247 Abgene (Epsom, UK) 
Anti-Akt1 antibody Sc-1618 Santa Cruz Biotechnology (Santa 
Cruz, Ca, USA) 
Anti-arginase I antibody 
(mouse) 
610708 BD Biosciences (Oxford, UK) 
Anti-arginase I antibody 
(rabbit) 
Sc-20150 Santa Cruz Biotechnology (Santa 
Cruz, Ca, USA) 
Anti-β-actin 4967 Cell Signaling Technology (Boston, 
USA) 
Anti-human IL-13 Rα2  AF146 R&D Systems (Abingdon, UK) 
Anti-phosphoSer
473
-Akt 
antibody 
9271 Cell Signaling Technology (Boston, 
USA) 
Anti-PI3K p110δ antibody Sc-7176 Santa Cruz Biotechnology (Santa 
Cruz, Ca, USA) 
Aprotonin from bovine lung A3428 Sigma-Aldrich (Poole, UK) 
Bovine serum albumin A6003 Sigma-Aldrich (Poole, UK) 
Bromophenol blue B8026 Sigma-Aldrich (Poole, UK) 
Carbamoylcholine chloride C4382 Sigma-Aldrich (Poole, UK) 
Chloroform C2432 Sigma-Aldrich (Poole, UK) 
Citrate Buffer for Heat-
induced Epitope Retrieval 
AP-9003-050 Fisher Scientific (Loughborough, UK) 
Collagen from calf skin  C9791 Sigma-Aldrich (Poole, UK) 
Cork disks - 20mm x 3mm - Raymond Alamb (Eastbourne, UK) 
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Cryogenic vials 368632 Fisher Scientific (Loughborough, UK) 
Custom primers - Invitrogen (Carlsbad, USA) 
Deoxyribonuclease I from 
bovine pancreas 
D5025 Sigma-Aldrich (Poole, UK) 
DePeX mounting media 361252B BDH (Poole, UK) 
Dimethyl sulfoxide (DMSO) D8418 Sigma-Aldrich (Poole, UK) 
DNA Ladder 100 bp N3231S NewEngland Biolabs (Herts, UK) 
Dulbecco’s Modified Eagle's 
Medium (DMEM) 
41966-029 GIBCO (Paisley, UK) 
Dulbecco’s Phosphate 
Buffered Saline (D-PBS) 
(10X), liquid 
14200-067 GIBCO (Paisley, UK) 
EDTA ED2SS Sigma-Aldrich (Poole, UK) 
EDTA Buffer For Heat-
Induced Epitope Retrieval 
(10X) 
AP-9004-050 Fisher Scientific (Loughborough,UK) 
Enhanced Chemiluminescent 
Lumigen (ECL) Kit for 
Western blotting 
RPN2209 GE Healthcare (Buckinghamshire, 
UK) 
Eosin Y solution, aqueous HT110216 Sigma-Aldrich (Poole, UK) 
Ethylene glycol-bis(2-
aminoethylether)-N,N,N′,N′-
tetraacetic acid 
E4378 Sigma-Aldrich (Poole, UK) 
Fetal bovine serum-heat 
inactivated 
10082-147 GIBCO (Paisley, UK) 
Fibronectin, Bovine Plasma 33010018 GIBCO (Paisley, UK) 
FUJI Medical X-ray Film 2731261 Fisher Scientific (Loughborough, UK) 
Fungizone Antimycotic liquid 15290-026 GIBCO (Paisley, UK) 
Gel-Saver II Pipette Tip (1-
200 µl) 
NC9438173 Fisher Scientific (Loughborough,UK) 
Glycerol G5516 Sigma-Aldrich (Poole, UK) 
Glycine 50046 Sigma-Aldrich (Poole, UK) 
Goat anti-mouse peroxidase P0447 DAKO (Glostrup, Denmark) 
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Goat anti-rabbit peroxidase P0448 DAKO (Glostrup, Denmark) 
Hematoxylin Solution, Harris 
Modified 
HHS16 Sigma-Aldrich (Poole, UK) 
Histoclear  HS-200 Fisher Scientific (Loughborough, UK) 
Histoclear (II) HS-202 Fisher Scientific (Loughborough, UK) 
IC87114 - ICOS Corporation (Bothell, USA) 
Iso-Pentane B10361-74 BDH (Poole, UK) 
Isoprenaline hydrochloride I5627 Sigma-Aldrich (Poole, UK) 
The Label IT® RNAi 
Delivery Control 
MIR 7902 Mirus (Madison, USA) 
LAMB OCT embedding 
medium  
- Raymond Alamb (Eastbourne,UK) 
Leupeptin hemisulfate salt L8511 Sigma-Aldrich (Poole, UK) 
LHC- Basal Medium (1X) 12677-019 Invitrogen (Carlsbad, USA) 
LHC-9 medium (1X) 12680-013 Invitrogen (Carlsbad, USA) 
Lipofectamine 2000 11668-027 Invitrogen (Carlsbad, USA) 
L-Norvaline N7627 Sigma-Aldrich (Poole, UK) 
LY294002 L9908 Sigma-Aldrich (Poole, UK) 
Magnesium chloride - 
Solution  
A3888.0500 VWR International (Poole, UK 
Marvel non-fat dehydrated 
milk 
- Sainsbury’s (Bath, UK) 
2-Mercaptoethanol M3148 Sigma-Aldrich (Poole, UK) 
Methanol M/4056/17 Sigma-Aldrich (Poole, UK) 
Microscopic slides, superfrost 
Plus 
6310108 VWR International (Poole, UK) 
MOPS (4-
Morpholinepropanesulfonic 
acid) 
M1254 Sigma-Aldrich (Poole, UK) 
Nitrocellulose membrane 
(TransBlot Transfer 
membrane) 
162-0115 Bio-Rad (Hercules, USA) 
Nonidet P-40 56009 Sigma-Aldrich (Poole, UK) 
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Non-targeting predesigned 
siRNA duplex 
D-001210-01 Dharmacon (Erembodegem, Belgium) 
Omniscript RT Kit 205111 QIAGEN (Crawley, UK) 
Opti-MEM, Reduced-Serum 
Medium (1X), liquid 
31985-062 Invitrogen (Carlsbad, USA) 
Paraformaldehyde P6148 Sigma-Aldrich (Poole, UK) 
PAP pen for immunostaining Z377821 Sigma-Aldrich (Poole, UK) 
PCR Master Mix M7502 Promega (Southampton, UK) 
Penicillin/Streptomycin 15140-122 GIBCO (Paisley, UK) 
Peroxo-Block 00-2015 Zymed Laboratories, Invitrogen 
(Carlsbad, USA) 
Pepstatin A P5318 Sigma-Aldrich (Poole, UK) 
Phenylmethanesulfonylflouri
de 
P7626 Sigma-Aldrich (Poole, UK) 
Phosphate buffered saline P4417 Sigma-Aldrich (Poole, UK) 
Pipette (serological sterile, 10 
ml) 
FB55484 Fisher Scientific (Loughborough, UK) 
Polyvinylpyrrolidone (PVP) P5288 Sigma-Aldrich (Poole, UK) 
Potassium chloride P/4240153 Fisher Scientific (Loughborough, UK) 
Precision Plus Protein 
Standard (for Western 
blotting) 
161-0373 Bio-Rad (Hercules, USA) 
Predesigned siRNA duplex 
P110δ, human) 
D-006775-05 Dharmacon (Erembodegem, Belgium) 
Predesigned siRNA P110δ- 
(mouse) 
M-041078-
00 
Dharmacon (Erembodegem, Belgium) 
Recombinant human IL-13 200-13 Peprotech (London, UK) 
Recombinant murine IL-13 210-13 Peprotech (London, UK) 
Recombinant rat IL-13 400-16 Peprotech (London, UK) 
RNasin Plus RNase Inhibitor N2611 Promega (Southampton, UK) 
RNeasy mini kit 74106 QIAGEN (Crawley, UK) 
Sodium azide  S2360 Sigma-Aldrich (Poole, UK) 
Sodium chloride S7653 Sigma-Aldrich (Poole, UK) 
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Sodium dodecyl sulphate L4390 Sigma-Aldrich (Poole, UK) 
Sodium fluoride S1504 Sigma-Aldrich (Poole, UK) 
Sodium molybdate S6646 Sigma-Aldrich (Poole, UK) 
Sodium orthvanadate S6508 Sigma-Aldrich (Poole, UK) 
SuperPicTure™ Polymer 
Detection Kit  
87-9263 Zymed Laboratories, Invitrogen 
(Carlsbad, USA) 
Syring Filter Millex FDR-050-
071N 
Fisher Scientific (Loughborough, UK) 
TEMED T9281 Sigma-Aldrich (Poole, UK) 
TES (N-
[Tris(hydroxymethyl)methyl]-
2-aminoethanesulfonic acid) 
R1375 Sigma-Aldrich (Poole, UK) 
Thiazolyl Blue Tetrazolium 
Bromide 
M5655 Sigma-Aldrich (Poole, UK) 
Tissue culture 48-well plate 137101 NUNC (Roskilde, Denmark) 
Tissue culture 6-well plate 140675 NUNC (Roskilde, Denmark) 
Tissue culture dish 35x10 153066 NUNC (Roskilde, Denmark) 
Tissue culture flask 25 cm
2
 690175 Greinerbio-one (Stonehouse, UK) 
Tissue culture flask 75 cm
2
 658175 Greinerbio-one (Stonehouse, UK) 
TransIT-TKO® Transfection 
Reagent 
MIR 2150 Mirus (Madison, USA) 
Trizma base T87602 Sigma-Aldrich (Poole, UK) 
Trypan blue T6146 Sigma-Aldrich (Poole, UK) 
Trypsin, 0.05% (1X) /EDTA  25300 -.054 GIBCO (Paisley, UK) 
Trypsin inhibitor from 
Glycine max (soybean) 
T9003 Sigma-Aldrich (Poole, UK) 
Tween-20 P1379 Sigma-Aldrich (Poole, UK) 
UltraPure TBE Buffer (10X) 15581-044 Invitrogen (Carlsbad, USA) 
Vectashield mounting 
medium 
H-1000 Vector Laboratories (Peterborough, 
UK) 
Wortmannin W1628 Sigma-Aldrich (Poole, UK) 
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Chapter Three 
 
IL-13-induced hyperresponsiveness of ASM 
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3.1 Introduction 
 
The importance of using animal models of many human diseases is central to 
the drug discovery process. Each of the animal models currently used has advantages 
and disadvantages. Mouse and rat are by far the most widely used experimental 
models for human diseases and biology. Mice have been extensively used for genetic 
studies. However, rat is often the model of choice for physiological studies due to its 
large size (Gill, et al., 1989). The most commonly used experimental animal, the 
mouse, has some important advantages including the well-studied immune system, 
the wide range of tools e.g. antibodies available for characterizing the cells and 
cytokines, the potential for development of genetic knockouts and transgenic 
animals, the resemblance of the mouse Th2/Th1 system to that believed to be 
involved in human asthma, and the relatively low cost of the animals and their 
maintenance. The available tools for studies in rats are less than that of mice and 
even fewer of the required tools are available for the guinea pig, although the guinea 
pig has a robust bronchoconstriction response that is lacking in the other rodents. In 
order to gain more insight in the mechanisms of human lung diseases and potential 
beneficial therapeutic agents, adequate models are needed. (Hulsmann & de Jongste, 
1993). 
 
Although several Th2 cytokines have been implicated in antigen-induced 
AHR, IL-13 seems to play a pre-eminent role in AHR, a definite feature of asthma. 
Targeted deletion of IL-13 prevents expression of AHR in allergen-challenged mice, 
despite maintenance of elevated IL-4 and IL-5 release (Walter et al., 2001). 
Likewise, neutralization of IL-13 using IL-13 receptor constructs or antibodies 
reduces AHR (Grunig et al., 1998; Eum et al., 2005). 
 
The aim of studies represented in the present chapter is to demonstrate the 
responsiveness of ASM by pre-incubation with IL-13 in vitro. It was also necessary 
to identify which species to be used in this study. Isometric tension was recorded in 
isolated tracheal ring preparations and comparative studies using both rat and mouse 
isolated tracheal rings were investigated. The effects of mouse, rat or human IL-13 
on tracheal contractility of both species were compared. 
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3.2 The effect of m-IL-13 on mice tracheal smooth muscle  
 
As shown in Table 3.1 and Figure 3.1 A and B, initial experiments were 
carried out using isolated murine tracheae. m-IL-13 potentiated KCl (10-100 mM) 
and CCh (10
-8
–10
-5
 M)-induced contractions in which the agonist Emax of the 
concentration response curve was significantly higher in murine rings pretreated with 
m-IL-13 (10 or 100 ng/ml) compared with controls, with Emax values for KCl and 
CCh increased approximately 1.6- to 2-fold (Table 3.1). While m-IL-13 elevated the 
maximal response, limited changes in EC50 values were observed (Table 3.1), 
indicating that m-IL-13 seemed to increase smooth-muscle contractility rather than 
induce increased sensitivity to low concentrations of contractile agents.  
 
 
Table 3.1 Effect of IL-13 induced contractions in isolated murine tracheal rings. 
Tissues isolated from CD1 mice and were incubated with media alone (controls, n = 
24) or IL-13 (10 and 100 ng/ml, n = 12 per group) for 24 h prior to assessment of 
contractile responses to KCl or CCh. Values are mean ± s.e.m. of Emax values or 
pEC50 values. 
 KCl CCh 
 Emax pEC50 Emax pEC50 
Control mN/mg tissue 
1.2 ± 0.1 
-log[M] 
1.43 ± 0.03 
mN/mg tissue 
2.0 ± 0.2 
-log[M] 
6.53 ± 0.09 
IL-13 (10 ng/ml) 2.2 ± 0.3
a
 1.44 ± 0.03 3.8 ± 0.5
a
 6.54 ± 0.10 
IL-13 (100 ng/ml) 2.7 ± 0.4
a
 1.44 ± 0.03 3.8 ± 0.5
a
 6.53 ± 0.09 
a
p < 0.01 compared with matched control segments. 
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Figure 3.1 m-IL-13 enhanced KCl- and CCh-induced contraction of murine tracheal 
rings. Male, 8- to-10 weeks old, CD1 strain mice were used to obtain the tracheae, 
which were cut into two segments. Cumulative concentration-response curves to KCl 
(A) and CCh (B) in the absence or presence of m-IL-13 (10 or 100 ng/ml, 24 h). Data 
were expressed as mean mN per mg of tissue (wet weight) ± s.e.m. One-way 
ANOVA followed by Dunnett’s test were performed to determine the statistical 
significance of differences between Emax values of control and IL-13-treated tissues. 
**, p < 0.01 compared with non IL-13 treated tissue, n = 12. 
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3.3 The effect of r-IL-13 on rat tracheal smooth muscle 
 
To determine whether r-IL-13 would affect rat airway smooth muscle 
response after 24 h incubation, cumulative concentration response curve to KCl (10-
100 mM) or CCh (10
-8 
-10
-5
)
 
were carried out. From Table 3.2 and Figure 3.2, 
although the contractile responses (in mN/mg) to KCl and CCh were apparently 
increased there was no statistically significant difference observed between r-IL-13 
treated segments and control. There was also no difference in sensitivity between the 
control group and r-IL-13 treated group for both concentrations as shown by EC50 
values (Table 3.2). 
 
 
Table 3.2 Effect of r-IL-13 in isolated rat tracheal rings. Tissues isolated from Wistar 
rats were incubated with media alone (controls, n = 16), r-IL-13 (10 ng/ml, n = 10) or 
r-IL-13 (100 ng/ml, n = 6) for 24 h prior to assessment of contractile responses to 
KCl or CCh. Values are mean ± s.e.m. of Emax values or pEC50 values. 
 KCl CCh 
 Emax pEC50 Emax pEC50 
Control mN/mg tissue 
1.6 ± 0.2 
-log[M] 
1.59 ± 0.06 
mN/mg tissue 
2.3 ± 0.1 
-log[M] 
6.44 ± 0.07 
r-IL-13 (10 ng/ml) 1.9 ± 0.2 1.54 ± 0.08 2.8 ± 0.1 6.58 ± 0.05 
r-IL-13 (100 ng/ml)  2.4 ± 0.3 1.55 ± 0.06 2.9 ± 0.3 6.32 ± 0.05 
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Figure 3.2 r-IL-13 did not enhance KCl- and CCh-induced contraction of rat tracheal 
rings. Male, 8 weeks old, Wistar strain rats were used to obtain the tracheae which 
were cut into 4-6 segments. Cumulative concentration-response curves to KCl (A) 
and CCh (B) in the absence or presence of r-IL-13 (10 or 100 ng/ml, 24 h). Data 
were expressed as mean mN per mg of tissue (wet weight) ± s.e.m. One-way 
ANOVA followed by Dunnett's test were performed to determine the statistical 
significance of differences between Emax values of control and IL-13-treated tissues, 
n = 6-10. 
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3.4 Time course study of IL-13 enhanced contraction  
 
 As seen in Figure 3.1 m-IL-13 enhanced both KCl and CCh-induced 
contraction at both concentrations examined, however, m-IL-13 (100 ng/ml) was 
chosen, being more effective, for subsequent experiments. To investigate further the 
m-IL-13 induced enhancement of mice tracheal segments contraction, responsiveness 
was assessed after 1, 4, or 8 h incubation with m-IL-13 (100 ng/ml). There were no 
significant differences in IL-13 treated tracheal segments compared with control 
groups both to KCl and CCh at these times of incubation (Figure 3.3).  
 
 
 
 
Figure 3.3 Time course response of murine trachea after IL-13 treatment. Male, 8- 
to-10 weeks old, CD1 strain mice were used to obtain the tracheae, which were cut 
into two segments. Response to KCl (A) and CCh (B) in the absence or presence of 
IL-13 (100 ng/ml) 1, 4 and 8 h expressed as mean mN per mg of tissue (wet weight) 
± s.e.m. Student’s paired t-test was performed to determine the statistical 
significance of differences between control and IL-13-treated tissues for n = 4. 
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3.5 Effect of KCl or CCh in fresh and cultured tracheal segments 
 
 
 
 
 
Figure 3.4 The effect of KCl and CCh on isolated mice tracheal segments, fresh and 
cultured for 24 h. Concentration-effect curves of KCl (A) and CCh (B) obtained on 
fresh and cultured murine tracheal segments (24 h) expressed as mean mN per mg of 
tissue (wet weight) ± s.e.m. Student’s paired t-test was performed to determine the 
statistical significance of differences between fresh and cultured tissues for n = 4. 
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In control experiments, fresh murine tracheal segments and segments cultured 
for 24 h in the absence of IL-13 contracted similarly upon addition of KCl and CCh. 
The potency and maximal contraction of fresh and 24 h-cultured segments were not 
significantly different (Figure 3.4). KCl Emax values of fresh and cultured segments 
were 1.1 ± 0.1 and 1.2 ± 0.1 mN/mg respectively while CCh gave Emax values of 2.2 
± 0.3 and 1.8 ± 0.1 mN/mg for fresh and cultured segments respectively. The 
calculated pEC50 for KCl of fresh and cultured segments were 1.47 ± 0.03 and 1.47 
±0.03 mN/mg, respectively while those of CCh were 6.49 ± 0.22 and 6.46 ± 0.1 
mN/mg for fresh and cultured segments respectively. Those non-significant results 
were similar for both agonist used except for a relatively small nonsignificant degree 
of lower contraction following culture observed with CCh dose response curve. 
 
3.6 The effect of IL-13 on the relaxant response of isoprenaline  
 
The effect of IL-13 on the relaxant response induced by isoprenaline was 
studied. A sustained contraction of the tracheal rings obtained using submaximal 
dose of CCh (1 µM) determined from prior construction of a CCh dose response 
curve was established. Then, cumulative concentration-response relaxant curves to 
isoprenaline (10
-8
 to 10
-5
 M) were carried out. Expressing results as a percentage of 
the pre-determined submaximal CCh concentration normalized the obtained 
relaxation responses. As shown in Figure 3.5 A the effect of m-IL-13 on the 
isoprenaline relaxant response using murine tracheal rings was investigated. The 
concentration-response relaxant curve to isoprenaline was unaffected by m-IL-13 
(100 ng/ml) with maximal relaxant responses (as % of preconstriction) of 47 ± 8 % 
in the control rings and 43 ± 9 % in m-IL-13 treated rings (n = 12). 
 
In another set of experiments relaxation of rat tracheal rings pretreated with r-
IL-13 (10 and 100 ng/ml respectively) were not different from control groups given a 
maximal relaxant response of 36 ± 2 % in control group versus 34 ± 3 % in r-IL-13 
(10 ng/ml) treated group and a maximal relaxant response of 30 ± 2 % in control 
group versus 34 ± 2 % in r-IL-13 (100 ng/ml) treated group (Figure 3.5 B and C 
respectively). 
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Figure 3.5 The effect of IL-13 on the relaxant response of isoprenaline. Following 
pre-contraction with CCh (75% of maximal contraction, 1 µM), (A) cumulative 
concentration- response curves to isoprenaline (10
-8
 to 10
-5
 M) obtained on mice 
tracheal rings preincubated for 24 h with m-IL-13 (100 ng/ml, n = 12), (B) rat 
tracheal rings preincubated for 24 h with r-IL-13 (10 ng/ml, n = 10) and (C) r-IL-13 
(100 ng/ml, n = 5). All tension measurements from different groups are expressed as 
mean percentage of maximal contraction induced by CCh ± s.e.m.  
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3.7 Cross-species studies 
 
Previous investigators have reported enhanced airway responsiveness to 
various mediators in various species, as reviewed by Shore & Moore (2002). 
Different studies used human isolated bronchial strips or segments (Pype et al., 
2001) or mice isolated tracheal segments (Chen et al., 2003; Tliba et al., 2003; 
Bryborn et al., 2004; Moffatt et al., 2004; Walker et al., 2004; Bachar et al., 2005), 
however isolated tissues from other species were used such as rat tracheae, bronchi 
or bronchiol, (Koto et al., 1996; Van & Joos, 1998; Chiba et al., 2000; Liu et al., 
2003; Sakai et al., 2004), rabbit tracheae (Hakonarson et al., 1996; Grunstein et al., 
2002) and guinea pig tracheae (Wills-Karp et al., 1993). To examine species 
differences, response to m-IL-13 or r-IL-13 in rats or mice tracheal segments 
respectively was investigated. A significant response was only detected to CCh in rat 
tracheal rings incubated with m-IL-13 (100 ng/ml) (Figure 3.6) while the contractile 
effect of KCl was not significantly increased in either species (Figure 3.6 & 3.7). 
 
A comparison of the effect of h-IL-13 on mice or rat isolated tracheal rings to 
determine the role of h-IL-13 in hyperreactivity was carried out. Therefore, murine 
or rat tracheal rings were cultured with h-IL-13 (100 ng/ml) for 24 h. A significant 
h-IL-13 enhanced contraction to KCl was demonstrated in both isolated rat and 
murine tracheal rings (Figure 3.8 A and 3.9 A). None of the pre-treatments with 
h-IL-13 altered the cumulative dose response curves for CCh of the tracheae isolated 
from mice or rats as compared with control segments (Figure 3.8 B and 3.9 B).  
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Figure 3.6 Effect of m-IL-13 on rat tracheal smooth muscle contraction. Male, 8 
weeks old, Wistar strain rat were used to obtain the tracheae which were cut into 4-6 
segments. Cumulative concentration-response curves to KCl (A) and CCh (B) in the 
absence or presence of m-IL-13 (100 ng/ml, 24 h). Data were expressed as mean mN 
per mg of tissue (wet weight) ± s.e.m. Student’s paired t-test was performed to 
determine the statistical significance of differences between Emax values of control 
and IL-13-treated tissues for n = 7. 
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Figure 3.7 Effect of r-IL-13 on murine tracheal smooth muscle contraction. Male, 8- 
to-10 weeks old, CD1 strain mice were used to obtain the tracheae which were cut 
into two segments. Cumulative concentration-response curves to KCl (A) and CCh 
(B) in the absence or presence of r-IL-13 (100 ng/ml, 24 h). Data were expressed as 
mean mN per mg of tissue (wet weight) ± s.e.m. Student’s paired t-test was 
performed to determine the statistical significance of differences between Emax values 
of control and IL-13-treated tissues for n = 12. 
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Figure 3.8 Effect of h-IL-13 on murine tracheal smooth muscle contraction. Male, 8- 
to-10 weeks old, CD1 strain mice were used to obtain the tracheae which were cut 
into two segments. Cumulative concentration-response curves to KCl (A) and CCh 
(B) in the absence or presence of h-IL-13 (100 ng/ml, 24 h). Data were expressed as 
mean mN per mg of tissue (wet weight) ± s.e.m. Student’s paired t-test was 
performed to determine the statistical significance of differences between Emax values 
of control and IL-13-treated tissues for n = 12. 
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Figure 3.9 Effect of h-IL-13 on rat tracheal smooth muscle contraction. Male, 8 
weeks old, Wistar strain rat were used to obtain the tracheae which were cut into 4-6 
segments. Cumulative concentration-response curves to KCl (A) and CCh (B) in the 
absence or presence of m-IL-13 (100 ng/ml, 24 h). Data were expressed as mean mN 
per mg of tissue (wet weight) ± s.e.m. Student’s paired t-test was performed to 
determine the statistical significance of differences between Emax values of control 
and IL-13-treated tissues for n = 8. 
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3.8 Discussion 
 
Mice and rat airways are widely used as an experimental model to investigate 
airway smooth muscle contraction in vitro (Van & Joos, 1998; Bryborn et al., 2004; 
Moffatt et al., 2004; Barrio et al., 2006). Thus, the response of isolated tracheal rings 
from both species to IL-13, a key cytokine implicated in the pathogenesis of asthma, 
was studied. The selection of the species was studied. A review to demonstrate 
species differences in adenosine receptor-mediated bronchoconstrictor responses 
showed that Brown Norway rat provides a close model to the response of adenosine 
in human asthma when compared with guinea pig and rabbit (Fozard & Hannon, 
2000). In another study undertaken to clarify smooth muscle-stimulating effects of 
neuromedin U peptide in rats, mice and guinea pigs tracheal rings, it was 
demonstrated that neuromedin U peptide has no effect on trachea of any species. 
(Prendergast et al., 2006). These data demonstrate a marked variation in response 
among different species even for the same agonist. 
 
In isolated murine tracheal rings, incubation with m-IL-13 resulted in 
consistent and significantly enhanced responsiveness compared with the control 
group. As contractile responses to both KCl and CCh (which act via voltage gated ion 
channel-dependent and G-protein coupled receptor-dependent mechanisms 
respectively) were influenced to a similar extent by IL-13, it appears likely that the 
modulation is at the level of the smooth muscle contractile apparatus, rather than 
influencing receptor density or transduction. Fredberg (2004) defined the 
hyperreactivity component of airway hyperresponsiveness, represented by Emax, as the 
ability of the airways to narrow excessively and added that it accounts for the 
morbidity and mortality associated with asthma. These results demonstrated that the 
effects of IL-13 on contractility were principally to increase Emax, and no significant 
changes in EC50 were observed. A similar conclusion was demonstrated from an 
earlier in vitro study showing that cultured murine tracheal rings in the presence of 
IL-13 (100 ng/ml) resulted in enhanced KCl and CCh-induced contraction without 
changes in receptor affinity (Tliba et al., 2003). 
 
It was expected that r-IL-13 would enhance KCl and CCh induced contraction 
in Wistar rat tracheal segments, but it was observed that there was no significant 
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difference between KCl or CCh induced contraction in r-IL-13 (10 or 100 ng/ml)-
treated tissues compared with the control group. Previous work has demonstrated that 
bronchus isolated from male Wistar rats with TNF-α (300 ng/ml) for 24 h enhanced 
acetylcholine induced contraction compared with controls (Sakai et al., 2004). This 
discrepancy might be due to different responses of different airway tissues or 
different cytokine. However, no significant differences in relative contraction in 
response to CCh were found between the trachea, main bronchi and bronchioles of 
Fisher 344 rats (Van & Joos, 1998). Also no difference in sensitivity to acetylcholine 
was found between isolated trachea strips and small intrapulmonary bronchioles 
(Russell, 1978; Van & Joos, 1998). Results concerning insignificant r-IL-13 enhanced 
responsiveness using rat isolated tracheal rings may also suggest different functions 
of r-IL-13 in rats other than enhanced smooth muscle contraction. It was shown that 
rat B cells were able to bind IL-13 and proliferate when cultured with CD40 ligand 
and IL-13, but the administration of IL-13 does not enhance IgE production in vivo 
(Pierrot et al., 2001). Furthermore, it was found that mouse IL-13 does not have an 
effect on B cells, in contrast to human IL-13, supporting the different functions of IL-
13 in different species (Izuhara & Arima, 2004). 
 
The current study demonstrated an evaluation of the short term-effects of 
culturing murine tracheal segments with m-IL-13. Isolated segments cultured for 1, 4 
or 8 h in the presence of m-IL-13 showed no significant difference from control 
segments. It is apparent that more than 8 h incubation with IL-13 is needed for 
enhanced hyperresponsiveness. It was shown in primary fibroblasts cultured from 
asthmatic subjects and normal controls that an increase in eotaxin protein expression 
was not observed above the detection limit until 6 h incubation with IL-13 (30 ng/ml) 
with significant increase at 24 h, and 48 h (Wenzel et al., 2002). Another study 
reported no significant difference in contraction to electric field stimulation or CCh at 
24 h in Brown-Norway rats tracheal strips and bronchial rings between control and 
IL-1β treated tissue (Koto et al., 1996). Absence of a 24 h response in their study 
might be due to species-dependent differences and using a different cytokine. 
 
The effect of culture period of murine tracheal segments on KCl and CCh was 
evaluated by comparing 24 h-incubated rings with fresh segments. There was no 
significant difference in cultured tissue in response to KCl and CCh compared with 
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fresh segments. These data are in agreement with a study (Adner et al., 2002) using 
murine tracheal segments isolated from BALB/cJ mice showing that the maximal 
contraction was increased insignificantly for the first two days of culture compared 
with fresh segments and maximal contraction decreased to 40 and 70 % of initial 
contraction for KCl and CCh respectively by day 8 (Adner et al., 2002). However, a 
similar study using BALB/cJ strain mice showed no significant difference in response 
to CCh between fresh segments and segments cultured for 1, 2, 4 and 8 days (Bryborn 
et al., 2004). These studies support the use of 24 h as culture period as tissues were 
shown to maintain their contractile phenotype during culture. 
 
This study demonstrated that exposure of murine tracheal segments to 
m-IL-13 (100 ng/ml) did not modulate the relaxant responses to isoprenaline. These 
results are the opposite of what would be expected, but it may be due to high 
concentration used. Also, r-IL13 (10 or 100 ng/ml) did not modulate relaxant 
responses to isoprenaline would support different function of r-IL-13. It was studied 
in isolated human tracheal smooth muscle cell that the response to isoprenaline was 
significantly reduced in IL-13 (50 ng/ml)-treated cells (Laporte et al., 2001). 
 
Despite the fact that mouse and rat are closely related rodents (Scalzi & 
Hozier, 1998), an apparent variation in IL-13 enhanced contraction between species 
was demonstrated in this study. Cross-reactivity study using rat isolated tracheal rings 
incubated with m-IL-13 showed no significant difference in KCl induced contraction, 
but m-IL-13 significantly enhanced contraction to CCh. These findings suggest that 
functional homology exists between mouse and rat at the receptor level rather than at 
the IL-13 protein level. Furthermore, it was demonstrated that r-IL-13 did not 
enhance murine tracheal contraction to KCl and CCh, which might support a different 
function of r-IL-13 rather than hyperresponsiveness. These findings are consistent 
with the findings of other investigators in a guinea pig model. They demonstrated that 
a single exposure to nebulized m-IL-13 induces a significant increase in AHR with 
increased inflammatory cells in BAL fluid 24 h after exposure (Morse et al., 2002). 
 
Although this chapter emphasizes the differences in response to IL-13 across 
animal species, it was important to investigate the responsiveness to h-IL-13 in both 
species, which may provide a suitable and useful replacement to human tissue to 
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screen IL-13 enhanced contraction. This study showed that h-IL-13 enhanced 
contraction to KCl in tracheal rings isolated from both rat and mice but did not 
enhance contraction to CCh. This may suggest that h-IL-13 may not be able to 
enhance rat or mouse muscarinic receptors activity. In accordance with the present 
study, it was shown that pretreatment of guinea pig tracheal rings with h-TNFα, h-IL-
1β or h-IL-2 for 18 h had no effect on CCh-induced contraction (Wills-Karp et al., 
1993). However, these workers extended their study to test the effect of these human 
proinflammatory cytokines on the relaxant effect of isoprenaline. They demonstrated 
that h-TNFα, or h-IL-1β, but not h-IL-2 affect the relaxation elicited by isoprenaline 
(Wills-Karp et al., 1993). In a further study, it was demonstrated that incubation of 
guinea pigs tracheal strips with human TNFα for 30 min significantly increased the 
maximum response to methacholine, and this was completely inhibited by a specific 
TNFα antagonist i.e. rh-soluble TNF-receptor-p80 (Pennings et al., 1998). Although 
an anti-inflammatory effect of h-IL-13 was shown in a guinea pig model of 
eosinophilic inflammation induced by TNF-α (Watson et al., 1999), their study also 
supports cross reactivity between h-IL-13 and tissues or cells isolated from different 
species. A recent study showed that incubation of bovine tracheal smooth muscle 
cells incubated with h-IL-13 (20 ng/ml) for 6 h, but not h-IL-4, induced augmentation 
of the ATP-induced gel contraction (Ohta et al., 2008). Although different 
experimental design and cytokines were used in these previous studies, cross 
reactivity interactions were demonstrated. 
 
3.9 Summary 
 
From this chapter, it can be concluded that: 
 
 isolated murine tracheal rings incubated with m-IL-13 are a suitable model to 
further study IL-13-enhanced contraction; 
 culturing murine tracheal segments did not affect their contractile phenotype; 
 IL-13-enhanced contraction was not detected until overnight incubation with IL-13; 
 cross species studies may also signify different pharmacological function(s) of 
IL-13 from different species. 
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Chapter Four 
 
PI3K involvement in IL-13-induced ASM contraction 
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4.1 Introduction 
 
One of the aims of this work was to examine the mechanism(s) involved in 
IL-13-enhanced responsiveness of murine tracheal segments. Although most IL-13 
signalling studies have concentrated on the Janus kinase/signal transducers and 
activators of transcription-6 pathway, IL-13 also activates PI3K and downstream 
effector molecules (Wright et al., 1997; Ceponis et al., 2000; Hershey, 2003). PI3K 
signalling and its putative roles in lung disease have been extensively reviewed 
(Vanhaesebroeck et al., 2001; Medina-Tato et al., 2007; Ito et al., 2007). PI3K may 
contribute to the pathogenesis of asthma by effecting the recruitment, activation, and 
apoptosis of inflammatory cells. PI3K signalling is also important in the regulation of 
resident smooth muscle cells which play critical roles in airway inflammation and 
airway hyperresponsiveness (Halayko & Amrani, 2003). In smooth muscle, PI3K is 
implicated in the enhancement of agonist-induced contraction, as evidenced by the 
ability of pharmacological inhibitors or molecular manipulations of PI3K to reduce 
agonist-stimulated contraction of tissue from hypertensive rats (Northcott et al., 
2005) or insulin-treated airway smooth muscle (Schaafsma et al., 2007).  
 
Two commercially available broad-spectrum inhibitors of PI3K, wortmannin 
and LY294002, contribute greatly to our knowledge of the biological role of PI3K in 
lung inflammation. Administration of wortmannin or LY294002 attenuates 
inflammation in murine models of allergic asthma (Ezeamuzie et al., 2001; Kwak et 
al., 2003). Intratracheal administration of LY294002 significantly inhibits most of 
the pathological characteristics of the mouse asthma model, including increased 
eosinophil counts and eotaxin, IL-5, and IL-13 levels in bronchoalveolar lavage 
fluid. Furthermore, lung tissue eosinophilia, airway mucus production, and AHR to 
inhaled methacholine are all significantly suppressed (Duan et al., 2005). 
Furthermore, PI3K inhibitors can be delivered locally to minimize systemic exposure 
to the drugs and optimise their dosage (Finan & Thomas, 2004). 
 
Although these studies with broad-spectrum inhibitors provide good evidence 
for a role for PI3K in allergic airway dysfunction, these inhibitors do not distinguish 
among the four class I PI3K isoforms (Davies et al., 2000). The development of 
isoform selective inhibitors, as well as genetically modified mice, allow the 
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characterization of the different roles of individual PI3K isoforms in airway disease. 
As reviewed in Medina-Tato et al. (2007), a wide variety of therapeutic options are 
available for respiratory diseases but better drugs are required. Furthermore, a p110δ-
specific inhibitor seems to offer the most potential as a therapeutic target in 
respiratory disease. Such an inhibitor could offer the opportunity of reducing Th2 
responses without severely affecting Th1-mediated immunity, which would prove 
highly beneficial to the allergic patient. In addition, the effects of p110δ silencing on 
mucus production, mast cell degranulation and leucocyte recruitment are all very 
positive effects that an inhibitor could have in the clinic. 
 
The present section of this study examines the role of the PI3K signalling 
pathway in IL-13-induced hyperresponsiveness of murine tracheal smooth muscle. 
Evidence is provided that a PI3Kδ-dependent mechanism plays a key role in IL-13-
enhanced responsiveness. 
 
4.2 IL-13 induced Akt phosphorylation in tracheal lysate 
 
As discussed in chapter three, it was necessary first to identify the species to 
be used. Initial experiments presented in chapter 3 revealed consistent results with 
the use of murine tracheal segments. The ability of IL-13 to activate PI3K signalling 
in murine tracheal tissue was next investigated by assessing the phosphorylation of 
Akt, a downstream target of PI3K. This phosphorylation is dependent on PI3K 
activity. For these experiments, an antibody specific for Ser
473
 phosphorylated Akt, 
as well as an antiAkt antibody to act as the loading control was used. Time-course 
studies were carried out using m-IL-13 (100 ng/ml). Rapid phosphorylation of Akt 
Ser
473
 in murine tracheal tissue was detected after 2 min, which continued for 1 h and 
returned close to the basal level after 4 h stimulation. No significant changes in total 
Akt protein levels were observed in any of the group tested (Figures 4.1 and 4.2).  
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Figure 4.1 Effect of IL-13 on Akt phosphorylation at 2, 5 and 10 min. Tracheal rings 
from 8 CD1 mice treated with IL-13 (100 ng/ml) for 2 to 10 min were homogenized 
in ice-cold lysis buffer. Proteins (30 µg per lane) were separated by SDS-PAGE and 
probed with anti-phospho-Akt and anti-Akt antibodies before detection by enhanced 
chemiluminescence. A, immunoblot from one experiment representative of three. 
After probing for phospho-Akt, blots were reprobed for Akt to determine equal 
loading. B, densitometric analysis of phospho-Akt expression. Results are expressed 
as percentage phospho-Akt compared with total Akt, as determined using LabImage 
software (Lapelan Bio-imaging Solution, Halle, Germany). Bars indicate the mean 
density ratio ± s.e.m. from three independent experiments. **, p < 0.01, significant 
difference from control. 
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Figure 4.2 Effect of IL-13 on Akt phosphorylation at 1, 4 and 8 h. Tracheal rings 
from 8 CD1 mice treated with IL-13 (100 ng/ml) for 1 to 8 h were homogenized in 
ice-cold lysis buffer. Proteins (33 µg per lane) were separated by SDS-PAGE and 
probed with anti-phospho-Akt and anti-Akt antibodies before detection by enhanced 
chemiluminescence. The immunoblot shows samples prepared in two separate 
experiments. After probing for phospho-Akt, blots were reprobed for Akt to 
determine equal loading. 
 
 
4.3 PI3K and IL-13-induced hyperresponsiveness 
 
To examine the potential role of PI3K in IL-13-induced hyperresponsiveness 
in murine tracheal segments, the effects of two structurally distinct non–isoform-
selective PI3K inhibitors, wortmannin (100 nM) and LY29402 (10 µM) were 
assessed. Addition of either inhibitor 30 min before IL-13 prevented the induction of 
ASM hyperresponsiveness, reducing Emax values for both KCl and CCh to that of 
drug vehicle-treated control tissues (Figure 4.3 and Table 4.1). Under the conditions 
used, neither wortmannin nor LY29402 had any effect on the contractility of murine 
tracheal smooth muscle in tissues not pretreated with IL-13 (Table 4.1).  
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Figure 4.3 Effect of PI3K inhibitors on IL-13-enhanced contraction. Tissues were 
incubated for 30 min with drug vehicle (Control), wortmannin (100 nM), or 
LY294002 (10 µM) before exposure to murine IL-13 (100 ng/ml) for 24 h before 
assessing tissue responses to contractile agents KCl (A and B) and CCh (C and D). 
Data from groups are expressed as mean mN per mg of tissue (wet weight) ± s.e.m. 
One-way ANOVA followed by Dunnett's test were performed to determine the 
statistical significance of differences between Emax values. **, p < 0.01 compared 
with control; †† p < 0.01 compared with IL-13-treated tissue. 
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Table 4.1 Effect of broad-spectrum PI3K inhibitors on IL-13-induced contraction in 
isolated tracheal rings. Tissues were preincubated for 30 min with drug vehicle 
(Control, DMSO, 0.05% v/v), wortmannin (100 nM) or LY-249002 (10 µM). Media 
or IL-13 (100 ng/ml) was then added for a further 24 h before assessing contractility 
responses to KCl and CCh. Data are expressed as mean Emax ± s.e.m for n = 5 - 7 
rings from different animals.  
 
 KCl CCh 
 mN /mg tissue 
Control 1.7 ± 0.1 2.2 ± 0.1 
Wortmannin 1.4 ± 0.2 1.8 ± 0.2 
LY294002 1.9 ± 0.4 2.5 ± 0.4 
IL-13 2.8 ± 0.3
a
 3.1 ± 0.2
b
 
IL-13 + Wortmannin  1.3 ± 0.2
c
 1.8 ± 0.3
c
 
IL-13 + LY294002 1.4 ± 0.1
c
 2.2 ± 0.3
d
 
    
a
 P < 0.05 compared with control. 
b
 P < 0.01 compared with control. 
c
 P < 0.05 compared with tissues treated with IL-13 alone. 
   d 
P < 0.05 compared with tissues treated with IL-13 alone. 
 
 
4.4 Effect of wortmannin on murine tracheal contraction 
 
Control experiments were performed to investigate the effect of wortmannin 
at concentrations ranging from 10 - 100 nM. For these experiments, each murine 
trachea was split into two segments. One segment was incubated with wortmannin 
and the other segment was incubated with wortmannin 30 min before m-IL-13 (100 
ng/ml) addition. Responses to KCl and CCh did not show any significant difference 
from vehicle control (DMSO). Mean KCl Emax values expressed in mN/mg for 
DMSO, wortmannin 10, 30 or 100 nM were 1.7 ± 0.1, 1.7 ± 0.3, 1.3 ± 0.1 and 1.3 ± 
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0.2 respectively and CCh mean values were 2.2 ± 0.1, 2.6 ± 0.3, 1.9 ± 0.2 and 1.8 ± 
0.2 in the same order (Figure 4.4). 
 
In another set of control experiments to examine the effect of wortmannin on 
KCl- or CCh- induced contraction, the same protocol was carried out with the 
exception that one segment was incubated with vehicle control and the other segment 
was incubated with m-IL-13 (100 ng/ml) for 24 h. After incubation and mounting the 
tissue in the organ bath, wortmannin (100 nM) was added 30 min before determining 
the KCl and CCh dose response curves. As seen in Figure 4.5, significant 
hyperresponsiveness was still observed, resulting in Emax values for KCl and CCh of 
2.8 ± 0.3 (p < 0.05) and 4.1 ± 0.4 (p < 0.001, n = 6) compared with control values of 
1.7. ± 0.1 and 2.2 ± 0.1 (n = 7) respectively. 
 
 
 
 
Figure 4.4 Effect of wortmannin on isolated murine tracheal rings. Isolated murine 
tracheal segments were exposed to wortmannin (10 –100 nM) for 24 h. Data are 
mean ± s.e.m. n = 4-7. Wortmannin did not significantly affect KCl (A) or CCh (B) 
induced contraction compared with vehicle control. 
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Figure 4.5 Effect of wortmannin (WT) addition before or after IL-13 incubation. 
Wortmannin (100 nM) was added to isolated murine tracheal rings 30 min before m-IL-
13 (100 ng/ml, 24 h) incubation; or 30 min after incubation with m-IL-13 (100 ng/ml, 
24 h) before assessing tissue responses to KCl (A) and CCh (B). Control (non-IL-13-
treated) tissues were incubated in parallel cultures for each protocol (light shaded bars). 
Data from groups are expressed as mean mN per mg of tissue (wet weight) ± s.e.m. 
Student’s paired t-test was performed to determine the statistical significance of 
differences between responses of control and IL-13-treated tissues * P < 0.05; ** P < 
0.01; n = 6-7.  
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4.5 Role of PI3Kδ in IL-13-enhanced contraction 
 
The previous results showed that the non–isoform-selective PI3K inhibitors, 
wortmannin and LY29402, prevented IL-13-induced hyperresponsiveness in isolated 
murine tracheal rings, however both inhibitors act on all four-class I PI3K isoforms. 
Recent in vivo studies support a major role for PI3K p110δ for IL-13-induced 
hyperresponsiveness (Lee et al., 2006a; Nashed et al., 2007), however these in vivo 
studies related the detected hyperresponsiveness to qualitatively altered immune 
responses, rather than alterations in structural cells. Therefore, tissues were treated 
with the selective PI3Kδ inhibitor IC87114 30 min before IL-13 addition (Figure 
4.6).  
 
 
 
Figure 4.6 IC87114 prevents IL-13-enhanced contraction. Isolated murine tracheal 
segments were treated for 30 min with vehicle (control) or with IC87114 (10 µM) 
then incubated for a further 24 h in the absence or presence of IL-13 (100 ng/ml). 
Dose response curves to KCl (A) or CCh (B) were studied. Data points indicate mean 
± s.e.m. for n = 5-7 animals. One-way ANOVA followed by Dunnett's test were 
performed to determine the statistical significance of differences between Emax 
values; **, significantly different compared with control, p < 0.01; ††, significantly 
different compared with tissues treated with IL-13 alone, p < 0.01.  
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IC87114 (10 µM) was able to inhibit completely the ability of IL-13 to elicit 
hyperresponsiveness to either KCl or CCh. In control experiments, this compound 
did not reduce tracheal smooth muscle contractility in the absence of IL-13 
treatment, giving Emax values for KCl and CCh of 1.7 ± 0.3 and 2.6 ± 0.5, 
respectively, compared with 1.7 ± 0.2 and 2.2 ± 0.1 in vehicle-control treated tissues. 
 
4.6 Effects of IL-13 using tracheal rings from p110δ
D910A/D910A
 mice 
 
To investigate further the role of PI3Kδ in IL-13-induced contraction, 
tracheal rings were obtained from mice expressing p110δ
D910A/D910A
, a catalytically 
inactive form of p110δ (Okkenhaug et al., 2002). These mice were generated by 
point mutation instead of deletion to prevent changes in the expression levels of the 
other PI3K catalytic and regulatory subunits. IL-13 was unable to enhance 
contraction in rings isolated from p110δ
D910A/D910A
 mice compared with control rings 
isolated from same mice (Table 4.2 and Figure 4.7). However, IL-13 did elicit 
enhanced contraction in response to KCl and CCh in tracheal rings isolated from 
control DO11-10 mice (Table 4.2 and Figure 4.6). 
 
 
Table 4.2 Effect of IL-13 on KCl- and CCh-induced contractions in isolated murine 
tracheal rings of p110δ
D910A/D910A
 and DO11-10 mice. Data are expressed as mean 
Emax ± s.e.m. for n = 6 pairs of tracheal rings. 
 KCl CCh 
 Control IL-13 Control IL-13 
 mN/mg tissue 
DO11-10 control mice 1.8 ± 0.2 2.9 ± 0.2
a
 2.5 ± 0.3 3.7 ± 0.3
a
 
p110δ
D910A/D910A
 mice  1.9 ± 0.3 1.8 ± 0.4 2.8 ± 0.3 2.4 ± 0.2 
 
a 
P < 0.01 compared with non-IL-13 treated control mice. 
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Figure 4.7 Effect of IL-13 on responsiveness of tissues from p110δ
D910A/D910A
 mice. 
Isolated murine tracheal segments from DO11-10 control or p110δ
D910A/D910A
 kinase-
dead mice were incubated with IL-13 (100 ng/ml, 24 h) before assessment of 
responsiveness to KCl (A) or CCh (B). Data indicate mean ± s.e.m. for n = 6 mice. **, 
p < 0.01 compared with matched tissue not treated with IL-13, Student's paired t-test. 
 
 
4.7 Discussion 
 
4.7.1 PI3K in IL-13 enhanced contraction 
 
After determining IL-13 enhanced contraction in murine tracheal segments, 
the mechanism by which IL-13 induces ASM hyperresponsiveness was 
characterized. Several lines of evidence in this study implicate PI3K signalling in IL-
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13-induced hyperresponsiveness. IL-13-treated tracheal segments express 
phosphorylated Akt. However, immunoblot analysis showed IL-13 induced a very 
early (after 2 min, as assessed by PI3K-dependent phosphorylation of Akt) activation 
of PI3K, while increased responsiveness was not observed until overnight 
incubation. These findings support an earlier study in which human alveolar 
macrophages obtained from normal non-smoking volunteers cultured with IL-13 (10 
ng/ml) for 1 min - 6 h showed phosphorylation of Akt at 5 min – 3 h (Monick et al., 
2002). In an in vivo allergen challenge model, other research group noted Akt 
phosphorylation at 1, 24, 48, and 72 h after OVA inhalation, likely as a consequence 
of an ongoing inflammatory response and persistent local cytokine production (Lee 
et al., 2006a). Furthermore, intratracheal administration of LY294002 significantly 
inhibits OVA-induced increases in total cell counts, eosinophil counts, and IL-5, IL-
13, and eotaxin levels in bronchoalveolar lavage fluid, and dramatically inhibited 
OVA-induced tissue eosinophilia and airway mucus production. This is associated 
with a significant suppression of OVA-induced AHR to inhaled methacholine (Duan 
et al., 2005). It is noteworthy that the study by Duan and co-workers showed that 
LY294002 markedly attenuated OVA-induced serine phosphorylation of Akt. Their 
findings support studies showing attenuated eosinophilic airway inflammation and 
AHR by LY294002 and wortmannin in asthma models (Ezeamuzie et al., 2001; 
Kwak et al., 2003) connecting PI3K and the immune system in hyperresponsiveness 
observed in these models. 
 
In this study using the isolated segments provide functional evidence for the 
role of PI3K in the regulation of IL-13-induced hyperresponsiveness to KCl and 
CCh, established by pharmacological blockade of PI3K activity using wortmannin 
and LY294002. These non–isoform-selective inhibitors prevented IL-13-induced 
hyperresponsiveness in isolated murine tracheal rings. 
 
4.7.2 Effect of wortmannin on murine tracheal contraction 
 
Results of this study demonstrated that wortmannin could be used to inhibit 
IL-13-enhanced contraction to both KCl and CCh. Wortmannin (10, 30 or 100 nM) 
did not suppress the maximum responses for either KCl or CCh, although a non-
significant decrease was observed with 30 and 100 nM wortmannin concentrations. It 
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was previously reported that wortmannin (0.3-3 µM) added for 5 or 30 min inhibited 
the contraction in rat aortic rings stimulated with KCl (Nakanishi et al., 1992). In a 
following study using male pig tracheal smooth muscle, it was demonstrated that the 
PI3K stimulating effect of acetylcholine (1 µM) was blocked by wortmannin (1µM) 
or LY294002 (10 µM), detected by the blocking of PI3K-induced incorporation of 
[
32
P] into the D-3 position on phosphatidylinositols (Mamoon et al., 2001) and 
wortmannin also blocked the phosphorylation of p110 in a concentration-dependent 
manner (10 nM - 1 µM). Although these previous studies demonstrated an inhibitory 
effect of wortmannin on acetylcholine and KCl responses, they used a higher 
concentration of wortmannin and implicated myosin light chain kinase inhibition for 
the wortmannin effect. A recent study supported a PI3K stimulating effect of IL-13 
(20 ng/ml) using wortmannin by testing contractions of collagen gels containing 
bovine tracheal smooth muscle cells (Ohta et al., 2008). This inhibition was detected 
with high (1 µM) wortmannin, but not seen at 100 nM, which indicate non- selective 
effect of wortmannin. 
 
An important question is whether IL-13 enhanced KCL and CCh contractions 
reflect a difference between pre-treatment and post-treatment with wortmannin (100 
nM). Therefore the effect of wortmannin added prior to or after incubation with IL-
13 was examined. Treatment of tissues with wortmannin after 24 h exposure to IL-13 
was unable to reduce the enhanced responsiveness, suggesting a role for PI3K in the 
development of hyper-contractility, rather than in the contraction response per se. 
Thus, it seems reasonable to conclude that the inhibitory effect of wortmannin is 
indicative of effect on IL-13 signalling rather than an effect on KCl or CCh action. 
 
4.7.3 PI3K p110δ in IL-13 enhanced contraction  
 
Recent in vivo studies support a role for PI3K p110δ for IL-13-induced AHR. 
Lee et al. (2006a) demonstrated that p110δ is the main component of class I PI3K-
dependent, allergen-induced Akt activation and inflammation in the lung and 
IC87114 significantly suppresses OVA-induced AHR to methacholine in vivo. It was 
also established that AHR to inhaled methacholine is markedly attenuated in p110δ-
inactivated mice after allergen challenge (Nashed et al., 2007). Using isolated 
tracheal rings treated with the p110δ-selective inhibitor, as well as tissue from 
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animals expressing the catalytically inactive PI3K subunit p110δ
D910A/D910A
, this 
chapter shows a crucial role of p110δ in inflammation-independent induction of 
hyperresponsiveness by IL-13. Hence, whereas previous studies implicate the 
involvement of the PI3K p110δ isoform in the inflammatory component of AHR, 
this work indicates an important role in IL-13-induced ASM contraction independent 
of effects mediated by infiltrating immune cells. These dual actions of IL-13-
stimulated p110δ activity, both in airway inflammation, and in the direct effects on 
structural cells shown in the present study, point to p110δ as an attractive target for 
the treatment of airway disease. An important feature of this study is that PI3K was 
involved only in IL-13-enhanced contractility, because contractility of control tissues 
treated with inhibitors, or tissue expressing p110δ
D910A/D910A
, had responsiveness 
similar to that of normal tissues. 
 
4.8 Summary 
 
In summary, in the present chapter the following was demonstrated: 
 IL-13 induced early Akt phosphorylation; 
 the non–isoform-selective PI3K inhibitors, wortmannin and LY29402, 
inhibited IL-13-enhanced contraction; 
 IC87114 selectively inhibited the p110δ isoform required for IL-13-induced 
tracheal smooth muscle contraction; 
 tissue from p110δ
D910A/D910A
 kinase-dead mice had responsiveness similar to 
that of normal tissues; 
 IL-13-enhanced contraction is due to an effect of p110δ activation in resident 
airway cells. 
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Chapter Five 
 
Effect of PI3K inhibition on IL-13–induced arginase I expression 
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5.1 Introduction 
 
Arginase is a key enzyme of the urea cycle in the liver. It exists as two distinct 
isoenzymes, arginase I, and II, which are encoded by different genes. Arginase I is 
expressed in the liver, as well as other tissues, including the airway epithelium 
(Cederbaum et al., 2004; Bergeron et al., 2007). Arginase I hydrolyzes L-arginine to 
urea and L-ornithine, precursors of polyamines and L-proline involved in smooth 
muscle cell growth and collagen synthesis respectively (Maarsingh et al., 2008a). 
Arginase I expression is upregulated by Th2 cells and their cytokines (Munder et al., 
1999). A potential mechanism of IL-13-induced hyperresponsiveness is the induction 
of arginase, which can compete with nitric oxide synthase (NOS) for the common 
substrate arginine, and remove the modulatory effects of NO on airway smooth 
muscle contraction (Meurs et al., 2003). Furthermore, attenuation of IL-13-induced 
airway hyperresponsiveness was observed in vivo using RNA interference towards 
arginase I (Yang et al., 2006). Microarray analysis in two distinct models of 
experimental asthma, as well as in the lungs of asthma patients, revealed up-
regulation of three genes involved in arginine metabolism, arginase I, arginase II, and 
the cationic amino acid transporter 2. Of particular note is that arginase I is up-
regulated in perivascular and peribronchial pockets of inflammation within the lungs 
of asthmatic mice (Zimmermann et al., 2003). Zimmermann and co-workers also 
demonstrated that up-regulation of arginase occurs in response not only to allergens 
but also in response to IL-4 and IL-13. The development of AHR has also been linked 
to the regulation of L-arginine catabolism by arginase I (Meurs et al., 2002; Yang et 
al., 2006). In chapter four of this study it was demonstrated that IL-13-induced 
hyperresponsiveness depends on PI3K activity. However, IL-13 induced a very early 
activation of PI3K, whereas increased responsiveness was not observed until 
overnight incubation denoting further downstream effector molecule(s).  
 
This study was extended to investigate the role of IL-13-induced 
hyperresponsiveness and arginase I protein expression in murine tracheal segments. A 
number of reports have shown that IL-13 may exert its deleterious effects in asthma 
by directly acting on airway resident cells, including epithelial cells and airway 
smooth muscle cells (Kuperman et al., 2002; Tliba et al., 2003). This section of 
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results also investigated the role of epithelium in IL-13-enhanced contraction as well 
as the effect of epithelial denudation on IL-13-induced expression of arginase I. 
 
5.2 Effect of L-norvaline on IL-13 enhanced contraction 
 
The results in chapter 4 show that IL-13 treatment of tracheal tissue is 
associated with an early activation of PI3K, as assessed by phosphorylation of Akt, 
(after 2 min, using immunoblot analysis) whereas increased responsiveness is not 
observed until overnight incubation. Hence, the mechanism by which IL-13-induced 
contraction remains unclear. For this purpose this chapter investigates a further 
downstream effector molecule of IL-13-induced contraction mechanism. A potential 
mechanism of IL-13-induced hyperresponsiveness is the induction of arginase, which 
can compete with nitric oxide synthase for the common substrate arginine, and 
remove the modulatory effects of NO on airway smooth muscle contraction and 
could be involved in the regulation of cholinergic airway reactivity. Therefore, the 
role of arginase I was investigated in IL-13 induced hyperresponsiveness.  
 
As previously observed, incubation of murine tracheal rings with m-IL-13 for 
24 h potentiated KCl (10-100 mM) and CCh (10
-8 
– 10
-5
 M)-induced contractions 
(Figure 5.1). The agonist Emax of the concentration response curve was significantly 
higher in rings pretreated with m-IL-13 (100 ng/ml) compared with controls, with 
Emax values for KCl and CCh increased approximately 1.6-fold (Table 5.1). Addition 
of L-norvaline before IL-13 prevented the enhanced contraction, reducing Emax values 
for both KCl and CCh to that of drug vehicle-treated control tissues (Figure 5.1, Table 
5.1). Under the conditions used, L-norvaline had no effect on the contractility of 
murine tracheal smooth muscle in tissues not pretreated with IL-13 (Table 5.1). 
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Figure 5.1 Effect of L-norvaline on IL-13-induced hyperresponsiveness to KCl (A) 
and CCh (B). Exposure of tracheal rings to IL-13 (100 ng/ml, 24h) resulted in 
enhanced responsiveness to KCl and CCh compared with control (n = 8), whereas 
responsiveness was reduced when contraction was assessed in the presence of L-
norvaline (10 mM) (n = 4). Tissues were incubated without IL-13 (Control), with IL-
13, with L-norvaline (10 mM) before exposure to murine IL-13, or with L-norvaline 
alone for 24 h, before assessing tissue responses to contractile agents. Data from 
groups were expressed as mean mN per milligram of tissue (wet weight) ± s.e.m. 
One-way ANOVA followed by Dunnett’s test were performed to determine the 
statistical significance of differences between Emax values. **, p < 0.01 compared 
with control; #, p < 0.05 compared with IL-13-treated tissue. 
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Table 5.1 Effect of L-norvaline on responsiveness to KCl and carbachol of IL-13 
incubated murine tracheal segments 
 KCl CCh 
 Emax (mN / mg) 
Control 1.2 ± 0.1 1.9 ± 0.1 
L-norvaline  1.3 ± 0.1 1.7 ± 0.04 
IL-13 1.9 ± 0.2
a
 3.0 ± 0.1
a
 
IL-13 + L-norvaline 1.2 ± 0.1
b
 1.9 ± 0.1
b
 
a
p < 0.01 compared with matched control. 
b
p < 0.05 compared with tissues treated 
with IL-13 alone (n = 4). 
 
5.3 Detection of arginase I protein expression 
 
5.3.1 Western blotting of tracheal homogenates 
 
To correlate IL-13-enhanced contraction detected after 24 h and IL-13-
induced arginase I protein expression, it was necessary to examine the concentration- 
and time-dependent effect of m-IL-13 on arginase I protein expression. Arginase I 
protein expression was determined after incubating murine tracheal rings with 
various concentrations (10-100 ng/ml) of m-IL-13 for 24 h. Figure 5. 2 A shows that 
mice tracheae exhibits a low resting level of arginase I in the absence of IL-13. 
Arginase I protein expression was increased by m-IL13 at the different 
concentrations tested with the largest increase seen at 100 ng/ml. The time-dependent 
study of arginase I protein expression in murine tracheal segments treated with 100 
ng/ml
 
is shown in Figure 5.2 B. Arginase I protein expression was not detected at 1 
and 4 h but was first observed to increase 8 h after the addition of IL-13. 
Densitometric analysis of arginase I protein expression after treating the rings with 
m-IL-13 (100 ng/ml) for 24 h is shown in Figure 5.3. As ascertain from these 
immunoblotting results, IL-13-induced arginase I protein expression coincided with 
the organ bath results showing hyperresponsiveness in response to m-IL-13 (10 and 
100 ng/ml, 24 h). 
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Figure 5.2 Induction of arginase I by IL-13. Tissues were treated with IL-13 (10-100 
ng/ml, 24h) (A) or IL-13 (100 ng/ml) for 1, 4, 8h (B). The lysates were subjected to 
immunoblotting against arginase I (probed with mouse monoclonal anti-arginase I). 
IL-13-induced arginase I protein expression was observed when tissues were treated 
with different concentrations of IL-13 for 24 h, but not at earlier incubation times. 
 
 
 
 
Figure 5.3 Effect of IL-13 on arginase I protein expression in tracheal rings. Tracheal 
rings from 6 CD1 mice treated with IL-13 (100 ng/ml) for 24 h were homogenized in 
ice-cold lysis buffer. Proteins (30 µg per lane) were separated by SDS-PAGE and 
probed with mouse monoclonal anti-arginase I and anti-β-actin antibodies before 
detection by enhanced chemiluminescence. After probing for arginase I, blots were 
reprobed for β-actin to determine equal loading. Densitometric analysis of arginase I 
protein expression was determined using Labimage software (Lapelan Bio-imaging 
Solution, Halle, Germany) and were expressed as percentage arginase I compared 
with β-actin. Bars indicate the mean density ratio ± s.e.m from four independent 
experiments. ***, p < 0.001, significant difference from control. 
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5.3.2 IHC detection of arginase I in murine tracheal rings 
 
To determine the cellular source of the IL-13-induced arginase I protein 
expression demonstrated by Western blotting, IHC staining of arginase I in murine 
tracheal segments was carried out. It was necessary to validate the method used in 
this system, therefore the murine liver served as a positive control, since it is 
established that arginase I is highly expressed in the liver (a synonymous name of 
arginase I is liver arginase). Validity of this method using the liver as a positive 
control was confirmed by the perivenular absence of arginase I expression (Figure 5.4 
A). A negative control in which the rabbit polyclonal anti-arginase I antibody was 
omitted showed no background staining (Figure 5.4 B). 
 
To examine the expression and localization of arginase I in murine tracheal 
segments incubated for 24 h with m-IL-13 (100 ng/ml), paraffin-embedded sections 
were immunostained with rabbit polyclonal anti-arginase I antibody. Strong 
immunostaining for arginase I protein was observed in both epithelium and smooth 
muscle (Figure 5.4 D) compared with control (Figure 5.4 C). 
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Figure 5.4 IHC analysis of arginase I in IL-13 treated segments. Murine Liver served 
as positive control (A) showed expression of arginase I probed with rabbit polyclonal 
anti-arginase I antibody in hepatocyte with perivenular absence of arginase I. No 
staining was observed in control Liver section (B). Increased expression of arginase I 
in both epithelium (Ep) and smooth muscle (SM) compared with control (C & D). 
Positive staining is indicated by the brown colour. Images are representative of 
experiments with 3 mice with positive staining indicated by the brown colour. X 400 
magnification. 
 
5.4 PI3K and IL-13-induced arginase I protein expression 
 
To examine further the potential role of PI3K in IL-13-induced arginase I 
protein expression, the effects of two structurally distinct non–isoform-selective PI3K 
inhibitors, wortmannin (100 nM) and LY29402 (10 µM), were assessed. LY294002 
clearly inhibited IL-13 induced arginase I protein expression in murine tracheal rings 
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(Figure 5.5). Additionally, IHC analysis using LY29402 established increased 
expression of arginase I in IL-13 treated segments in both epithelium and smooth 
muscle (Figure 5.6 B) compared with control (Figure 5.6 A), and inhibited by prior 
treatment with LY294002 30 min before addition of m-IL-13 (Figure 5.6 C). Similarly 
increased expression of arginase I in both epithelium and smooth muscle was seen in 
IL-13 treated segments (Figure 5.6 E) compared with control (Figure 5.6 D), and this 
was also inhibited by prior treatment with wortmannin 30 min before addition of 
m-IL-13 (Figure 5.6 F). These results obtained from immunoblotting and IHC 
established a link between PI3K activity and IL-13 induced-arginase I protein 
expression. 
 
 
 
Figure 5.5 LY294002 inhibits IL-13–induced arginase I protein expression in murine 
tracheal rings. Tracheal rings from 8 CD1 mice treated with LY294002 (10 µM) for 
30 min before exposure to IL-13 (100 ng/ml) for 24 h were homogenized in ice-cold 
lysis buffer. Proteins (30 µg per lane) were separated by SDS-PAGE and probed with 
mouse monoclonal anti-arginase I antibody before detection by enhanced 
chemiluminescence. After probing for arginase I, blots were reprobed for β-actin to 
determine equal loading. Densitometric analysis of arginase I protein expression are 
expressed as percentage arginase I compared with β-actin, determined using 
Labimage software (Lapelan Bio-imaging Solution, Halle, Germany). Bars indicate 
the mean density ratio ± s.e.m. from three independent experiments. **, p < 0.01, 
significant difference from IL-13-treated tissue. 
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Figure 5.6 LY294002 or wortmannin inhibited IL-13–induced arginase I protein 
expression in murine tracheal rings. Tracheal rings from CD1 mice were treated with 
or without LY294002 (10 µM), upper panels, or wortmannin (100 nM) lower panels 
for 30 min before exposure to m-IL-13 (100 ng/ml) for 24 h and subjected to IHC 
analysis. Increased expression of arginase I (probed with rabbit polyclonal anti-
arginase I antibody) in both epithelium and smooth muscle of IL-13 treated segments 
(B & E for LY294002 or wortmannin respectively) compared with control (A & D for 
LY294002 or wortmannin respectively). IL-13 induced arginase I protein expression 
was inhibited by pretreatment with LY294002 or wortmannin (C & F respectively). 
The graphs are representative of experiments with 3 mice for each inhibitor, with 
positive staining indicated by the brown colour. 
 
 
5.5 p110δ and IL-13-induced arginase I protein expression 
 
It has been demonstrated in chapter 4 of this study that IL-13-induced smooth 
muscle contraction in isolated murine tracheal rings depends on PI3Kδ activity, the 
role of PI3Kδ on IL-13–induced arginase I protein expression was investigated by 
Western blot analysis and IHC. Western blot analysis revealed that the PI3K p110δ 
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selective inhibitor IC87114 (10 µM) added 30 min before m-IL-13 addition did not 
inhibit IL-13 induced arginase I protein expression (Figure 5.7). IHC analysis of 
tracheal segments treated with m-IL-13 showed expression of arginase I (Figure 5.8 
B) compared with control sections (Figure 5.8 A). However, Arginase I expression 
was decreased in tracheal segments pretreated with IC87114 below basal expression 
in control tracheal segments (Figure 5.8 C). 
 
 
 
Figure 5.7 IC87114 did not inhibit IL-13–induced arginase I protein expression in 
murine tracheal rings. Tracheal rings from 6 CD1 mice treated with IC87114 (10 µM) 
for 30 min before exposure to m-IL-13 (100 ng/ml) for 24 h were homogenized in 
ice-cold lysis buffer. Proteins (30 µg per lane) were separated by SDS-PAGE and 
probed with mouse monoclonal anti-arginase I antibody before detection by enhanced 
chemiluminescence. After probing for arginase I, blots were reprobed for β-actin to 
determine equal loading. The blot shows bands from two independent experiments, 
and was confirmed in further independent experiment. 
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Figure 5.8 Effect of IC87114 on m-IL-13–induced arginase I protein expression by 
IHC analysis. Tracheal rings from CD1 mice treated with IC87114 (10 µM) for 30 
min before exposure to m-IL-13 (100 ng/ml) for 24 h were subjected to IHC analysis. 
Increased expression of arginase I was seen in both epithelium and smooth muscle of 
IL-13 treated segments (B) compared with control (A). IL-13 induced arginase I 
protein expression was decreased below control level by prior treatment with 
IC87114 (C). The graphs are representative of 2 experiments out of 3 with positive 
staining indicated by the brown colour. 
 
5.6 Role of epithelium in IL-13 enhanced contraction 
 
To elucidate the role played by the epithelium in IL-13 enhanced contraction 
using isolated murine tracheal rings, two sets of experiments were carried out. Firstly, 
in experiments in which the epithelium was denuded before incubation with m-IL-13 
(100 ng/ml, 24 h) resulted in Emax values of 1.4 ± 0.1 and 1.8 ± 0.1 compared with 
control values of 1.2 ± 0.0 and 2.0 ± 0.1 for KCl and CCh respectively. Secondary, in 
experiments in which the epithelium was denuded after 24 h incubation with IL-13, 
significant hyperresponsiveness was still observed, resulting in Emax values for KCl 
and CCh of 1.6 ± 0.2 and 2.2 ± 0.1 compared with control values of 1.0 ± 0.2 and 1.4 
± 0.2 respectively (*p < 0.05, **p < 0.01, n = 6) (Figure 5.9). Denudation of the 
epithelium was confirmed by histological examination of sections of tracheal ring 
(Figure 5.10). Organ bath results obtained from segments with retained or partially 
denuded epithelium were excluded. Epithelial denudation did not appear to damage 
submucosal tissue or the underlying trachealis muscle. 
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Figure 5.9 IL-13-induced contraction in isolated murine tracheal rings requires 
epithelium. Cumulative concentration-response curves to KCl (A&B) and CCh 
(C&D) in the absence (control) or presence of IL-13 (100 ng/ml, 24 h). Data are 
expressed as mean mN per milligram of tissue (wet weight) ± s.e.m. for n = 6. *, p< 
0.05; **, p< 0.001 compared with control, Student’s paired t-test. Murine tracheal 
hyperresponsiveness was lost when epithelium was denuded before incubation with 
IL-13 (100 ng/ml) (A&C) and was maintained when epithelium was denuded after 
incubation with IL-13 (100 ng/ml) (B&D). 
 
 
 
 
24 h 24 h 
Dissection ► IL-13 ► Denudation ► Organ Bath Dissection ► Denudation ► IL-13 ►  Organ Bath  
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Figure 5.10 Haematoxylin and eosin-stained murine tracheal segments. H.& E stain 
of histological sections of tracheal segments before (left panel) and after (right panel) 
removal of the epithelium, X400 magnification. 
 
 
5.7 The epithelium and IL-13-induced arginase I expression 
 
To investigate the role of epithelium in IL-13 induced arginase I protein 
expression, the dissected mouse trachea was cut into four segments. One segment, 
with intact epithelium was incubated with m-IL-13 (100 ng/ml). Another segment 
with still intact epithelium was employed as a control. The epithelium was denuded in 
the remaining two segments and the segments were incubated with or without 
m-IL-13. Arginase I protein expression was induced significantly in IL-13 treated 
tracheal segments as detected by Western blot analysis compared with control in both 
intact and denuded tissues (Figure 5.11). Although IL-13-induced arginase I protein 
expression in the airway smooth muscle was still observed, arginase I protein 
expression in IL-13 treated, epithelium-intact segments was significantly higher than 
IL-13 treated, epithelium-denuded segments. These data implicate the involvement of 
epithelium in IL-13 induced arginase I induction. 
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Figure 5.11 IL-13 induces arginase I in epithelium intact and denuded tissue. 
Removal of the epithelium was associated with a decrease in the amount of arginase 
I protein expression. Tracheal rings from 8 CD1 mice were homogenized in ice-cold 
lysis buffer. Proteins (30 µg per lane) were separated by SDS-PAGE and probed with 
arginase I and β-actin antibodies before detection by enhanced chemiluminescence. 
After probing with mouse monoclonal anti-arginase I antibody, blots were reprobed 
for β-actin to determine equal loading. Densitometric analysis of arginase I protein 
expression are expressed as percentage arginase I compared with β-actin, was 
determined using Labimage software (Lapelan Bio-imaging Solution, Halle, 
Germany). Bars indicate the mean density ratio ± s.e.m. from three independent 
experiments. **, p < 0.01, ***, p < 0.001 significant difference from control,  ###  
significant difference between intact and denuded tissue expression levels, p < 0.001, 
n = 3, each using tissue from 8 mice. 
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5.8 Discussion 
 
5.8.1 L-Norvaline inhibits IL-13 enhanced contraction 
 
To investigate of the role of arginase in IL-13-induced hyperresponsiveness, 
the effect of L-norvaline, an arginase inhibitor, was assessed using murine tracheal 
segments. Although L-norvaline has low potency, it was used in this study because it 
does not affect NOS activity (Chang et al., 1998). A study by the same group (using 
the murine macrophage cell line J774A.1) demonstrated that both actinomycin D and 
cycloheximide completely inhibited the increase in arginase activity and hence is a 
result of inhibition of de novo synthesis of arginase I mRNA and protein (Chang et 
al., 2000). They also showed that IL-13 (5 ng/ml)-inhibited LPS-induced NO 
production was restored by about 70 % when L-norvaline (20 mM) was added for 18 
h, which indicates the contribution of IL-13-induced arginase activity in inhibition of 
NO production. In the present study, the results obtained by modulating arginase 
activity by L-norvaline showed that IL-13 is a potent arginase inducer, which 
contributes significantly to IL-13-enhanced contraction. Similar observations were 
made in mice that had received IL-13 to induce AHR (Yang et al., 2006). In their 
study AHR to methacholine was completely inhibited by arginase I targeted RNAi. 
Moreover, in a recent study conducted in a guinea pig model of asthma, pretreatment 
with the non-selective arginase inhibitor ABH reversed ovalbumin-induced AHR 
(Maarsingh et al., 2008b). 
 
5.8.2 IL-13 induced arginase I protein expression  
 
Once the inhibitory profile of L-norvaline had been investigated, the study 
was continued by immunoblot analysis at various IL-13 concentrations and times of 
treatment. Arginase I is expressed constitutively in murine tracheae, which was 
induced by exposure to m-IL-13 at different concentrations. Notably, changes in the 
expression of arginase I correlate with IL-13 enhanced responsiveness to KCl and 
CCh detected in chapter 3 in this study. Arginase I protein was detected in murine 
tracheal tissue lysate as two immunoreactive bands. These are believed to result from 
translational initiation from two different methionine codons (Ohtake et al., 1988; 
Akiba et al., 2002). A comparable study to this current investigation showed that rat 
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aortic smooth muscle cells contain basal arginase I protein that is elevated at 12 h, 
peaks at 24-48 h and starts to decline at 72 h after the addition of IL-13 (10 ng/ml) 
(Wei et al., 2000). Exposure of rat airway fibroblast to 10 ng/ml of either IL-4 or 
IL-13 causes a time-dependent increase in arginase activity, and increased 
concentration of either cytokines does not cause larger effects (Lindemann & Racke, 
2003). 
 
Arginase I was investigated in this study. It has been previously studied that 
arginase I but not arginase II is the induced isoform both in vitro (in cultured rat 
peritoneal cells) and in vivo (in rat lung) after LPS treatment (Sonoki et al., 1997). IL-
4 and IL-13 are major arginase inducers since schistosome egg-induced granuloma 
arginase I expression and activity are reduced in IL-13-deficient and nearly 
completely eliminated in double IL-4/IL-13-deficient mice (Hesse et al., 2001). This 
is in agreement with studies using murine dendritic cells (Munder et al., 1999) and rat 
aortic smooth muscle cells (Wei et al., 2000) where IL-4 and IL-13 specifically 
induce arginase I but not arginase II mRNA and protein. However, Yang et al. (2006) 
stated that IL-13 alone was sufficient for the induction of AHR, and shRNAi 
inhibition of arginase I results in marked attenuation of IL-13-induced AHR. Their 
study also demonstrated enhanced expression of arginase I, but not arginase II, which 
was directly correlated with the presence of IL-13-induced AHR while the 
recruitment of eosinophils and induction of mucus production persisted after the 
resolution of AHR (Yang et al., 2006). 
 
IHC analysis was carried out and the 24 h time-point was selected to support 
immunoblotting results obtained in this current study. After validation of the 
technique using the liver as a positive control as described by (Multhaupt et al., 
1987), it was demonstrated that murine tracheal segments express a basal level of 
arginase I detected in both epithelium and smooth muscle cells which was notably 
increased after 24 h incubation with m-IL-13.  
 
5.8.3 PI3K role in IL-13-induced arginase I protein expression 
 
To test the hypothesis that IL-13-induced arginase I depends on PI3K 
activation, and that is the key mechanism required for IL-13 enhanced 
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hyperresponsiveness, additional immunoblotting and IHC studies were carried out. 
Pretreatment of murine tracheal segments with LY294002 before IL-13 addition 
resulted in inhibition of IL-13 induced arginase I protein expression below basal 
levels of expression. Comparing results obtained from Western blotting with those 
from IHC analysis, similar results were obtained in murine tracheal section pretreated 
with LY294002. These results were confirmed using another non-selective inhibitor 
wortmannin. The link between PI3K and arginase was studied previously in 
peritoneal or bone marrow-derived macrophages (Rauh et al., 2003; Sakai et al., 
2006; MacKinnon et al., 2008). It was demonstrated that both IL-4 and IL-13 increase 
arginase activity in bone marrow-derived macrophages and that LY294002 blocks IL-
4-stimulated arginase activity (MacKinnon et al., 2008). These findings support 
studies showing increased arginase I protein expression in the SHIP
−/−
 macrophages 
(Rauh et al., 2003), although an increase in arginase activity was not detected in 
PI3K-deficient macrophages (Sakai et al., 2006).  
 
To test the hypothesis of selective PI3K p110δ involvement in IL-13 induced 
arginase I protein induction, in these experiments IC87114 was added to murine 
tracheal segments before m-IL-13 and p110δ expression assessed by Western blotting 
did not inhibit IL-13-induced arginase I protein expression. However, IL-13-induced 
expression was decreased below control level by prior treatment with IC87114 in two 
out of three experiments demonstrated by IHC. This discrepancy between Western 
blotting and IHC results maybe due to regional differences or inconsistent decrease of 
p110δ. The findings obtained using IC87114 question the role of p110δ in IL-13-
induced arginase I and its link to IL-13-enhanced responsiveness. Taken together, 
these results suggest that PI3K plays a role in IL-13- induced-arginase I protein 
expression, but the role of p110δ is not clear. 
 
5.8.4 Epithelial role in IL-13 enhanced ASM contraction 
 
This work demonstrates the role of the epithelium in IL-13-enhanced 
hyperresponsiveness in murine tracheal segments. When the epithelium was denuded 
before incubation with IL-13 hyperresponsiveness was lost, suggesting that the 
potential mechanism of IL-13 to promote hyperresponsiveness is epithelial 
dependent. However, when the epithelium was denuded after incubation with 
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m-IL-13, the increased contractile responses to KCl and carbachol compared with 
control is still observed. Epithelium removal can be carried out mechanically or 
chemically (reviewed in Hulsmann & de Jongste, 1993), however mechanical 
removal was chosen because chemical removal of epithelium necessitates the use of 
the entire length of the trachea since it decreases the maximal contractile force 
(Moffatt et al., 2004). Mechanical removal was verified by histological examination 
of the sections. Mechanical removal of the epithelium could have influenced tracheal 
smooth muscle contraction but, on comparing responses obtained from epithelium-
denuded control with epithelium -intact control segments, the obtained tensions were 
not different. In vivo results obtained by Kuperman et al. (2002) demonstrated that 
reconstitution of STAT6 expression in airway epithelial cells in transgenic mice 
expressing murine IL-13 was sufficient for complete restoration of IL-13-induced 
AHR to methacholine and acetylcholine. 
 
Airway epithelium is a major location of polyamines in the asthmatic lung, 
but they can be found in other cell types in the lung such as smooth muscle cells and 
macrophages (Hoet & Nemery, 2000). As discussed above, the epithelium is needed 
in IL-13-induced hyperresponsiveness. Therefore, the site(s) of IL-13-induced 
arginase I expression were studied. A previous study demonstrated that the 
respiratory epithelium, mononuclear cells with macrophage morphology, and some 
granulocytes isolated from bronchoalveolar lavage fluid stained positive for arginase I 
protein in allergic asthmatic patients (Zimmermann et al., 2003). Current findings 
show IL-13-induced arginase I in both epithelium-intact and denuded tracheal 
segments. However, there was still a significant difference between IL-13-treated 
denuded epithelium segments and IL-13- treated intact epithelium segments pointing 
to the involvement of other cells beside the epithelium in IL-13-induced arginase and 
hyperresponsiveness. Although arginase I expression is reported to be induced by Th2 
cells and their cytokines (Yang et al., 2006), a recent study using human bronchial 
epithelial cells demonstrated that IL-13 (10 ng/ml) decreases arginase I protein 
compared with the control group (Chibana et al., 2008). Their group also shows that 
arginase II is constitutively expressed and is not affected by IL-13 treatment at 
mRNA or protein levels. However, this discrepancy may be due to the use of human 
epithelial cells after 10 days of culture (Chibana et al., 2008).  
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5.9 Summary 
 
 IL-13-induced hyperresponsiveness is reduced by the arginase inhibitor, L-
norvaline, which may point to arginase induction as downstream mediator of 
IL-13-enhanced hyperresponsiveness; 
 concentration and time-course studies correlated IL-13-induced arginase I 
protein expression with hyperresponsiveness; 
 IHC analysis confirmed 24 h as the time point for maximal IL-13 induced 
arginase I protein expression; 
 inhibition of PI3K signalling prevents IL-13-induced arginase I expression in 
isolated tracheal rings detected by both Western blotting and IHC analysis; 
 the epithelium is needed for IL-13-induced hyperresponsiveness; 
 IL-13 upregulates epithelial and smooth muscle arginase I expression but the 
epithelium has a key role in IL-13 induced hyperresponsiveness. 
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Chapter Six 
 
Inhibition of IL-13-induced hyperresponsiveness by PI3Kδ-targeted 
siRNA 
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6.1 Introduction  
 
An aim of many smooth muscle studies is directed towards investigating the 
biophysical factors governing muscle properties and molecular biology including the 
roles of different genes. Currently DNA or RNA transfer is a common method used 
in many studies. An efficient and safe method of delivery of genetic material is a 
continuing problem. The development of methods suitable for efficient intracellular 
targeting of genetic material in intact tissues is very important for therapeutic use and 
the determination of affected function (s), such as contractility, that are not normally 
expressed and/or readily measured in cultured cells 
 
Nonviral transfection strategies include chemical and physical approaches. 
The chemical methods include the use of cationic liposomes (lipoplex), polymers 
(polyplex), combinations of the two (lipopolyplex), calcium phosphate, and 
diethylaminoethyl-dextran. In almost all of these chemical methods the reagents 
promote transfection by complexing with the genetic material to neutralize the 
charge. The condensed DNA or RNA will then interact with the cell membrane and 
enter the cell via endocytosis.  
 
Cationic lipid-mediated gene transfer can use cationic lipids alone but are 
often formulated with a noncharged phospholipid or cholesterol to form liposomes, 
which condense genetic material into small stable particles called lipoplexes. 
Lipoplexes enter the cells and release the genetic material before reaching destructive 
lysosomal compartments (Felgner et al., 1987). Many cationic lipids show good 
transfection activity in cell culture. Once administered in vivo, lipoplexes undergo 
marked changes in size, surface charge, and lipid composition due to interaction with 
negatively charged blood components and formation of large aggregates which 
prevent their access into the intended target (Li et al., 1999; Simberg et al., 2003). 
Intravenous (Thierry et al., 1995; Templeton et al., 1997) and airway (Hyde et al., 
2000; Bragonzi et al., 2000) gene delivery of lipoplexes to the lung have been 
studied. One of the obstacles that face lipoplex-based gene delivery to the airways is 
that a negatively charged and viscous mucus layer that traps and neutralizes 
lipoplexes covers upper airway epithelial cells. Furthermore, in CF patients the 
epithelial cells are also covered with a thick sputum layer that contains DNA released 
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from dead cells and bacteria that increase the negativity state. The presence of 
several phospholipids and surfactant proteins can also inhibit the transfection activity 
of lipoplexes. In addition, well-differentiated upper airway epithelial cells are less 
active in taking up lipoplexes (Duncan et al., 1997; Rosenecker et al., 2003). 
Toxicity related to gene transfer by lipoplexes has been reported especially with 
systemic delivery in the form of induction of proinflammatory cytokines, leukopenia, 
thrombocytopenia, and liver injury with elevated serum transaminase (Tousignant et 
al., 2003). Improved chemical design of lipids with increased biodegradability can 
decrease lipoplex toxicity (Tang & Hughes, 1999). 
 
Cationic polymer-mediated gene transfer is another approach, which is 
similar to lipoplex in action and toxicity. Cationic polymer condenses genetic 
material into small particles to facilitate endocytosis. Airway gene delivery of low-
dose polyplex by aerosols shows efficient lung delivery with no evidence of acute 
inflammation (Gautam et al., 2000). Lipopolyplex is a combination of lipoplex and 
polyplex. Linear poly-L-lysine, protamine, histone, and several synthetic 
polypeptides have been used to condense DNA; the polyplexes formed are then 
coated with a lipid layer. Better protection and more efficiency are achieved with this 
approach (Gao & Huang, 1996). 
  
 Physical methods allow the direct entry of uncomplexed genetic material into 
cells by transient defects on cell membranes, so that the gene enters the cells by 
diffusion. Physical methods include gene transfer by gene gun, electroporation, 
ultrasonic gene transfer and hydrodynamic gene transfer. Needle injection of naked 
genetic material is simple and safe but leads to low level gene expression (Meyer et 
al., 1995). DNA-attached gold particles accelerated by pressurized gas and expelled 
onto cells or a tissue is the principle of the “gene gun” method. It is simple and 
efficient method but only suitable for exposed tissues as skin and mucosa (O'Brien & 
Lummis, 2002). Electroporation is a physical method in which a pair of electrodes is 
inserted on the target tissue. Although electroporation is efficient method (Molnar et 
al., 2004) it needs surgical procedures for non-topical applications and the associated 
high voltage applied to tissues can result in tissue damage (Durieux et al., 2004). 
Ultrasound-facilitated gene transfer creates membrane pores and facilitates gene 
transfer by passive diffusion. Although it has the advantage of site-specific gene 
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delivery, low efficiency is a major problem which might be solved by complexing 
DNA and cationic lipids (Koch et al., 2000). Hydrodynamic gene delivery introduces 
genes into cells of highly perfused internal organs, for example the liver. Although 
simple it is effective in small animals (Liu et al., 1999), although surgical procedure 
may be needed for localized gene delivery (Eastman et al., 2002). The real barrier for 
gene transfer by the hydrodynamic method is the very large volume of fluid required 
for delivery to humans. 
 
Reverse permeabilization is a method originally used to introduce fluorescent 
heparin and the calcium indicator aequorin into smooth and cardiac muscle 
respectively (Morgan et al., 1984; Kobayashi et al., 1989). The mechanism of 
reversible permeabilization is not established but it depends on adding ATP in high 
concentration in divalent cation–free solutions. ATP binds to cell surface receptors 
and removes membrane-associated divalent cations, which leads to increased 
membrane permeability. The induced membrane permeability is then reversed by 
removal of extracellular ATP and addition of high Mg
2+
 followed by graded 
restoration of the physiological concentrations of extracellular Mg
2+
 and Ca
2+ 
(Steinberg et al., 1987). Although the introduction of high molecular weight 
molecules could restrict the use of this technique (Lesh et al., 1995), the possibility 
of introducing siRNA into intact tissue, combined with survival of these preparations 
in organ culture for long periods, suggest that the application of this technique may 
be promising for studying the effects of genetic manipulation on smooth muscle 
contractility.  
 
The objective of investigations represented in this final part of the study is to 
deliver PI3K p110δ-targeted siRNA into IL-13-treated murine tracheal segments and 
assess contractility of smooth muscle rings containing siRNA after organ culture. 
C20 and C22 are new synthesized lipospermines in our department that efficiently 
deliver siRNA in both primary and cancer cell lines (Ghonaim et al., 2008). The 
ability of C20 or C22 to deliver fluorescein-tagged nonselective RNA into 9HTEo- 
and A549 epithelial cell lines and murine tracheal segments was investigated, to 
compare efficiency with a commercially available transfecting agent, TransIT-TKO. 
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6.2 p110δ-targeted siRNA delivery into BEAS-2B cell line 
 
Isolation of primary murine tracheal epithelium was attempted using method 
described in (Davidson et al., 2004) but insufficient isolated epithelial cell was 
demonstrated. Isolation of murine smooth muscle was also attempted (Figure 6.1) 
and elevation in intracellular calcium was measured in response to different agonists 
CCh (10, 30, 100 µM and 1 mM), KCl (100 mM) and ATP (1 or 10 mM). However, 
none of the tested agonists had an effect on intracellular calcium. This raised the 
question if those isolated ASM were functioning cells and were not investigated 
further. Therefore human epithelia cell lines were employed in this study 
 
  
 
       
 
Figure 6.1 Murine tracheal smooth muscle express muscle specific α-actin. Isolation 
of primary murine smooth muscle from enzymatically digested tracheae (left panel). 
Immunocytochemical analysis of isolated murine tracheal smooth muscle cells 
demonstrates α-actin smooth muscle immunopositive staining (right panel). 
 
 
BEAS-2B is a human bronchial epithelial cell line transformed with adenovirus 
12-SV40 virus. For transfection 4 × 10
5
 cells per well were seeded in a 6-well plate 
and incubated overnight to reach 50–70% confluency. Cells were transfected with 100 
nM p110δ-targeted siRNA in the presence of 10 µl Lipofectamine 2000. Lysis of cells 
was carried out after 72 h of culture. Western blot analysis of total cell lysates (Figure 
6.2) demonstrated a strong reduction of p110δ protein in the siRNA-treated samples. 
Transfections without siRNA or with scrambled siRNA served as a control.  
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Figure 6.2 Effect of p110δ-targeted siRNA in BEAS-2B cells. BEAS-2B cells were 
transfected with p110δ-targeted siRNA in the presence of Lipofectamine 2000. After 
72 h, the cells were lysed and p110δ expression assessed by Western blotting and 
detection with specific antibodies for p110δ. β-actin served as equal loading control. 
Representative of 2 experiments. 
 
 
6.3 Expression of IL-13 receptors in human tracheal 9HTEo- cells 
 
As described in chapter 5 the epithelium has a key role in IL-13 enhanced 
hyperresponsiveness, and additionally plays a role in IL-13-induced arginase I 
protein expression. 9HTEo- are a transformed human tracheal epithelial cell line 
(Gruenert et al., 1988). To assess the suitability of 9HTEo- in siRNA experiments 
and study the role of IL-13 on human epithelium, the expression of IL-13Rα1 and 
IL-13Rα2 was examined in unstimulated 9HTEo-. As shown in Figure 6.3 and 6.4, 
IL-13 Rα1 and IL-13 Rα2 mRNA were detected by PCR in unstimulated 9HTEo-. 
To study the effect of IL-13 on IL-13 Rα2 gene expression in 9HTEo-, the cells were 
incubated with h-IL-13 (10 or 100 ng/ml, concentrations previously used in the organ 
bath experiments). The level of IL-13 Rα2 mRNA was not altered in IL-13 (10 
ng/ml)-treated cells compared with unstimulated 9HTEo-
 
cells (Figure 6.4). In 
contrast, a decrease in IL-13 Rα2 mRNA was seen when 9HTEo-
 
cells were 
incubated with IL-13 (100 ng/ml) (Figure 6.4). The cell surface expression of IL-13 
Rα2 was also investigated by flow cytometry following treatment with h-IL-13 (1, 
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10, 30 and 100 ng/ml) in 9HTEo-cells. Basal expression of IL-13 Rα2 protein was 
detected on the cell surface of non-stimulated 9HTEo- cells, and similar levels of IL-
13 Rα2 expression were observed in 9HTEo- cells when different IL-13 
concentrations were investigated (Figure 6.5). Again, a small decrease in IL-13 Rα2 
protein expression was suggested in IL-13 (30 or 100 ng/ml) stimulated cells. 
 
 
 
 
 
 
  
Figure 6.3 Detection of IL-13-Rα 1 mRNA in 9HTEo- cell line. Gel was stained 
with ethidium bromide and visualized under U.V. light. Lane 1:  no template 
(negative) control; Lane 2:  negative control where reverse transcriptase was omitted 
from the reaction; Lane M: DNA molecular marker. Representative of 2 experiments. 
 
  
 
 
 
 
 
      1        2                  1          2                   1           2 
 
 
 
Figure 6.4 Effect of IL-13 (10 or 100 ng/ml) on IL-13 Rα2 expression in 9HTEo-
 
cell line. Gel was stained with ethidium bromide and visualized under U.V. light. 
Lane 1:  no template (negative) control; Lane 2:  negative control where reverse 
transcriptase was omitted from the reaction; Lane M:  DNA molecular marker. 
Representative of 2 experiments. 
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Effect of h-IL-13 on IL-13R alpha 2 expression in 9-HTEo- cells by flow cytometry
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Figure 6.5 Expression of IL-13 Rα2 in 9HTEo- cell line. 9HTEo- cells were cultured 
without or with IL-13 (1, 10, 30 or 100 ng/ml) for 24 h and flow cytometric analysis 
was performed using antihuman IL-13 Rα2 antibodies or isotype control to detect 
surface expression of IL-13Rα2. No Ab ▬, an isotype control ▬, non-stimulated 
cells ▬, IL-13 (1ng/ml)-stimulated cells ▬, IL-13 (10 ng/ml)-stimulated cells ▬, 
IL-13 (30 ng/ml)-stimulated cells ▬, (100 ng/ml)-stimulated cells ▬. Linear graphs 
in the top figure are % total positive cells. Each bar in the lower graph is % total 
positive cells of indicated treated cells after subtraction of isotype control % total 
positive cells. The histogram data is a mean of two different experiments. M1 is live 
gate during acquisition. 
M1
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6.4 RNA delivery into 9HTEo- and A549 cell lines 
 
 The transfection of fluorescein-tagged RNA (RNAi Delivery Control, Mirus) 
into 9HTEo- and A549 cell lines was investigated and compared with a market leader 
TransIT-TKO (Mirus). A fluorescein-labelled RNA duplex has the same length, 
charge, and configuration as standard siRNA was used. C20 (eicosenoyl) and C22 
(erucoyl) are novel nonviral lipospermines, which were chosen according to their high 
transfection efficiency (Ghonaim et al., 2008). The fluorescein-tagged RNA 
transfection efficiency experiments, carried out in triplicate on three separate 
occasions demonstrated that the transfection ability of C20 or C22 were comparable to 
the results of TransIT-TKO in both cell lines (Figure 6.6 A). Also, the cell viability 
(MTT assay) results demonstrated that there was no significant difference in the 
viability of A549 and 9HTEo- cells exposed to the commercially available TransIT-
TKO or lipospermines (Figure 6.6 B).  
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Figure 6.6 Lipofection and cytotoxicity effects of fluorescein-tagged RNA 
complexed with C20, C22 or TransIT-TKO on 9HTEo- and A549 cell lines. 
(A) % of transfected cells, bars represent the mean ± s.e.m of 3 experiments, each 
performed in triplicate. (B) % of viable cells, bars represent the mean ± s.e.m of 3 
experiments. One-way ANOVA was performed to determine any statistical 
significance of differences between mean values. 
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6.5 Assessment of siRNA uptake 
 
 The transfection of fluorescein-tagged RNA into murine tracheal rings was 
also investigated with the use of two newly synthesized lipospermines in our 
department, N
4
,N
9
-dieicosenoyl spermine (eicosenoyl or C20), N
4
,N
9
-dierucoyl 
spermine (erucoyl or C22). The transfection efficiency of C20 or C22 was compared 
with TransIT-TKO (Mirus), a commercially available transfection agent. (Figure 6.7) 
The fluorescein-tagged RNA has the same length, charge, and configuration as 
standard siRNA. It is a 21 nucleotide “target” sequence with UG-3′ overhangs: 
 
      GAGGCGCAACUGGCUGACCUG 
GUCUCCGAGUUGACCGACUGG 
 
The sequence of the duplex (above) is inert and not known to affect any 
cellular events. The concentrations for the tested transfecting agents were previously 
determined (Ghonaim et al., 2008). Also to validate siRNA uptake using the reverse 
permeabilization technique the fluorescein-tagged RNA was introduced into isolated 
murine tracheal rings at different concentrations (20, 50, and 100 nM). 
Lipospermine, TransIT-TKO and reversibly permeabilized treated segments were 
subsequently cultured for 72 h. After tissue embedding, sectioning and fixation (see 
section 2.4.1, 2.4.4), the intracellular localization and efficacy of fluorescein-tagged 
RNA incorporation was determined by confocal microscopy. In control experiments, 
in which murine tracheal rings were incubated without being reversibly 
permeabilized (Control 1) or reversible permeabilized in the absence of fluorescein-
tagged RNA  (Control 2), only minimal epithelial fluorescence was detected by 
confocal microscopy (Figure 6.8) The transfection of fluorescein-tagged RNA (50 or 
100 nM) by C20, C22 or TransIT-TKO (Figure 6.7) showed the same fluorescence 
compared with controls seen in Figure 6.8.This indicates low efficiency of those 
transfecting substances; there was a mild increase in fluorescence with the use of 
TransIT-TKO, which may enabled transfection with 100 nM fluorescein-tagged 
RNA (Figure 6.7 F). As demonstrated in Figure 6.8 reverse permeabilization enabled 
the influx of fluorescein-tagged RNA (50 and 100 nM) into murine tracheal rings. 
The lining epithelium was more brightly fluorescent following treatment with 50 and 
100 nM than with 20 nM concentration of fluorescein-tagged RNA. There was 
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minimal fluorescence in controls and segments reversibly permeabilized and treated 
with 20 nM fluorescein-tagged RNA. 
 
 
 
Figure 6.7 Confocal images of lipoplex-treated murine tracheal segments. Confocal 
microscopy of murine tracheal segments showing the absence of an increased 
fluorescent signal at either 50 or 100 nM RNA concentrations tested. A is C20 / 
fluorescein-tagged RNA 50 nM, B is C20 /100 nM fluorescein-tagged RNA, C is 
C22 /50 nM fluorescein-tagged RNA, D is C22 /100 nM fluorescein-tagged RNA, E 
is TransIT-TKO/ 50 nM and F is TransIT-TKO/ 100 nM fluorescein-tagged RNA. 
Sections are representative of 2 independent experiments. 
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Figure 6.8 Confocal images of reversibly-permeabilized tracheal rings. Murine 
tracheal segments were reversibly permeabilized  (RP) and exposed to fluorescein-
tagged RNA at concentrations 20, 50 and 100 nM. Confocal microscopy 72 h after 
reversible permeabilization shows the presence of fluorescent signal mainly in the 
lining epithelium of tissues treated with 50 and 100 nM concentrations of RNA. For 
control experiments to exclude autofluorescence, the tracheal ring was exposed to 
culture media (Control 1) or to the reversible permeabilization protocol without 
addition of fluorescein-tagged RNA siRNA (Control 2). Sections are representative 
of 2 independent experiments. 
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6.6 PI3Kδ-targeted siRNA attenuates IL-13-enhanced contraction 
 
 To confirm the role of p110δ in the IL-13-enhanced responsiveness studied in 
chapter 4, contraction response in tissues treated with p110δ-targeted siRNA delivered 
by reverse permeabilization was assessed. Controls with or without the introduction of 
scrambled siRNA were also studied. Segments were reversibly permeabilized without 
siRNA, with p110δ-targeted siRNA or with scrambled siRNA then cultured for 2 days. 
m-IL-13 (100 ng/ml) was then added to all three groups for an additional 24 h before 
measurement of isometric force. There was no significant difference between murine 
tracheal segments that were reversibly permeabilized with or without the introduction 
of scrambled siRNA. KCl Emax values of control and scrambled siRNA-treated 
segments were 1.0 ± 0.15 and 1.1 ± 0.17 mN/mg respectively (Figure 6.9 A) while 
CCh gave Emax values of 1.8 ± 0.26 and 2.0 ± 0.14 mN/mg for control and scrambled 
siRNA-treated segments respectively (Figure 6.9 B). KCl (Figure 6.9 C) and CCh 
(Figure 6.9 D) responses in IL-13-treated segments reversibly permeabilized and 
treated with p110δ-targeted siRNA were significantly reduced compared with tissues 
reversibly permeabilized in the absence of siRNA or in the presence of scrambled 
siRNA. 
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Figure 6.9 p110δ-targeted siRNA prevents IL-13-enhanced contraction in response 
to KCl and CCh. Isolated murine tracheal segments were reversibly permeabilized in 
absence of siRNA (control) or in the presence of scrambled siRNA (20 nM) then 
incubated for 72 h before determining Emax for KCl (A) or CCh (B). Reverse 
permeabilization in the absence of siRNA or presence of p110δ siRNA (20 nM) or 
presence of scrambled siRNA (20 nM) then cultured for 48 h. IL-13 (100 ng/ml) was 
then added to the three groups and the tissue were cultured for additional 24 h 
followed by determination of KCl (C) or CCh (D) Emax values. Data indicate mean 
Emax tension (mN/mg) ± s.e.m. for n = 4 animals. Student’s paired t-test was 
performed to determine the statistical significance of differences between control and 
scrambled siRNA-treated tissues for n = 4. One-way ANOVA followed by Dunnett's 
test were performed to determine the statistical significance of differences between 
Emax values of IL-13 treated tissues; *, significantly different compared with p110δ-
targeted tissue, p < 0.05. 
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6.7 PI3Kδ-targeted siRNA downregulates p110δ protein 
 
 Murine tracheal segments employed for tension measurements in section 6.6 
were rapidly transferred into liquid nitrogen prior to preparation of samples for 
Western blot analysis for the detection of p110δ. For these experiments, an antibody 
specific for p110δ as well as β-actin antibody to act as the loading control was used. 
There was no difference between scrambled-siRNA treated tissue and control, but 
p110δ-targeted siRNA in IL-13 treated segments showed lower p110δ protein levels 
compared with segments treated with scrambled siRNA or IL-13 alone (Figure 6.10). 
The same membrane was reprobed with an antibody specific for arginase I. Arginase 
I protein expression was increased in IL-13-treated murine tracheal segments 
compared with controls, and was not reduced by p110δ-targeted siRNA. These 
findings demonstrated an absence of a link between p110δ and arginase I. No 
changes in β-actin were observed, demonstrating that p110δ is downregulated as a 
result of p110δ-targeted siRNA (Figure 6.10). 
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Figure 6.10 p110δ knock-down in tracheal rings by reverse permeabilization. 
Tracheal rings from 4 mice were reversibly permeabilized in the presence or absence 
of scrambled siRNA and cultured for 72 h. Tracheal rings from another 4 mice were 
reversibly permeabilized in the absence or presence of p110 δ-targeted siRNA or the 
presence of scrambled siRNA and cultured for 48 h. IL-13 (100 ng/ml) was added to 
the intended groups, then recultured for additional 24 h. Western blotting analysis 
was carried out with anti-p110δ, and mouse monoclonal anti-arginase I antibodies 
before detection by enhanced chemiluminescence. The β-actin band shown in the 
lower blot was used to ensure equal loading. Immunoblot from one experiment is a 
representative of two.  
 
 
6.8 Discussion 
 
 RNAi so far has been used mainly as a functional rather than a therapeutic 
tool. It faces many challenges to step from cell culture and preclinical in vivo models 
to the clinic. Delivery to the right cell type, in the right organ, at the right time with 
no or minimal nonspecific, including immunological, effects are obstacles to be 
overcome (Caplen, 2004).  
 
 In order to assess the delivery of siRNA epithelial cell lines were examined. 
The knock-down of p110δ was demonstrated in the human bronchial epithelial cell 
line BEAS-2B. p110δ-targeted siRNA treated cells showed lower protein levels 
◄p110δ 
◄arginase I 
◄β-actin 
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compared with cells treated with scrambled siRNA or untreated cells. In a similar 
study it was demonstrated that STAT6 knock down by siRNA results in decreased 
eotaxin-3 level in BEAS-2B (Rippmann et al., 2005).  
 
 Further experiments were carried out with human tracheal epithelial cell line 
9HTEo-. Work shown in this chapter demonstrates that unstimulated 9HTEo- 
express both IL-13Rα1 and IL-13Rα2 and flow cytometric analysis revealed similar 
levels of IL-13 Rα2 in IL-13-stimulated 9HTEo-cells. These findings encouraged the 
application of 9HTEo- for siRNA studies. 
 
 C20 and C22 were found to be efficiently delivery vectors to both 9HTEo- 
and A549 cell lines, which were comparable to the results obtained with TransIT-
TKO, C20 and C22, novel very long chain lipopolyamines. A549 cell line viability 
was 80.9 % and 80.1 % for C20 and C22 respectively, which was similar to TransIT-
TKO recorded viability of 86.4 %. A recent study to deliver enhanced green 
fluorescence protein siRNA to A549 using polyplex was both efficient and safe and 
the delivery of shRNA efficiently silenced Akt1, confirmed by Western blot analysis 
(Jere et al., 2008). 
 
  Both C20 and C22 effectively transduce fluorescein-tagged RNA into 
9HTEo-, and similar viability was observed compared with TransIT-TKO. In a 
similar study to test cytotoxic effects of polyplexes in A549 and 9HTEo- cells by 
measuring the release of lactate dehydrogenase (LDH), A549 cell cytotoxicity was 
not increased by transfecting substance but 9HTEo- showed a slight increase 
(Carrabino et al., 2005) which may indicate the vulnerability of 9HTEo-. Another 
study showed that 9HTEo- were transfected with nanospheres contain DNA 
encoding the CFTR gene resulted in CFTR expression in about 50%-60% of the cells 
(Truong-Le et al., 1999). 
 
 C20 or C22, the lipospermines, were tested as well as TransIT-TKO in 
murine tracheal segments with the use of two different concentrations of fluorescein-
tagged RNA (50 or 100 nM). The level of fluorescence in tested murine tracheal 
segments was comparable to that of control segments denoting low efficiency entry 
of the tested lipospermines. The use of siRNA for respiratory system delivery has 
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focused on direct delivery of siRNA to lung epithelial cells through intratracheal or 
intranasal route and most reported successful studies have used simple saline 
formulations (reviewed in de Fougerolles & Novobrantseva, 2008). Although the 
cationic lipid GL has been utilized in human clinical trials, GL-formulated siRNA 
was found in alveolar macrophages while protein levels of β-galactosidase (as a 
functional tool to test siRNA targeting) was not decreased in murine airway 
epithelial cells (Griesenbach et al., 2006). Many factors can account for the failure of 
lipoplexes to efficiently transfect airways (see section 6.1), but it was recently 
demonstrated that IL-13-targeted siRNA complexed with a polyethylenimine 
derivative jetPEI delivered via the tail vein of OVA-sensitized mice resulted in 
reduced lung resistance in response to inhaled methacholine compared with controls 
(Lively et al., 2008). 
 
 Fluorescein-tagged nonselective RNA was used also to assess siRNA uptake 
into murine tracheal segments by the reverse permeabilization technique. 
Fluorescein-tagged RNA was introduced into the epithelial lining of murine tracheal 
segments as assessed by confocal microscopy, which also showed higher 
fluorescence with the use of higher concentrations, a result consistent with other 
reports demonstrating accumulation of FITC-labelled oligodeoxynucleotides into rat 
ileum smooth muscle cells (Lesh et al., 1995), and FITC-conjugated nonselective 
siRNA into rat isolated aortic smooth muscle cells (Corteling et al., 2007). It was 
demonstrated that fluorescein-tagged nonselective RNA showed higher fluorescence 
when applied at 50 nM compared with 100 nM, which maybe due to a saturation 
effect. Fluorescence detected in the epithelium is consistent with role of epithelium 
as a site of IL-13 enhanced hyperresponsiveness demonstrated earlier in this study.  
 
 RNAi can be used as means to induce transient loss of function of molecules 
involved in respiratory diseases. Efficient introduction of siRNAs into cells in intact 
tissue and the maintenance of normal contractility of smooth muscle rings containing 
siRNA for at least 3 days in organ culture are major obstacles. The reverse 
permeabilization method to deliver p110δ-targeted siRNA was carried out. The 
tension of control murine tracheal segments exposed to reverse permeabilization 
solutions and recorded after three days of culture was maintained compared with 
previously recorded tension in control segments cultured for 24 h. This is consistent 
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with a previous siRNA reverse permeabilization approach for intact cerebral arteries 
in which siRNA effectively decreased Gq and RhoA mRNA levels over a 5-day 
period of organ culture, and importantly RhoA siRNA-targeted arteries did not 
constrict to UTP after 4 days of organ culture. The main objective of these studies 
was to deliver siRNA or antisense oligodeoxynucleotides into smooth muscle cells 
(Lesh et al., 1995; Corteling et al., 2007; Smolock et al., 2007). In the current study, 
epithelium-intact murine tracheal segments were investigated to simulate in vivo 
conditions. These data using p110 δ-targeted siRNA support the results shown in 
chapter 4 that demonstrated an essential role of p110δ using the p110δ–selective 
inhibitor, as well as tracheal segments from animals expressing the catalytically 
inactive PI3K subunit p110δ
D910A/D910A
. In the current chapter p110δ-targeted 
siRNA-treated tissue no longer demonstrates IL-13-enhanced responsiveness to KCl 
or CCh compared with scrambled siRNA-treated segments. Studies carried out with 
denuded rat cerebral or swine carotid arteries showed decreased contraction after 
RhoA or casin kinase 2-targeted siRNA respectively, which were delivered by 
reverse permeabilization (Corteling et al., 2007; Smolock et al., 2007). Although 
fluorescein-tagged nonselective RNA (20 nM) did not indicate transfection, the 
functional study using this concentration of p110δ-targeted siRNA revealed loss of 
IL-13 enhanced responsiveness. This can be explained by decreased fluorescence 
after 3 days incubation at 20 nM concentration.  
 
 Reversibly permeabilized murine tracheal rings that were studied for 
isometric tension contraction were processed for measurements of p110δ protein 
content. Although there were small differences between p110δ content in controls 
(segments with or without scrambled siRNA) and IL-13-treated segments, this is 
likely due to animal-to animal variation. Because it was difficult to dissect more than 
2 rings to study isometric contraction, control and IL-13-treated segments were 
obtained from two different groups. However, it was demonstrated that the 
introduction of p110δ-targeted siRNA into murine tracheal rings downregulated 
p110δ protein content and scrambled siRNA had no effect on p110δ level. No 
significant changes in β-actin (used for equal loading) were observed and p110δ 
downregulation was a result p110δ-targeted siRNA. Yang et al. (2006) showed that 
arginase I expression correlated with the development, persistence and resolution of 
IL-13-induced AHR and silencing arginase I in murine lung by RNAi resulted in 
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marked attenuation of IL-13-induced AHR to methacholine. Although the results 
presented in this chapter indicate that IL-13 upregulates arginase I protein 
expression, the possibility that PI3K p110δ contributes to IL-13-induced arginase I-
protein expression is not supported by the data shown in this chapter and other 
signalling mechanism (s) such as STAT6 may be involved. In STAT6-deficient mice, 
Yang et al. (2006) showed that STAT-6 regulates arginase I protein expression in 
response to IL-13.  
 
 Delivery of p110δ-targeted siRNA by reverse permeabilization into murine 
tracheal segments followed by functional evaluation seems to be a step forward to 
assess the delivery of RNAi. This method was evaluated both by functional loss of 
IL-13-enhanced hyperresponsiveness and detection of fluorescein-tagged 
nonselective RNA in tissue. However, the lipospermines C20 and C22 investigated 
were not suitable to deliver siRNA into tissue, although these can be efficiently 
delivered to cell lines and can serve to further elucidate signalling mechanisms. 
Efficient delivery and viability of tissues or cell lines following siRNA delivery are 
important to evaluate the methods used. 
 
6.9 Summary 
 
 p110δ- was knocked down in  BEAS-2B cell line; 
 human tracheal 9HTEo- cells express IL-13 receptors; 
 RNA was efficiently delivered into 9HTEo- and A549 cell lines by novel 
lipospermines; 
 PI3Kδ-targeted siRNA attenuates IL-13-enhanced contraction using reverse 
permeabilization method. 
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Chapter Seven 
 
General conclusions 
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 IL-13 has a range of effector functions, with key roles in asthma. Although 
IL-13 potentially contributes to the effector phase of the allergic response for 
example recruitment of inflammatory cells into the airway spaces, IgE production 
and airway remodelling, it is likely that some effects of IL-13 maybe through its 
action on resident cells such as epithelial cells, fibroblasts, and smooth muscle cells 
(Wills-Karp, 2004). AHR is a hallmark of asthma and IL-13 can induce AHR in the 
absence of inflammatory cells (Grunig et al., 1998). 
  
The main objective of this project was to identify and characterize 
pharmacological target(s) for the treatment of altered lung function seen in 
inflammatory lung disease. Although a disadvantage of using airway strips and ring 
preparations is the inability to stimulate the mucosal or the serosal side selectively 
(Hulsmann & de Jongste, 1993) tracheal rings were selected over tracheal strips 
because the configuration of the ASM bundles is largely preserved in this 
arrangement, and their contraction is directly related to in vivo airway narrowing. 
Animal models of inflammatory lung disease can reflect short-term or acute 
inflammation seen in human chronic airway diseases. At the start of this project, 
comparison of the responses using smooth muscle preparations from two common 
laboratory animals (rat and mice) to investigate IL-13-induced hyperresponsiveness 
was carried out. It was observed that murine tracheal segments produced consistent 
and significant enhanced responsiveness to both KCl and CCh after incubation with 
m-IL-13. These findings, added to the availability of a wide range of tools of mice 
genetics, provided support for the use of isolated murine tracheal segments in the 
following experiments. A 24 h incubation period also proved to be important in m-
IL-13 enhanced hyperresponsiveness. This period was most probably needed for 
protein synthesis for IL-13 enhanced contraction. As shown in chapter three, the 24 h 
culture period had no effect on murine tracheal segments contraction as demonstrated 
by insignificant difference between fresh and cultured rings. However, it was 
determined that rat tracheal rings incubated with r-IL-13 at different concentration 
were not significantly different from control group. It was anticipated that IL-13 
might attenuate the relaxant responses to isoprenaline, but this was not detected in 
either rat or mice isolated tracheal segments. Cross-reactivity studies demonstrated 
that m-IL-13 significantly enhanced contraction to CCh in rat tissue while r-IL-13 
did not enhance contraction to either KCl or CCh. This may imply a different 
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function of r-IL-13 rather than induction of hyperresponsiveness. While r- and m-IL-
13 represent a much more homologous system for rat and mice isolated tracheal 
segments respectively, it was important to test h-IL-13 on both rat and murine 
tracheal segments. h-IL-13 enhanced contraction to KCl in tracheal rings isolated 
from both rat and mice, but did not enhance contraction to CCh which may indicate 
that h-IL-13 does not enhance rat or mice muscarinic receptors activation.  
 
 The next part of this study involved investigating the mechanism(s) by which 
IL-13 induces hyperresponsiveness. Previous studies have focused on the Janus 
kinase/signal transducers and activators of transcription-6 pathway (Kuperman et al., 
1998; Roy et al., 2002; Kuperman et al., 2002), although IL-13 was shown to 
activate PI3K and downstream effector molecules in a range of other systems 
(Wright et al., 1997; Ceponis et al., 2000; Hershey, 2003). The role of PI3K p110δ in 
IL-13-induced hyperresponsiveness was recently studied (Lee et al., 2006a; Nashed 
et al., 2007). Work presented in this thesis provides several lines of evidence that 
implicate PI3K signalling in IL-13-induced hyperresponsiveness. IL-13 induced a 
very early (after 2 min) PI3K-dependent phosphorylation of Akt. Wortmannin and 
LY294002, non-isoform-selective PI3K inhibitors, prevented IL-13-induced 
hyperresponsiveness in isolated murine tracheal rings. When studying wortmannin at 
different concentrations, it did not suppress the maximum tension elicited for either 
KCl or CCh. Moreover, the enhanced responsiveness was maintained when the 
segments were treated with wortmannin after 24 h exposure to IL-13. Isolated 
tracheal rings treated with IC87114, p110δ-selective inhibitor, as well as segments 
isolated from animals expressing the catalytically inactive PI3K subunit 
p110δ
D910A/D910A
, had responsiveness similar to that of normal tissues. These findings 
indicate an important role of IL-13-induced ASM contraction independent of effects 
mediated by infiltrating immune cells. 
 
Akt phosphorylation downstream of IL-13 signalling was detected early, 
whereas increased responsiveness was not observed until overnight incubation, which 
suggested further downstream effector molecule (s) involved in IL-13-induced 
contraction. A potential mechanism of IL-13-induced hyperresponsiveness is the 
induction of arginase (Maarsingh et al., 2008b). The next finding in this study was 
inhibition of IL-13 enhanced contraction by L-norvaline, an arginase inhibitor, 
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implying a role for arginase in this system. Arginase I protein expression as detected 
by Western blotting was induced by m-IL-13 after 24 h, but not at earlier times tested, 
which correlated with IL-13 enhanced hyperresponsiveness. IHC analysis supported 
IL-13-induced arginase I protein expression after 24 h treatment with IL-13. 
Therefore, is there a link between PI3K and arginase I in IL-13-enhanced 
responsiveness? IL-13-induced arginase I protein expression was inhibited by 
wortmannin and LY294002 as determined by Western blot analysis and IHC 
suggesting a role of PI3K. Surprisingly, IL-13-induced arginase I protein expression 
remained unchanged when murine tracheal segments were pretreated with the p110δ-
selective inhibitor IC87114. Although these findings imply a role for PI3K in IL-13-
induced arginase I induction, p110 δ does not appear to be the important isoform. 
This contrasts with the role of p110δ in IL-13-enhanced responsiveness shown earlier 
in this study. The reason for this discrepancy could be multiple signalling pathways 
related to IL-13-enhanced contraction. The first pathway could be IL-13/p110δ 
enhanced hyperresponsiveness. Another pathway could be IL-13/ PI3K/arginase I 
enhanced responsiveness. Moreover, off-target effects of LY294002 on other PI3K-
related or PI3K-unrelated kinases have been reported (Gharbi et al., 2007), including 
mTOR (mammalian target of rapamycin), DNA-PK (DNA-dependent protein kinase) 
and casein kinase 2 (reviewed in Kong & Yamori, 2008). PI3K-independent 
inhibition of signalling via Ca
2+
 and transcription factors such as NF-κB have also 
been reported for LY294002 (Tolloczko et al., 2004; Kim et al., 2005). Based on 
these previous studies, it is possible that PI3K-independent effects contribute in the 
current study to LY294002-induced inhibition of arginase I protein expression. 
 
A key finding of this thesis is the role of epithelium in IL-13-enhanced 
hyperresponsiveness. To elucidate the action of IL-13 on airway epithelial cells, the 
epithelium was denuded before incubation with IL-13. IL-13-induced 
hyperresponsiveness was lost suggesting that the potential mechanism of IL-13 to 
promote hyperresponsiveness is epithelial-dependent. The lack of response was not a 
consequence of mechanical trauma to the muscle as the obtained tension in 
epithelium-denuded control was not different from that obtained in epithelium -intact 
control segments. When the epithelium was denuded after incubation with m-IL-13, 
the increased contractile responses to KCl and CCh compared with control were 
maintained. IL-13-enhanced contraction is epithelial dependent, therefore, the site(s) 
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of IL-13-induced arginase I expression were studied. IL-13 induced arginase I in 
both epithelium-intact and denuded murine tracheal segments. 
 
Throughout the course of this research a key aim was to find target(s) by 
which IL-13 induced hyperresponsiveness and find a method to inhibit those targets 
while retaining functionality of murine tracheal segments. Gene silencing by siRNA 
can be not only a research tool, but also a therapeutic drug. Efficient introduction of 
siRNA into cells in intact tissue and the maintenance of normal contractility of 
smooth muscle rings containing siRNA for at least 3 days in organ culture were 
essential in this study. Thus, a reverse permeabilization method to deliver p110δ-
targeted siRNA was carried out. Recorded tension in response to KCl and CCh in 
control murine tracheal segments exposed to reverse permeabilization solutions was 
not significantly different compared with recorded tension in control segments. 
Hence reverse permeabilization appeared to be a suitable method to deliver siRNA as 
it did not affect measured tension. p110δ-targeted siRNA inhibited IL-13-enhanced 
responsiveness and Western blot analysis of the same segments showed that 
introduction of p110 δ-targeted siRNA downregulated p110δ protein content with no 
observed effect of inactive siRNA on p110δ level. 
 
To assess siRNA uptake into murine tracheal segments after reverse 
permeabilization, the delivery of fluorescein-tagged nonselective RNA was studied. 
It was demonstrated that fluorescence in the epithelial lining of murine tracheal 
segments as assessed by confocal microscopy increased with the use of higher 
concentrations of fluorescein-tagged nonselective RNA, although no uptake was 
demonstrated at low (20 nM) concentration. 
 
To test another method to deliver siRNA into intact tissue, two lipospermines 
(C20 or C22) synthesized in our department were compared with a commercially 
available transfecting agent, TransIT-TKO, as delivery agents for fluorescein-tagged 
nonselective RNA. 9HTEo- and A549 epithelial cell lines were used to test C20, C22 
or TransIT-TKO delivery of fluorescein-tagged nonselective RNA. All tested 
fluorescein-tagged nonselective RNA-lipospermine complexes were efficiently 
delivered to both 9HTEo- and A549 cell lines. Viability of A549 and 9HTEo cell 
lines with the use of C20 or C22 was similar to that of TransIT-TKO. When delivery 
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to tracheal segments was attempted it was not possible to demonstrate any increased 
fluorescence compared with control segments, which may denote low efficiency 
entry or the need to test earlier time points for efficient delivery. 
 
The results of this research demonstrate that PI3K p110δ is the main isoform 
involved in IL-13-induced hyperresponsiveness in isolated murine tracheal rings and 
its inhibition using different pharmacological and genetic tools (selective inhibitor, 
p110δ kinase-dead mice and p110δ-targeted siRNA) leads to inhibition of 
IL-13-induced hyperresponsiveness. PI3K is also important in IL-13 induced 
arginase I induction and IL-13-induced hyperresponsiveness is epithelial dependent. 
Gene therapy and especially the knock-down of p110δ by RNAi techniques may be 
important in future research in this important topic, pharmacological targets in 
inflammatory lung diseases. 
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Figure 7.1 Mechanism(s) of IL-13 enhanced contraction in murine ASM. The work 
carried out in this thesis demonstrates the role of PI3Kp110δ in IL-13-induced 
hyperresponsiveness in murine tracheal segments. Inhibition of p110δ, using the 
selective inhibitor (IC87114), tracheal segments isolated from mice expressing a 
catalytically inactive p110δ isoform of PI3K, or p110δ-targeted siRNA, resulted in 
inhibition of IL-13-enhanced hyperresponsiveness. PI3K is also important in IL-13- 
induced arginase I protein expression which was inhibited by the non-selective 
inhibitors wortmannin and LY294002. Other kinases e.g. CK2, mTOR may be 
implicated in IL-13-enhanced contraction. 
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9.1 Solution used in organ bath studies 
 
Krebs-Henseleit buffer solution 
Components Concentration (mM) 
NaCl 118 
KCl 4.7 
CaCl2 2.5 
MgSO4 1.2 
NaHCO3 25 
KH2PO4 1.2 
glucose 11.1 
 
 
9.2 Conditions used  for  9HTEo-, A549 and BEAS-2B cells 
 
Cell 
line 
Thawing/subculture 
media 
Freezing 
media  
Centrifugation 
(g) 
Cell 
Seeding 
value  
Trypsin/ EDTA 
9HTEo-
-
 
Complete media 
(DMEM + 10% 
FBS + 100 U/ml 
penicillin + 100 
µg/ml streptomycin 
+ 2 mM glutamine) 
10% 
DMSO, 
40% 
FBS and 
50% 
complet
e media. 
375  5x10
4
 
cells/ml 
0.05% Trypsin 
0.02% EDTA 
A549 Complete media 10% 
DMSO, 
40% 
FBS and 
50% 
complet
e media. 
375  3x10
4
 
cells/ml 
0.05% Trypsin 
0.02% EDTA 
BEAS-
2B 
LHC-9 medium LHC-9 
with 1% 
PVP and 
7.5% 
DMSO 
125  1.5 X10
4
 
cells/ml 
0.25% Trypsin-0.02 
% EDTA) 
containing 0.5% 
PVP 
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9.3 Immunoblot buffers 
 
Lysis buffer (50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 5 mM EDTA, 1% (v/v) 
Nonidet P40, 1 mM Na3VO4, 1 mM Na2MoO4, 10 mM NaF, 10 
µg/ml leupeptin, 10 µg/ml aprotinin, 10 µg/ml soybean trypsin 
inhibitor, 1 mM phenylmethylsulfonyl fluoride, and 1 µg/ml pepstatin 
A) with 10% (v/v) glycerol 
Sample buffer 10% sodium dodecyl sulphate, 50% glycerol, 200 mM Tris-HCl pH 
6.8, 0.01% bromophenol blue and 5% 2-mercaptoethanol to be added 
freshly to the sample buffer 
Running buffer 192 mM glycine, 25 mM Trizma base, 0.1% (w/v) SDS, MilliQ-filtered 
water) 
Semi-dry transfer 
buffer 
39 mM glycine, 48 mM Trizma base, 0.0375% SDS, 20% (v/v) 
methanol, MilliQ-filtered water 
Tris-buffered 
saline (TBS)  
20 mM Tris-HCl pH 7.5, 150 mM NaCl and deionized water 
 
 
9.4 Basic recipe for gel electrophoresis 
 
 Resolving gel  
(20 ml) 
Stacking Gels 
(12 ml) 
 5% 7.5% 10% 12% 14% 15% 5% 
MilliQ-filtered H2O (ml) 11.51 9.84 8.17 6.84 5.51 4.84 6.85 
Resolving gel buffer 
, pH 8.8 (ml) 
5.0 5.0 5.0 5.0 5.0 5.0 Stacking gel buffer,  
pH 6.8 (3.0 ml) 
30%  Acrylamide-Bis 
acrylamide Solution (ml) 
3.33 5.0 6.67 8.0 9.33 10 2.0 
AMPS (µl) 150 150 150 150 150 150 150 
TEMD (µl) 15 15 15 15 15 15 15 
 
*AMPS (10% w/v) and TEMED are added to resolving or stacking gel mixtures just before 
pouring into the gel cassettes. 
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9.5 Immunoblotting conditions  
 
Protein targeted 
by primary 
antibody  
Primary 
antibody 
species 
Molecular 
weight (kDa) 
Blocking 
buffer
a
 
Primary 
antibody 
concentration
b
 
Secondary 
antibody 
concentration
c
 
Akt1 Goat 60 5% 1 : 1000 1 : 10000 
phosphoSer
473
-
Akt 
Rabbit 60 5% 1 : 700 1 : 7000  
PI3K p110δ Rabbit 110 5% 1 : 700 1 : 7000 
Arginase I  mouse 35 5% 1 : 1000 1 : 5000 
Arginase I Rabbit 35 5% 1 : 1000 1 : 5000 
β-actin Rabbit 45 5% 1 : 1000 1 : 5000 
a 
Expressed as percentage (w/v) non-fat milk diluted w/v in TBS-Tween 20 
b 
Diluted v:v in 0.01% (w/v) sodium azide TBS-Tween 20 
c
 Diluted v:v in 0.01% (w/v) sodium azide TBS-Tween 20 
 
 
9.6 Reverse transcriptase (RT) reaction mixture 
 
Component Volume (µl) 
10X RT buffer 2 
dNTP (5 mM) 2 
Anchored oligo dT primers (500 ng / ml) 2 
RNasin plus  0.25 
Reverse transcriptase (RT) 1 
RNA template 1-12 
PCR grade H2O to 20 
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9.7 Primers used in this study  
 
 
Primer* 
 
Sequence 
Forward GTCCCTGGGTGTTCTTCCTGA IL-13 Rα1 
Reverse CGACGATGACTGGAACAAGT 
Forward TCCCTATTTGGAGGCATCAG IL-13 Rα2 
Reverse GAAACCCTGGATAAGGTCGT 
 
*Primers were designed using Primer3 (Whitehead Institute for Biomedical 
Research) and ProbeFinder Version 2.04 (Roche Applied Science, Mannheim, 
Germany), after retrieving gene specific sequences and intron-exon information from 
Pubmed (Entrez Gene) and Ensembl v37 (Homo sapiens genome). Primers were 
analysed by NetPrimer software (PREMIER Biosoft International) to detect any 
primer-dimer, haipins or other secondary structures. Each primer was then blasted on 
Pubmed/Ensembl to ensure its specificity to the gene required. All primers were 
intron spanning to avoid amplification of any genomic DNA and their product sizes 
are approximately 200 bp, which is optimal size for PCR. 
 
9.8 Paper  published from this study 
